



























There!has! been! significant!progress! in! the!basic! science!of! regenerative!medicine!
over!the!past!two!decades,!but!clinical! translation!has!been!more!halting.!Clinical!
trials! are! a! key! step! in! the! translational! process! and! have! been! highlighted! as! a!
particular!challenge!for!the!field.!This!thesis!adopts!an!analytical!framework!informed!
by! Jasanoff’s! idiom!of! coMproduction! to! investigate! trials!of!one!particular! type!of!







tend! to! be! affected! by! a! specific! set! of! local! factors,! the! most! important! being!
financial!constraints,!the!logistics!of!working!with!cells,!the!temporality!of!the!trial!




priority! evidenceMbased! medicine! places! on! this! supposedly! neutral,! objective!
















































































































































support!my! efforts! to! pursue! a! novel,! nonMdisciplinary! approach! to! the! research.!
Thanks!are!also!due!to!Nik!Brown,!whose!advice!as!part!of!my!Thesis!Advisory!Panel!
helped!me!resolve!some!of!the!thorniest!issues!I!faced.!I!have!been!very!lucky!in!the!
network! of! other! researchers! I! have! worked! alongside,! both! as! part! of! the!
REGenableMED! project! and! the! White! Rose! DTC.! I! particularly! benefited! from!










have! been! riddled! with! errors,! and! my! sister! Rosie! and! friend! Pete! have! been!




























the! CRISPR! process! for! gene! editing.! So! far,! however,! effective! treatments! in!
widespread! clinical! use! have! failed! to! materialise.! The! recent! history! of! clinical!
regenerative!medicine! is! largely! one! of! setbacks! rather! than! breakthroughs! M! for!
instance,! the!move! away! from!neural! cell! transplantation! for! Parkinson’s!Disease!
after! early! trials! failed! to! demonstrate! efficacy,! and! the! early! closure! of! the! first!
clinical! trial! to! use! human! embryonic! stem! cells! (hESCs)! after! the! company!
sponsoring! the! trial,! Geron,! discontinued! its! stem! cell! research! programme.! The!
halting!progress!of!clinical!regenerative!medicine!is!exemplified!by!the!fact!that!only!
eight! advanced! therapy! medicinal! products! (ATMPs)! had! received! marketing!
authorisation! from! the! European!Medicines!Agency! (EMA)! at! the! time!of!writing!
(June!2017).!Of!these,!four!have!since!been!suspended!or!withdrawn,!leaving!only!
four! ATMPs! currently! authorised! for! use! in! Europe.! Thus,! although! regenerative!
medicine! is! generally! thought! to! have! great! potential! for! both! public! health! and!
wealth!creation,!there!is!a!growing!recognition!that!there!are!significant!obstacles!to!
be!overcome!if!this!potential!is!to!be!realised.!In!2013,!a!House!of!Lords!Science!and!
Technology! Committee! report! on! regenerative! medicine! concluded! that:!
“regenerative!medicine!has!the!potential!to!save!lives!and!to!help!support!the!UK!





















regenerative! medicine,! it! also! provides! a! lens! through! which! to! examine! the!
dynamics!of!innovation!and!translation!more!broadly.!I!examine!how!clinical!trials!fit!
into! the! innovation!process! for!one!particular! type!of! regenerative!medicine! (cell!
therapies),! looking! at! how,! why! and! to! what! extent! trials! are! challenging! for!
translation,! and! how! these! challenges! might! be! overcome.! In! this! introductory!
chapter! I! will! introduce!my! theoretical! and! analytical! framework,! provide! a! brief!
background!to!translational!cell! therapy!research,!and!detail! the!specific!research!
questions!and!how!they!are!addressed!in!the!remainder!of!the!thesis.!Before!this,!





information!provided! to!applicants!explained! that! the!aims!of! these! studentships!









White! Rose! Doctoral! Training! Centre.! Throughout! the! fourMyear! studentship! I!
undertook! a! range! of! activities! intended! to! facilitate! and! support! the!
multidisciplinary!nature!of!the!research,!including!auditing!an!MSc!module!in!biology,!
taking! part! in! the! regular! meetings! held! by! my! biology! supervisor’s! lab! team,!
completing! a!Medical! Research! Council! training! course! on! cell! therapy! trials! and!






therapies! and! sociological! approaches! to! the! topic.! However,! I! quickly! began! to!
experience!what!Lyle!(2016)!calls!“the!epistemological!and!theoretical!void”!between!
the! social! and! natural! sciences.! To! give! an! example,! during! the! first! few!weeks! I!
attended!a!poster!presentation!which!reported!the!work!of!doctoral!students!in!the!
biology!department,!with!a!view!to!finding!areas!of!relevance!to!my!own!research.!A!





with! stem! cells,! focussed! entirely! on! the! discourses! and! narratives! constructed!
around!the!term!and!how!these!were!mobilised!by!different!actors,!without!engaging!
at!all!with!the!materiality!of!the!cells!themselves.!!Despite!both!being!relevant!to!my!
study,! and! both! dealing!with! similar! topic! areas,! there!were! no! obvious! areas! of!
overlap!between!the!two!disciplines.!!
The! scale! of! these! ontological,! epistemological! and! methodological!
differences!between!sociology!and!biology!made!it!difficult!to!conceptualise!a!study!









scientific.! Thus,! although! my! involvement! in! each! individual! discipline! was!
informative,!and!the!intention!of!the!studentship!was!clearly!to!undertake!research!










term! appears! to! be! most! commonly! used! to! describe! collaborative! work! where!
scholars!from!different!disciplines!come!together!to!work!on!a!common!problem!or!
research! question,! with! the! work! that! each! does! remaining! within! their! own!
disciplinary!boundaries!(Lyall!et!al.,!2011).!Clearly!this!was!not!a!viable!approach!for!
my!own!work,!as!doctoral!research!is!by!definition!conducted!by!a!single!researcher.!
In! contrast,! Lyall! and! colleagues! define! ‘interdisciplinary’! as! “research! which!
approaches!an!issue!from!a!range!of!disciplinary!perspectives”,!and!Nissani!(1997)!
suggests! that! it! describes! work! that! “combines! components! of! two! or! more!
disciplines!in!the!search!or!creation!of!new!knowledge.”!This!suggests!an!approach!
that! combines! some,! but! not! all,! aspects! of! different! disciplines,!which!would! be!





Both! the! monoMdisciplinary! institutional! setting! and! my! own! research! training!













research! that! spans! the! natural! and! social! sciences.! Lyall! and! colleagues! (2011)!
suggest!that!there!are!two!different!types!of!interdisciplinary!research:!academicallyM






analysis! or! understanding! of! a! practical! problem! that! can! be! bridged! by! bringing!
together!insights!from!more!than!one!discipline.!Interdisciplinary!studies!can!focus!
entirely! on! one! or! other! approach! or! can! combine! elements! of! both,! although!
normally! there! would! be! a! greater! emphasis! on! one! or! the! other.! Although! I!
incorporate! both! approaches! to! some! extent! there! is! an! emphasis! on! problemM
focussed! research,! which! appeared! to! be! best! suited! to! my! study! as! it! is! more!
practical! for!research!that!aims!to!address!both! the!natural!and!social!sciences.!A!
largely! problemMfocussed! approach! also! aligns! most! closely! with! the! initial!






approach! for! successful! interdisciplinary! research,! but! it! also! by! implication!
introduces!a!normative!slant!in!that!it!aligns!the!research!with!a!policy!aim,!thereby!





encountered! numerous! examples! of! these! differences! during! my! studies;! for!
instance,!most!of!the!health!sciences!and!biology!and!literature!I!read!makes!a!case!
for! a! specific! approach! to! stem! cell! research,! cell! therapy! policy! or! clinical! trials!
methods.!In!contrast,!the!STS!literature!tends!instead!to!highlight!the!contextualised!
and! sociallyMcontingent! nature! of! trials! or! innovation,! with! less! focus! on! explicit!
judgements! or! recommendations.! I! also! experienced! these! differences! first! hand!
when! I! discussed! or! presented! my! research! in! different! disciplinary! contexts.!
Biologists,! clinicians,! cell! manufacturers! and! trials! professionals! were! invariably!
interested!in!what!recommendations!I!could!make,!and!how!things!could!be!‘done!





Webster! highlights! the! potential! role! of! STS! as! an! intermediary! “working! at! the!
boundaries! of! science! and! society”,! and! argues! that! STS! can! move! beyond!
deconstructivism! and! undertake! “reconstructivist! engagement! with! science! and!
science!policy!making.”!With!this!in!mind,!I!adopt!an!approach!whereby!I!not!only!
examine!cell!therapy!trials!from!a!variety!of!perspectives,!uncovering!the!multiple!





! Developing! a! ‘reconstructivist’! framework! between! STS! and! the! natural!
sciences! involved! attempting! to! find! areas! of! mutual! interest! between! them.!
Contingency,!complexity!and!reflexivity!are!by!no!means!completely!absent!from!the!
scientific! and! health! science! literature,! and! differences! between! the! disciplines!
sometimes!appear!to!be!more!a!matter!of!emphasis!than!content.!For!instance,!the!
scientific!community!might!acknowledge!the!provisionality!of!terms!such!as!‘MSC’!or!
‘stem!cell’,!but! it!will! continue! to! use! them!as!working!definitions! that!allow! the!
scientific!debate!to!move!forwards,!whereas!an!STS!account!might!focus!entirely!on!
unpicking! the! terms! themselves.! Likewise,! STS! research!might! examine! the! social!
context! of! trials! in! order! to! highlight! the! contingent! nature! of! clinical! research,!
whereas!the!health!sciences!literature!might!make!similar!points!but!with!a!view!to!




there! is! one! ‘truth’! that! can! be! accessed! through! research,! whereas! sociological!
research!tends!to!assume!a!more!relativist!standpoint,!which!holds!that!rather!than!








both! social! and! natural! determinism,! focussing! on! the! relationship! between!
knowledge! and! reality! without! affording! primacy! to! either! (Fletcher! 2016).! Two!







exist! whether! or! not! we! observe! them,! whilst! still! accounting! for! the! sociallyM
constructed!nature!of!our!observations.!Fundamental!to!this,!and!the!second!aspect!
of!critical!realism!that!particularly!informed!my!thinking,!is!an!understanding!that!the!










both! social! and! material.! I! do! not,! therefore,! uncritically! accept! a! purely! realist!
account! of! these! cells! M! that! what! is! observed! and! reported! is! an! infallible!
representation!of!what! these!cells!are!or! can!do! M!but! likewise,! I! am!do!not! limit!
myself! to! an! entirely! symmetrical! analysis! of! the! various! sociallyMconstructed!
representations!of!MSCs,!without!any!consideration!of!how!well!they!might!reflect!
‘reality’.!
! As! well! as! having! different! ontological! positions,! another! significant!
difference!between!the!disciplines!I!worked!in!is!their!approach!to!communicating!
research.!In!line!with!a!more!realist!ontological!perspective,!the!natural!sciences!tend!
to!write! in! a! style! that! aims! to! convey! clarity,! precision! and! objectivity,!whereas!
sociological! research! tends! to! be! presented! in! a!much!more! narrative,! discursive!








have! multiple! outputs,! it! would! not! be! possible! to! adopt! two! entirely! different!
reporting! styles! in! a! PhD! thesis! without! losing! some! of! the! internal! consistency.!
Secondly,!although!this!research!has! interdisciplinary!elements!it! is! located!within!
sociology!and!adopts!sociological!methods!and!analytical!techniques,!therefore!there!
















sciences! the! thesis! chapters! might! be! more! likely! to! resemble! a! series! of!
interconnected! journal!articles,!each!dealing!with!a!specific!question!and!perhaps!
even!a!different!set!of!data!or!methods.1!l!take!a!moderate!approach!here!as!well,!
largely! following! sociological! conventions! but! incorporating! some! elements! of!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1! The! different! disciplinary! expectations! of! thesisMwriting! often! became! apparent! during! my!
supervision!meetings.!For!instance,!the!sociology!department!requires!a!significant!amount!of!work!
to! be! written! up! in! the! first! 18! months! of! a! doctoral! studentship,! which! surprised! my! biology!
supervisor!as!the!entirety!of!a!biology!thesis!would!typically!be!written!up!at!the!end!of!the!research,!














This!was! a! challenge! from! the! very! beginning! of!my! research;! as! I! engaged!with!
researchers!in!both!sociology!and!biology!I!encountered!a!vast!array!of!literature!that!
dealt!with!cell!therapy!trials,!and!when!reading!the!most!prominent!STS!literature!
about! regenerative! medicine! I! found! very! few! references! to! scientific! or! health!
sciences!articles,!but!I!would!often!later!come!across!papers!in!a!scientific!journal!
that!appeared!to!deal!with!the!same,!or!very!similar!issues.!Further!complexity!was!
introduced! by! the! large! body! of! soMcalled! ‘grey! literature’,! including! policy!
documentation,!commercial!publications!and!third!sector!research,!much!of!which!
dealt! with! the! same! issues! as! the! academic! literature! but! in! different! ways.! If!
adopting!an!interdisciplinary!approach,!then,!I!would!clearly!not!be!able!to!simply!
review! the( literature! on!cell! therapy! trials,! I!would!actually!need! to! find!a!way!of!









‘bottomMup’! approach! to! identifying! relevant! literature,! which! avoids! the!
preconceptions! of! approaching! a! literature! search! from! a! particular! disciplinary!
1.(Introduction!
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perspective.! This! approach! aligned! with! my! ontological! position,! allowing! me! to!
incorporate! both! relativist! and! realist! viewpoints,! and! also! with! my! aim! of!
contributing!to!a!serviceable!STS!because!it!engaged!with!the!range!of!perspectives!
within!the!field! itself,! rather!than!being! limited!to!one!paradigmatic! framework.! I!
therefore!decided!not!to!confine!my!literature!search!to!one!particular!discipline,!or!
indeed! to! academic! literature!per( se,! but! rather! I! read! as!widely! as! possible! and!
allowed! the! emerging! themes! from!my! fieldwork! to! determine!which! literature! I!














nor! the! relativist! understanding! of! reality! but! rather! aiming! to! explore! the!
relationship!between!the!two.!This!informed!both!the!theoretical!perspectives!that!I!
draw!on,!which!I!will!discuss!shortly,!and!the!methodological!approach!that!I!will!set!
out! in! Chapter! 2.! Thirdly,! I! adopt! a! continuum! approach! to! the! writing! and!
presentation!of!the!thesis,!adopting!a!writing!style!that!is!aimed!at!an!intelligent!lay!
reader! rather! than! a! disciplinary! specialist,! taking! a! slightly! more! or! less! realist!
approach! in!different! chapters!depending!on!the!specific! themes!being!addressed!















appraising,! and! using! contemporaneous! research! findings! as! the! basis! for! clinical!
decisions”!(Rosenberg!and!Donald,!1995).!The!concept!emerged!in!the!early!1990s!in!














applied! in! any! context! to! produce! objective,! valueMfree! evidence.! Central! to! this!
narrative! is! the! assertion! that! RCTs! are! separate! from,! and! immune! to,! social!
processes!M!that!they!fall!within!the!realm!of!‘science’!rather!than!‘politics’!and!are!































“fullMfledged! coinvestigators”,! how!patients! became! “the! subject! of! a! network! of!
evolving!rules,!norms,!restrictions,!and!ethical!and!epistemological!dilemmas”,!and!










writers! have! raised! concerns! about! EBM’s! phenomenal! success! in! exclusively!









and! illness! are! conceptualised! overall.! As! Borgerson! and!Bluhm! (2005)! point! out,!
“standards!of!evidence,!wherever!they!are!designed!and!employed,!serve!to!shape!
the!direction!of!the!field!or!discipline! in!which!they!are!adopted.”! In!particular,!a!
number!of!writers!have!highlighted!how! the!EBM! framework!has! led! to! research!
money!being!channelled!into!areas!that!lend!themselves!to!RCTs,!whilst!also!shaping!
medical!research!around!the!requirements!of!the!method,!for!instance!limiting!the!














Kuhn’s! The! Structure! of! Scientific! Revolutions! was! published,! challenging! the!
dominant! understandings! of! science! as! rational! and! naturallyMdetermined! and!
turning!attention!instead!to!the!concept!that!science!actually!emerges!from!‘what!
scientists!do’!(Kuhn,!1962).!!In!the!1970s!the!‘strong!programme’!of!the!sociology!of!
scientific! knowledge! (SSK)! began! to! examine! the! development! of! scientific!
knowledge! from! a! position! of! methodological! symmetry,! arguing! that! scientific!
beliefs!require!explanation!regardless!of!whether!they!are!deemed!to!be!rational!or!
irrational,! ‘right’! or! ‘wrong’.! This! shifts! the! emphasis! away! from! ‘rational’! or!
‘material’!explanations!of!science!and!technology!and!focusses!instead!on!the!work!
undertaken!by!scientists!and!the!interactions!between!different!actors,!underpinning!
many! different! strands! of! work! within! STS! which! can! broadly! be! termed!




claim! to! represent! (see! for! instance! KnorrMCetina! 1977,! 1999).! Other! traditions!
attribute!a!greater!role!to!material!objects,!for!instance!actor!network!theory!(ANT)!
understands!technoMscience!as!emerging!from!the!interests!and!actions!of!networks!




the! recursive! nature! of! innovation,! and! the! extent! to! which! factors! other! than!






methodology! (which! I! discuss! in! Chapter! 2).! From! a! theoretical! and! analytical!
perspective,!however,!I!particularly!draw!on!Sheila!Jasanoff’s!work!on!coMproduction.!
Presented!as!an!‘idiom’!which!underpins!a!wide!range!of!work!in!STS,!including!ANT!
and! SSK,! rather! than! a! formal! theoretical! framework,! coMproduction! argues! that!
scientific!knowledge!cannot!be!separated!from!the!context!in!which!it!is!generated,!
and!focuses!attention!on!the!role!that!that!social! institutions!play! in!ordering!and!
reordering! our! understanding! of! nature! (Jasanoff! 2004).! Jasanoff! distinguishes!
between!constitutive!coMproduction,!which!focuses!on!the!construction!of!science!
and!technology!and!can!be!seen!in!STS!theories!such!as!ANT,!and!interactional!coM




of! science! and! scientific! progress,! but! rather! both! emerge! concurrently! in! one!
integrated!process.!!







four! common! pathways,! or! ‘ordering! instruments’,! of! coMproduction:! making!
identities,!making!institutions,!making!discourses!and!making!representations,!which!
are!visible!in!much!of!the!STS!literature!on!regenerative!medicine.!The!concurrent!









and! shared! understandings! of! cell! therapies! (Webster! et! al.,! 2011,! Eriksson! and!
Webster,! 2008,! Eriksson! and! Webster,! 2015);! and! discourses! are! the! focus! of!
research!highlighting!how!expectations!and!‘promissory!narratives’!about!the!future!





emerging! technologies! regulatory! decisionMmaking! is! not! a! rational,! objective!
process,!but!rather!emerges!from!the!attempts!of!regulators!to!construct!order!out!
of! messiness! and! uncertainty,! in! which! endeavour! they! rely! on! the! expertise! of!
scientists! themselves.! STS! research!has!highlighted! that! just!as! scientific! certainty!
cannot! be! entirely! explained! as! rational! and!materiallyMdetermined,! so! too!must!
uncertainty!also!be!understood!in!terms!of!social!construction.!There!is!thus!no!‘real’!
or! ‘objective’! measure! of! uncertainty,! but! rather! it! must! be! understood! as! a!
conceptual! tool! that! is!mobilised!in!negotiations!about!the!credibility,!validity!and!
usefulness!of!scientific!knowledge.!Thus,!uncertainties!create!an!area!of!“interpretive!
subjectivity”! in!which! various! actors! can! promote! agendas! that! conform! to! their!
interests!(Jasanoff!and!Wynne!1998).!
! Wynne! (1992)! provides! a! useful! classification! of! risks! and! uncertainty,!
distinguishing! between! risk,! which! can! be! measured! and! predicted,! uncertainty,!
which!relates!to!gaps!in!knowledge!that!are!known!and!have!understood!parameters,!
ignorance,! which! arises! from! gaps! in! knowledge! that! are! not! known! or! have!
undefined! parameters,! and! indeterminacy,! which! relates! to! the! causal! chains! or!
outcomes!of!decisions!being!open.!Wynne!makes!two!important!arguments!about!
this! conceptualisation! of! uncertainty:! firstly,! that! ignorance! is! endemic! in,! and!
fundamental!to,!scientific!research,!and!only!becomes!problematic!when!scientific!
knowledge!is!“institutionalised!in!policy!making”!without!recognition.!Secondly,!he!







has! explored! the!ways! that! emerging! technologies! create! new! and! unpredictable!
uncertainties! in! practice.! For! instance,! Mesman! (2008)! explores! how! neonatal!
diagnostic!and!prognostic!innovations!have!led!to!new!treatment!options!but!have!
also!raised!new!questions!about!the!treatment!and!prospects!of!ill!babies,!and!about!
which! voices! and! evidence! should! be! given! most! weight! in! decision! making.! In!
another!example,!Franklin!and!Roberts!(2006)!examine!the!rise!of!preimplantation!
genetic!diagnosis,!which!they!show!to!be!a!complex!and!multiMlayered!phenomenon!
which! is! a! technological! solution! to! reducing! and! ‘controlling’! uncertainty,! but! in!
another! sense! an! uncontrolled! and! uncertain! process! that! introduces! new! and!




! Unlike! some!branches! of! STS,!which! focus! primarily! on! the! emergence! of!
science! and! technology! from! the! dayMtoMday! practice! of! science,! the! idiom!of! coM






thesis,! in! particular! my! analytical! approach! (which! I! discuss! in! Chapter! 2),! the!











methodological! approach! (discussed! in! Chapter! 2)! and! the! analysis! of! challenges!
presented! in! Chapter! 5.! These! critiques,! and! in! particular! the! style! of! practice!





context! of! Keating! and!Cambrosio’s! findings.! I! also! return! to! the! concepts! of! coM
production!and!uncertainty!in!the!concluding!chapter,!where!I!draw!together!the!key!







purposes.! Firstly,! it! locates!my!work!within! the!wider!academic!discussion!on!cell!
therapies,!and!thus!demonstrates!how!it!was!shaped!by!and!what!it!adds!to!these!
debates.! Secondly,! it! provides! important! factual! information! about! cell! therapies,!
which!will!be!necessary!for!any!reader!unfamiliar!with!the!field!to!fully!understand!
the!remainder!of!the!thesis.!Thirdly,!and!perhaps!most!importantly,!it!elucidates!the!













developing! genuinely! revolutionary! therapeutic! applications! (Murry!and!Keller,!
2008).!Pluripotent!cells!have!the!ability!to!differentiate!into!any!cell!in!the!human!





cells! (iPSCs),!which!are!terminallyMdifferentiated!or! ‘adult’!cells! that!have!been!
reprogrammed!to!a!pluripotent!state.!!
HESCs!were!first! isolated! in!1998,!and!at! least!225! lines!have!now!been!
developed! (Bajada! et! al.,! 2008).! Isolating! embryonic! stem! cells! requires! the!
destruction!of!a!human!embryo,!making!hESC!research!one!of!the!most!ethically!
challenging! areas! of! stem! cell! research,! but! scientific! research! on! hESCs! is!
growing!both!in!terms!of!output!and!geographical!spread!(BenMDavid!et!al.,!2012).!
The! main! issue! that! will! need! to! be! addressed! in! order! for! the! therapeutic!












the! process! is! still! in! its! infancy,! however,! and! there! are! many! hurdles! to!
overcome!before!widespread!clinical!application!becomes!a! realistic!possibility!
(Jopling!et!al.,!2011).!Firstly,!the!reprogramming!process!is!extremely!inefficient,!
with! typically! only! 1%! of! cells! being! reprogrammed,! and! the! outcome! of! the!
process! appears! to! be! highly! dependent! on! microMenvironmental! conditions!
within!the!lab,!all!of!which!would!cause!significant!manufacturing!challenges!in!a!
clinical! context! (Yamanaka,! 2012).! Secondly,! the! reprogramming! process! itself!
appears!to!increase!the!tumorigenicity!of!the!cells!(Daley!and!Scadden,!2008),!and!
also!exposes! them!to! stress,!which! selects! for! cells!where! the! stress! response!
gene!is!mutated,!making!them!potentially!more!susceptible!to!tumour!formation!
than!hESCs!(Jopling!et!al.,!2011;!Ren!et!al.,!2012).!The!scale!of!the!challenges!facing!







tissues.! Unlike! pluripotent! cells,! they! are! not! thought! to! have! the! ability! to!
differentiate!into!any!cell!in!the!human!body,!but!can!differentiate!into!specific!
cell! lines!within! their!germ! layer.!The!properties!and!behaviour!of!multipotent!
stem! cells! are! largely! determined! by! the! surrounding! microenvironment,! or!
niche,!and!much!recent!scientific!research!has!focussed!on!better!understanding!
how!the!niche!affects!stem!cell!proliferation,!and!how!these!mechanisms!could!
be! manipulated! for! clinical! purposes! (Jopling! et! al.,! 2011).! Four! main! types! of!
multipotent! cells! are! currently! being! researched! with! a! view! to! clinical!
applications:!hematopoietic,!mesenchymal,! limbal!and!neural! cells.! These!cells!
are!generally! thought! to!pose!a! lower! risk!of! teratoma! formation!due! to! their!









the! clinic! first! (Colman,! 2008;! Ren! et! al.,! 2012).! ! The! clinical! potential! of!
multipotent!stem!cells!is!also!dependent!on!a!number!of!other!factors,!including!
how! easy! the! cells! are! to! harvest,! how! effectively! they! can! be! expanded! in!
culture,!and!how!easily!they!can!be!transplanted!to!the!desired!treatment!site.!
! The!categorisation!of!stem!cells!that!I!describe!above!is!useful!for!gaining!






a! variety! of! cells.2! The! term! ‘stem! cell’! itself! is! frequently! used! in! the!media,!
academic! literature! and! policy! and! legal! documentation! without! question! or!
clarification,! suggesting! that! the! term! refers! to! an! object! whose! definition! is!
fixed,! uncontested! and! universally! understood.! However,! recent! scientific!






at!which! cells! of! the! same! type! become! reprogrammed! suggests! that! the! cell!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
2! In! the! interests! of! brevity,! and! clarity,! I! have! largely! skimmed! over! the! complexity! and!










conception! of! ‘stem! cells’! as! discrete! and! unchanging! physical! objects.! For!
instance,!Geesink!et!al.!(2008)!suggest!that!stem!cells!should!not!be!considered!
as! a! distinctive! category! of! cells,! but! rather! should! just! be! seen! as! cells! at! a!








be! considered! in! three! dimensions:! physical,! spatial! and! temporal.! This! has!
significant!implications!for!the!therapeutic!application!of!stem!cells,!particularly!




in! 1998,! the! development! of! iPSCs! in! 2006,! and! human! somatic! cell! nuclear!
transfer!in!2013.!There!have!also!been!false!starts,!of!course,!such!as!the!Huang!
scandal!in!2005,!and!wrong!turns,!such!as!pursuing!the!theory!that!MSCs!could!
become! pluripotent! when! exposed! to! a! different! niche! (Daley,! 2012).!
Nevertheless,!the!tone!of!the!scientific!literature!is!generally!one!of!enthusiasm!
and! progress,! for! instance! the! swift! development! of! the! cell! reprogramming!
process!which!can!be!seen!between!the!initial!paper!on!iPSCs!published!in!2006!
and! the! update! in! 2012! (Takahashi:2006hi! and! Yamanaka,! 2012! respectively).!
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achieved! by! other! treatment! regimes.! For! instance,! Lindvall! (2012)! notes! that!
scientific!breakthroughs!have!not!so!far!led!to!useful!stem!cell!treatments!for!CNS!
disorders,! Wainwright! et! al.! (2006)! report! that! scientists! are! sceptical! of!
developing!even!experimental!embryonic!stem!cell!treatments!for!diabetes!in!the!






treatment! options! M! for! instance! Huntingdon’s! disease! but! not! Parkinson’s!
(Lindvall,!2012).!Clearly,! this! is!a! far!cry! from!the!rhetoric!of! ‘regeneration’!and!
‘cure’:!the!anticipated!future!where!ageing!is!reversed!and!chronic!diseases!such!
as!diabetes!and!Alzheimer's!are!cured!(Cooper,!2006).!This!gap!between!rhetoric!
and! current! scientific! reality! creates! the! sense! that! stem! cell! research,! like!
pluripotent! cells! themselves,! is! defined! by! its! ‘notMyetMness’! (Eriksson! and!
Webster,!2008).!To!understand!the!reasons!for!this!it!is!necessary!to!explore!the!
dynamics!of!stem!cell! research!as!a!clinical! field!rather!than!simply!a!scientific!




also!on! these!breakthroughs!being!developed! into!effective,!affordable! clinical!






to! the!potency!of! the!cells! (undifferentiated!cells!being!more! likely!to!become!




! TransplantationMbased! treatments! can! use! either! autologous! (patient’s!
own)!or!allogeneic! (donor)!cells.!The!most!appropriate!source!of!cells!depends!
on! a! number! of! factors,! including! the! type! of! disease! being! treated,! ease! of!
obtaining!donor!cells,!and!number!of!cells!required!for!treatment.!For!autologous!
treatments,! it! will! often! be! a! challenge! to! source! enough! healthy! cells,! the!
process! for! harvesting! them! could! introduce! additional! trauma,! and! the! cells!
transplanted! will! be! genetically! identical! to! those! being! replaced,! so! may! be!
prone! to! the! same! problems! causing! disease! in! the! first! place! (unless! some!
genetic! modification! is! undertaken).! This! makes! allogeneic! treatments! an!
important! alternative,! but! these! encounter! immune! response! problems!which!
will!have!to!be!overcome!if!‘offMtheMshelf’!products!are!to!become!a!reality!(Daley,!
2012).!Various!ways!of!addressing!this!issue!are!being!explored!M!for!instance,!one!
potential! solution! for! diabetes! treatments! is! a! method! of! encapsulating! the!
transplanted! cells,! so! they! can! perform! their! basic! function! but! not! allow! the!
diffusion!of!larger!molecules,!cells,!or!antibodies!which!would!trigger!an!immune!
response!(Lysy!et!al.,!2012).!
! In! addition! to! engraftment,! another! potential! mode! of! action! involves!
harnessing! the! immunological,! antiMinflammatory! and/or! trophic! properties! of!
certain!cells.!These!treatments,!which!can!be!allogeneic!or!autologous,! involve!





common! with! the! pharmaceutical! treatment! model,! in! that! the! cells! are! not!
intended! to! remain! in! the! body.! These! treatments! may! therefore! be!
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! Both! transplantation! and! systemic! application! present! plausible! clinical!
applications!for!cell!therapies,!however!real!breakthroughs!in!clinical!cell!therapy!













led! to! corresponding! advances! in! the! clinic,! it! is! necessary! to! examine! the!
complex! interactions! between! science,! technology! and! society.! Salter! (2013)!
describes! a! ‘triangle! of! tensions’! facing! innovation! in! health! technology:! “the!
science!may!prove!inadequate,!society!unsympathetic!or!the!market!unwilling.”!
Below,!I!consider!how!these!three!tensions!have!affected!the!development!of!cell!





The! previous! section! of! this! chapter! touched! on! a! number! of! basic! scientific!
issues!which!are!currently!perceived!as!hindering!the!development!of!effective!
stem!cell!therapies.!Some!of!these!issues!are!relatively!wellMdefined,!such!as!the!
need! to! improve! the! process! for! reprogramming! iPSCs! to! reduce! the! risk! of!
tumour! formation,! or! to! better! understand! the! immunogenicity! of! hESCs.!
Although!such!wellMdefined!problems!cannot!yet!be!overcome,!their!parameters!
are! broadly! understood,! and! they! can! be! addressed! using! wellMestablished!
scientific! experimental! techniques.! These! ‘known! unknowns’! (Eriksson! and!
Webster,!2008)!can!therefore!to!some!extent!be!considered!practical!problems,!
and!it!could!be!expected!that!progress!in!these!areas!will!be!relatively!linear,!such!
as! the! process! of! incremental! discoveries! described! in! Yamanka’s! 2012! paper!




the!model! used! to! test! Parkinson’s! Disease! in!mice! is! very! different! from! the!
human!disease!(Lindvall,!2012),!and!the!safety!of!iPSCs!cannot!be!proved!through!
















unusual,! or! necessarily! unwelcome,! in! the! scientific! world,! but! presents! a!
challenge! for! clinical! translation! because! a! fundamental! change! in! scientific!
understanding!of!stem!cell!properties!can!also!significantly!alter!the!likely!clinical!
potential! of! those! cells.! Clinical! research,! however,! is! often! not! able! to! adapt!
quickly! enough! to! keep! up! with! the! pace! of! change! in! the! basic! science,!
demonstrated!by!the!continuation!of!trials!based!on!outMdated!understanding!of!
the!properties!of!MSCs!(Bianco!et!al.,!2013b).!There! is! therefore!a! fundamental!
tension! between! the! time! needed! to! sufficiently! develop! the! basic! scientific!
knowledge! base,! and! the! societal! push! to! develop! clinically! useful! and!
commercially!viable!treatments.!
! Scientific!unknowns!(whether!known!or!unknown)!can!be!understood!as!
the! current! limits! of! scientific! understanding,! and! there! is! an! unspoken!
assumption! in! the! scientific! literature! that! the! challenges! they! pose! will!
eventually!be!overcome!through!the!acquisition!of!sufficient!knowledge.!It!is!also!
possible,!however,! that!barriers! to! clinical! translation!may! stem! from! limits! to!




aim! to! treat)! potentially! imposes! finite! boundaries! on! the! clinical! potential! of!
stem!cells!(Wainwright!et!al.,!2006).!For!instance,!both!Lindvall!(2012)!and!Daley!
(2012)!question!whether!regeneration!of!the!central!nervous!system!will!ever!be!




clinical!obstacles! for! cell! therapies:! the! risk!of! tumour! formation!presented!by!










much!greater! challenge! than!mass!production! of!drugs!or!biopharmaceuticals,!
because! the! human! cell! is! a! complex! living! organism! rather! than! a! relatively!
simple! protein! (Mason! and! Dunnill,! 2007).! Small! variations! in! the! laboratory!
environment!or!culturing!process!can!have!a!significant!impact!on!the!resulting!
cell!populations!(Eriksson!and!Webster,!2008;!Yamanaka,!2012),!making!it!difficult!
to! ensure! consistent! results! when! production! takes! place! in! more! than! one!





of! potency! being! a! stage! rather! than! a! state,! suggest! that! some! level! of!
heterogeneity! may! be! integral! to! the! ‘stemMness’! of! the! cell.! Thus,! achieving!
complete! consistency! may! actually! reduce! or! even! eliminate! the! therapeutic!
potential!of!the!cells.!
! Effective!mass! production! of! cell! therapies!will! clearly! require! a! better!
understanding! of! the! impact! of! the! production! process! on! the! quality! of! the!
resulting!therapeutic!product!(Mason!and!Dunnill,!2007;!Foley!and!Whitaker,!2012).!
However,! there! is! currently! no! consensus! about! how! to! measure! the!
characteristics! and! quality! of! clinicalMgrade! cell! batches.! For! instance,! no! one!
marker! has! been! discovered! that! can! be! used! to! identify! hESCs! (Eriksson! and!
Webster,!2008),!and!Yamanaka!(2012)!reports!so!much!crossMover!in!the!markers!
used! to! test! hESCs! and! iPSCs! that! it! is! not! possible! to! use! markers! alone! to!
distinguish!whether!two!populations!were!different!cell!types,!or!the!same!cells!
simply! produced! in! different! labs.! The! agreement! of! standard! markers! for!
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identifying! clinicalMquality! cells! will! be! an! important! factor! in! the! clinical!
translation!of!stem!cell!science.!However,!although!the!first!steps!are!being!taken,!





Using! stem! cells! for! biological! or! clinical! research! raises! a! number! of! ethical!
issues,! perceptions! of! which! differ! both! geographically! and! politically.! The!
interaction! between! these! different! ethical! responses! is! a! significant! factor! in!
shaping!cell! therapy! research!and!commercialisation!globally.!One!of! the!most!
important! ethical! considerations! is! the! creation! and/or! destruction! of! human!
embryos!for!research!purposes,!which!is!required!for!isolating!hESCs!(Prainsack!
et!al.,!2008;!Lo!and!Parham,!2009;!SleeboomMFaulkner,!2008).!Another!factor!that!
complicates! embryonic! research! is! the! need! for! donated! embryos! or! oocytes.!
Donating!oocytes!is!invasive!and!presents!some!medical!risk!to!the!woman,!and!
raises! significant! issues! surrounding! informed! consent! and! financial!
compensation/incentivisation! (Schultz!and!Braun,!2013).!Egg! sharing!during! IVF,!
like!the!use!of!unused!embryos!from!IVF!cycles,!is!arguably!less!problematic,!as!
it!does!not!expose!women!to!additional!physical! risk,!however! it! raises!similar!
concerns! about! consent! and! financial! incentives! (Lo!and!Parham,!2009).! These!
ethical!issues!largely!affect!basic!scientific!research,!as!they!relate!to!the!process!
of!sourcing!embryonic!cells!for!research!purposes.!However,!they!can!also!feed!
through! into! clinical! trials! M! for! instance,! donated! oocytes! are! used! to! create!
allogeneic!embryonic!stem!cell!lines!for!clinical!use.!!
! There!are!also!specific!ethical!considerations!that!arise!directly!from!the!
clinical! use! of! stem! cell! therapies,! particularly! when! these! therapies! are!
experimental.!Lo!and!Parham!(2009)!highlight!the!problematic!nature!of!informed!






to! avoid! having! cells! implanted! that! were! sourced! from! an! embryo,! so! the!
information! provided! before! consent! must! be! sufficient! for! them! to! make! an!
informed! choice! on! ethical! as!well! as!medical! grounds.! Linked! to! the! issue! of!
informed!consent,!there!is!also!the!possibility!of!patients!agreeing!to!take!part!in!
trials! under! the! misconception! that! these! experimental! treatments! offer! a!
genuine!possibility!of!curing!them.!These!expectations!may!be!out!of!step!with!
reality,!as!early!trials!are!only!intended!to!assess!safety,!and!even!in!later!efficacy!
trials!many! treatments! do! not! prove! any! better! than! existing! options! (Lo! and!
Parham,! 2009).! Although! this! therapeutic! misconception! is! to! some! extent! an!
issue!with!all!clinical!trials,!it!is!likely!to!be!particularly!prominent!in!trials!of!stem!
cell! treatments,! where! expectations! have! been! raised! by! the! promise! of!
revolutionary! treatments! that! will! cure! disease! and! reverse! ageing! (Cooper,!
2006),! and! which! aim! to! treat! severe! and! debilitating! conditions! for! which!
patients!often!have!no!other!treatment!options.!
! Alongside,!and!linked!to,!these!ethical!constraints,!cell!therapies!have!also!
been! affected! by! an! increasingly! cautious! approach! to! regulation,! which! has!
particularly!limited!clinical!research!of!the!most!experimental!therapies.!Gaining!





the! chance! of! seeing! benefit! (Foley! and! Whitaker,! 2012).! Differing! trial!
requirements!between!member!states!have!also!been!a!complicating!factor!for!
cell! therapy! trials! in! the! EU,! although! steps! are! being! taken! to! improve! the!
efficiency!of!the!process! (NHS!European!Office,!2014).!Because!of!the!costs!and!
time! involved! in!undertaking!fullMscale!clinical! trials,!there!has!been!a!focus!on!
treatments!for!orphan!diseases,!which!have!less!stringent!requirements!as!well!
as! longer! patent! protection! on! approved! products! (Haddad!et!al.,!2013).!Much!
clinical! development! is! also! carried! out! under! the! ‘Hospital! Exemption’,!which!
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provide! a! less! onerous! regulatory! framework! for! individual! clinicians! using!
experimental! treatments! on! a! patientMspecific! basis! (Faulkner,! 2009;! Foley! and!
Whitaker,!2012).!Nevertheless,! lack!of! flexibility! in!trial! regulations,!particularly!
in! earlyMphase! trials,! and! the! onerous! demands! placed! on! researchers! to!
demonstrate! safety! prior! to! trial! approval,! are! still! perceived! by! many! in! the!




of!acceptable! research,!and!can!also!play!a!more! indirect! role!by!affecting! the!
funding! available! for! that! research.! This! phenomenon! was! particularly! visible!
under!the!Bush!administration!in!the!US,!when!federal!funding!could!not!be!used!
for! research!using!embryonic! stem!cells! (Lo!and!Parham,!2009).!The! regulatory!
framework! can! also! have! an! indirect! impact! on! innovation,! for! example! by!
affecting! the! relative! financial! viability! of! research! in! different! areas,! or! the!
commercial! potential! of! the! treatment! being! researched.! Indeed,! financial!
considerations! can!often!outweigh! scientific!and!clinical! factors! in! shaping! the!
direction!of!translational!research.!This!was!the!case!when!the!prohibitive!costs!
of! running! Phase! 3! clinical! trials! led! to! one! clinic! changing! the! primary! target!
indication! for! one!of! its! treatments,!not!because! this!was! the!area!of!greatest!
clinical! need,! or! the!most! likely! to! be! successful,! but! in! order! to! gain! orphan!
indication!status!and!reduce!the!cost!of!the!trial! (Haddad!et!al.,!2013).!Another!
example! is! Geron’s! surprising! decision! to!withdraw! from! embryonic! stem! cell!
research!shortly!after!gaining!approval!for!the!first!hESC!trial,!which!was!partly!








! A! challenging! regulatory! environment! is! not! the! only! factor! that! has!
constrained!funding!for!clinical!stem!cell!research.!During!the!early!years!of!tissue!
engineering,! translational! research! was! largely! commerciallyMfunded,! but!





cell! therapies! is!expected!to!be! longer!than!for!more!conventional! treatments,!
making!it!difficult!to!secure!venture!capital!funding!(Colman,!2008;!Morrison!et!al.,!
2013).! This! issue! has! also! deterred! significant! investment! from! the! big!
pharmaceutical! companies,!who!are!also! concerned!about! the! business!model!
for!scaling!up!and!commercialising!cellMbased!treatments,!and!about!the!ethical!
implications!of!hESCs!(Wainwright!et!al.,!2008).!There!is!also!uncertainty!about!the!
extent! to! which! products! based! on! embryonic! cells! will! be! patentable,! and!
therefore! profitable.! Various! countries! have! used! patent! law! in! an! attempt! to!
restrict! the! commercialisation! of! embryonic! stem! cells,! however! the! language!
used! in! these! laws! is! (perhaps! deliberately)! vague.! Thus,! instead! of! creating!
greater!clarity!they!have!in!reality!led!to!a!great!deal!of!uncertainty!as!to!what!is!





! In! summary,! then,! the! translational! environment! for! cell! therapies! is!
characterised!by!a!number!of!scientific!challenges,!considerable!ethical!issues,!a!
complex! and! prohibitive! regulatory! framework,! and! significant! funding!
constraints.!These!issues!are!relatively!wellMestablished!in!the!literature,!as!is!the!
fact!that!clinical!trials!of!cell!therapies!present!specific!methodological,!practical!




therapies,! and! the!extent! to!which! the!challenges! they!pose!have! shaped!and!
constrained! innovation.!By!putting!trials! ‘under!the!spotlight’!so!to!speak,!this!
thesis!will!examine!the!wider!challenges!facing!the!field,!and!explore!how!trials!
could!be!used! to! overcome! rather! than!add! to! these!challenges.!The! research!










trial! activity!and!by!exploring! the!policy,! institutional!and! social! contexts! in!which!
these!trials!take!place.!This!question!is!first!addressed!in!Chapter!3,!which!explores!
the!regulatory!and!policy!environment!for!cell!therapy!trials!in!the!UK,!and!details!the!









and! the! fact! that! the!majority! of! trialling! is! actually! taking! place! in! the! academic!















both! the! policy! and! academic! literature,! and! these! commentaries! suggest! some!
specific! aspects! of! trials! that! may! be! problematic! for! cell! therapies! (such! as!
methodological!issues,!financial!constraints!and!practical!challenges).!However,!there!
is!no!detailed!analysis!of!how!these!challenges!are!experienced! in,!and!affect,! the!




crucial! factor! in! the! development! of! new! ways! of! thinking,! suggesting! that!
“understanding! the! political! and! economic! contexts! in! which! clinical! trials! are!
conducted! and! reported! should! help! identify! creative! approaches! to! knowledge!












As! I! discussed! earlier! in! this! chapter,! one! of! the! most! difficult! challenges! facing!
translational!cell!therapy!research!is!the!significant!uncertainties!that!remain!as!yet!









and! the! ways! in! which! these! uncertainties! interact! during! trials.! This! analysis!
demonstrates!that!although!clinical!trials!are!a!vital!means!of!resolving!both!scientific!
and!clinical!uncertainty,!the!linearity!of!the!trialling!process!and!the!rigidity!of!trial!






evidence! is! understood! and!mobilised! by! different! stakeholders! in! the! field.! This!
allows!us!to!widen!the!scope!of!our!inquiry,!looking!not!just!at!individual!trials!but!
also! at! how! knowledge! governance! structures,! and! in! particular! the! specific!
conceptualisation! of! evidence! promoted! by! evidenceMbased! medicine! (EBM)! and!







idea! of! the! RCT! as! the! ‘gold! standard’! for! evidence! in! healthcare! holds! up! in! the!
context!of! cell! therapy! trials.! This!discussion! suggests! that!although! the! supposed!
objectivity!of!the!method!is!valued!in!principle!by!both!trialists!and!decision!makers,!
the!complexity!of! cell! therapies! creates! significant! contingency! surrounding! trials,!
suggesting! a! flexible! and! nuanced! approach! to! evidence! is! warranted.! In! the!
concluding!chapter!of!the!thesis!I!discuss!how!this!might!be!achieved!and!make!some!





In! line! with! the! conceptual! framework! I! set! out! in! the! previous! chapter,! my!
methodological! approach! situates! trials! not! as! a! ‘gold! standard’! of! generating!
evidence!in!healthcare,!but!as!a!social!process!that!both!shapes!and!is!shaped!by!the!
dayMtoMday! work! of! scientific! and! clinical! practice.! In! the! specific! context! of! cell!
therapies,!trials!take!place!at!the!intersection!between!science!and!the!clinic!and!are!
thus!integral!to!the!process!of!‘translation’!in!bioMmedicine,!and!the!coMproduction!of!
social! order! around! this.! Following! the! coMproduction! idiom! and! the! wider! STS!
traditions! it!draws! from,!my!methodology! thus! focuses!on! the! ‘doing’!of! trials.! In!
particular! I! was! interested! in! exploring! the! various! interactions! involved! in! the!
trialling!process!M!for!instance!between!different!social!actors,!between!institutions!
and! individual! actors,! between! professions! and! academic! disciplines! and! the!







the! ontological! position! I! set! out! in! the! previous! chapter! M! not! adopting! a! purely!
realist! or! relativist! approach! to!materiality,! but! rather! looking! at! the! relationship!
between! reality! and! our! understanding! of! it.! In! order! to! do! so! I! adopt! an!
















so! in! the! context! of! (co)production.! This! approach! echoes! the! notion! of!
‘contextualism’,!which!“retains!an!interest!in!the!truth!which!constructivism!rejects,!
but! still! sees! knowledge! as! emerging! from! social! contexts! and! reflecting! the!
researcher’s!position”!(Clarke!and!Braun,!2013,!p.30).!This!epistemological!position!
underpins!my!methodological!and!analytical!approach,!which!I!set!out!below,!and!
then! informs!my! choice! and! use! of! research!methods,! which! are! detailed! in! the!
second!part!of!this!chapter.! !
2.1!Methodological!and!analytical!approach!
Three! key! considerations! influenced! my! methodological! approach.! Firstly,! the!




orientation!of! the! study!as!broadly!problemMfocussed!and! the!overarching!aim! to!
contribute! to! a! ‘serviceable’! STS.! Thirdly,! although! incorporating! interdisciplinary!





to! different! disciplinary! expectations! and! allow! for! different! ontological! and!
epistemological!perspectives!to!be!incorporated.!!
! Alexander!and!colleagues!(2008)!describe!a!number!of!reasons!for!using!a!










to! characterise! the! field! using! quantitative! methods! and! qualitative! data! from!
interviews,!and!also! to!understand! the!dayMtoMday!challenges!experienced! though!
direct!observation.!Another!secondary!benefit!of!using!mixed!methods!was!initiation,!
whereby!puzzles!that!appear!in!one!part!of!a!study!can!be!explored!in!other!parts!
using! different! methods.! In! my! case! this! was! particularly! apparent! during! the!
planning!of!my!research,!when!I!started!to!encounter!the!‘puzzle’!of!how!the!field!of!
cell! therapy! trials! is! defined! (which! I! expand! on! below! in! the! discussion! of! the!
construction! of! the! trials! dataset).! This! initial! puzzle! led! me! to! incorporate! a!
quantitative!characterisation!of!the!field!in!addition!to!the!planned!qualitative!work,!




only! one! or! the! other! (Alexander! et! al.,! 2008).! In! fact,! it! has! been! argued! that!
qualitative! and! quantitative! research! represent! fundamentally! different!
epistemological! positions,! or! different! paradigms,! and! thus! adopting! both! in! the!
same!study!cannot!be!justified!(Spicer!2018).!Others,!such!as!Bryman!(2012,!1992)!
see!them!rather!as!different!approaches!to!social!research,!associated!with!a!certain!









the! scope! of!my! qualitative! research,! and! also! provided! a! sample! frame! for! the!
interviews.! Secondly,! they! provide! complementary! strengths! in! terms! of!
understanding! both! structure! and! process.! Quantitative! analysis! is! useful! for!
describing! structural! features! and! qualitative! analysis! is! better! suited! to!
understanding! processual! features,! both! of! which! are! important! in! analysing!
concepts!such!as!style!of!practice!and!coMproduction.!Thirdly,!the!use!of!both!helps!
to! address! the! problem! of! generality,! because! the! addition! of! some!quantitative!




often! an! expectation! that! research! will! be! generalisable.! Fourthly,! qualitative!
research!helps!to!facilitate!the!interpretation!of!relationships!between!quantitative!
variables,!which!was!helpful!in!challenging!conventional!representations!of!the!field!
and! proposing! a! more! nuanced,! contextualised! understanding.! Finally,! the!




toMday! work! of! individual! trials! and! the! broader! translational! and! knowledge!
governance!frameworks!that!these!trials!are!part!of.!
! Mixed! methods! can! relate! to! either! the! methods! of! data! collection,! the!
analytical!approach,!or!both!(Alexander!et!al.,!2008,!p.218).!My!methodology!used!a!




way.! I!undertook!two!types!of!analysis:! firstly,! I!constructed!a!dataset!of!UK!trials!
which!I!analysed!quantitatively!using!descriptive!statistics;!and!secondly,!I!analysed!
the! interview! transcripts,! field! notes! and! other! documents! and! sources! using!
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qualitative! thematic! analysis.! When! such! a! mixed! methods! design! is! used! the!
different!elements! can!either!be!given!equal!weighting!or!more!emphasis! can!be!
placed!on! one!or! the! other,! so! it! is! important! to! clarify! the! relative! status!of! the!
different!methods!used!(Alexander!et!al.,!2008,!p.218).!In!keeping!with!the!fact!that!
this! study! leans! towards! constructivism,! but!with! the! aim!of! also! incorporating! a!
realist!perspective,!the!emphasis!is!on!the!qualitative!aspects!of!the!analysis!with!the!






primary! focus! of! the! thesis! I! will! explain! my! overall! approach! to! it! here,! before!
providing! more! detail! pertaining! to! specific! research! methods! in! the! relevant!
sections.! I! analysed! qualitative! data! using! thematic! analysis! (or! thematic! content!
analysis),!which!unlike!other!techniques!such!as!grounded!theory!or!Interpretative!
Phenomenological!Analysis!(IPA)!is!solely!a!method!of!data!analysis!and!is!not!linked!
to!a!particular! theoretical! approach! (Clarke!and!Braun,!2013,!p.174).!As! such! it! is!
flexible!in!terms!of!ontological!and!epistemological!positions!and!approaches!to!data!
collection,!and!was!thus!wellMsuited!to!the!needs!of!my!study.!Thematic!analysis!has!
been! criticised! for! resulting! in! purely! descriptive! accounts! of! qualitative! data,!
however!it!can!be!taken!further!to!identify!and!interrogate!underlying!themes!(Rivas!
2018),!and!this!is!the!approach!that!I!aimed!for.!The!analytical!process!is!similar!to!
other! techniques! such! as! grounded! theory! and! IPA,! but! there! are! important!
differences! between! them! which! directed! my! choice! towards! thematic! analysis.!
Firstly,!although!their!coding!processes!are!similar,!thematic!analysis!focuses!on!what!
a!phenomenon!‘looks’!like!to!the!individuals!(their!lived!experience)!whereas!IPA!is!







a! largely! problemMfocussed! interdisciplinary! study,! the! production! of! disciplineM
specific! outcomes! was! of! secondary! importance! to! my! research,! and! thus! the!
construction!of!new!theory!was!not!a!primary!goal.!Thematic!analysis!allowed!for!a!
reflexive,! contextualised! interrogation! of! underlying! themes! with! a! view! to!
understanding! the! implications! for! trial!design!and!governance,!and! thus!was! the!
technique!that!best!aligned!with!the!overall!aims!of!my!study.!
! Qualitative! thematic! analysis! can! be! undertaken! either! inductively! or!
deductively.! In! a! similar! way! to! grounded! theory,! an! inductive! thematic! analysis!
begins!with!a!very!broad!research!topic,!with!the!final!research!questions!and!themes!
suggested! empirically! from! the! data,!whereas! a!more! deductive! approach!would!
have!at!least!some!themes!suggested!before!analysis,!and!a!fully!deductive!approach!
would!have!preMspecified!research!questions,!themes!and!code!frames!(Rivas!2018).!
My!approach!was! largely! inductive,! in!that!the!key!themes!and!the!final!research!
questions!emerged!from!the!data,!because!my!primary!goal!was!to!do!justice!to!the!
perspectives!and!experiences!of!practitioners!within!the!field,!and!as!such!it!would!
not! have! been! appropriate! to! impose! my! own! theoretical! framework! from! the!
outset.!I!did,!however,!approach!the!data!with!some!preconceptions,!influenced!by!
the! conceptual! framework! I! set! out! in! the! previous! chapter! and!my! background!
reading!on!the!topic!of!regenerative!medicine!and!cell!therapy!trials.!I!thus!used!a!
number! of! ‘sensitising! concepts’! to! direct! my! analysis! of! the! data.! Sensitising!
concepts! are! used! in! qualitative! research! to! direct! the! analyst’s! attention! to!
particular! areas! of! interest,! without! the! more! structured! analytical! framework!
imposed! by! the! use! of! definitive! concepts! M! in! other! words! “whereas! definitive!
concepts!provide!prescriptions!of!what!to!see,!sensitising!concepts!merely!suggest!
directions!along!which!to!look”!(Blummer,!1999!quoted!in!Clarke!and!Braun,!2013,!
p.118).! The! sensitising! concepts! I! used! included! Jasanoff’s! (2004)! ordering!





















that! I! began! developing! thematic! codes! before! I! had! completed! data! collection.!
These! preliminary! themes! then! informed! subsequent! data! collection,!which! then!
resulted!in!further!refinements!to!the!thematic!coding!and!so!on.!!
! Throughout! my! analysis! I! attempted! to! treat! the! accounts! of! different!
participants! (such! as! scientists,! clinicians! and! trial! professionals)! in! a! symmetrical!
way,! in! that! I! didn’t! privilege! one! perspective! over! another! but! rather! looked! to!





















to! understand!why! he!might! have! this! understanding! of! the! trial! data! and! have!
expressed!it!in!the!context!of!the!point!he!was!making!in!the!interview!at!that!time,!
just!as!I!would!have!done!if!the!published!data!had!contradicted!his!account.!
Methodological! symmetry!was! particularly! relevant!when! comparing! data!
from! the! interviews! and! observations! with! documentary! sources! such! as! peerM





do!use!them!as!such! in!certain!circumstances,! for! instance!when!constructing!the!
dataset,! characterising! the! policy! and! regulatory! framework! in! Chapter! 3,! and!
reviewing! the! scientific! literature!on!MSCs! in!Chapter!6.!However,! I! also!examine!
these!documents! in!terms!of!the!particular!perspectives!or!representations!of!the!
field!that!they!put!forward,!which!are!analysed!in!a!similar!way!to!other!perspectives!










having! a! purely! qualitative! part! of! the! study! and! a! purely! qualitative! part,! or! a!
continuum! approach!where! a!moderate! approach! is! taken! to! both! and! they! are!
considered! alongside! each! other.! My! study! involved! both! two! types! of! data!
(qualitative! and! quantitative)! and! two! types! of!analysis! (descriptive! statistics! and!
qualitative! thematic! analysis).! To! some! extent! I! took! a! dualist! approach! to! their!
integration,!in!that!I!analysed!qualitative!and!quantitative!data!separately,!however!
most!aspects!of!my!approach!were!integrative,!in!line!with!the!continuum!position!I!
took! to! the! overall! study! (as! explained! in! the! previous! chapter).! Firstly,! all! the!
qualitative! data! analysis! was! undertaken! in! an! integrated! way,! using! thematic!
analysis.!Secondly,!I!approached!the!quantitative!analysis!in!a!broadly!inductive!way!
that!aligned! to! the! qualitative! thematic!analysis,!which!meant! that! I!did! not! preM
specify!all!of! the!analytical!categories!or!undertake!any!formal!hypothesis!testing,!
but! rather! used! descriptive! statistics! to! identify! and! describe! trends! in! the! data.!
Thirdly,!my!focus!throughout!was!on!identifying!and!interrogating!themes!across!the!
various! types! of! data! and! analytical! frameworks,! using! a! process! described! by!
Alexander! and! colleagues! (2008)! as! “following! a! thread”.! This! involves! emerging!
findings!in!one!set!of!data!being!identified!as!having!resonance!in!another,!leading!to!
a! thematic! thread! that! is! then!explored! in!other!data,!eventually! resulting!a!data!
‘repertoire’! which! can! then! be! interrogated! further! to! generate! an! integrated!
account! concerning! that! theme! which! is! then! linked! back! to! the! wider! research!
question.!For!instance,!in!Chapter!5!I!discuss!a!number!of!themes!that!first!emerged!
in!the!case!study!and!are!then!examined!in!the!context!of!the!interview!data,!and!the!
theme! of! heterogeneity! which! I! introduce! in! Chapter! 3! first! emerged! in! the!
quantitative! analysis! of! the! dataset! and! is! then! further! explored! through! the!
interviews.! To! facilitate! this! integration! I! present! the! various! data! and! analyses!
alongside!eachMother,!for!instance!Chapter!3!presents!descriptive!statistics!from!the!









relationship! between! knowledge! and! reality! I!was! not! entirely! unconcerned!with!
understanding!what!that!reality!might!look!like,!however!I!did!not!privilege!one!type!
of!data!or!perspective!as!being!better!able!to!represent!that!reality.!Rather,!I!treated!
them!as!providing!various! interpretations!of!the! field,!and! it! is! in!the! interactions!
between! these! various! interpretations! that! we! can! understand! how! science! and!
social!order!are!coMproduced.!The!dataset!thus!does!not!present!a!more!or!less!valid!
perspective! than! the! interviews! or! the! case! study,! but! rather! they! all! attend! to!
different! issues,! and! in! different! ways.! The! dataset! presents! a! relatively! formal,!





account! of! cell! therapy! trials! which! is! factually! informative,! empirically! rich! and!












These! three! primary! strands!of! research!were! supplemented!with! less! structured!
forms! of! observation! and! documentary! analysis.! I! attended! a! variety! of! relevant!
events,!either!as!an!attendee!or!a!presenter,!including!a!Medical!Research!Council!
training! course! on! cell! therapy! trials,! an!Arthritis! Research!UK! Tissue! Engineering!
Conference,!an!MHRA!patient! consultative! forum!and! the! final! conference!of! the!
REGenableMED!collaborative!project! (to!which!my!studentship!was! linked).! I! also!
interrogated!a!range!of!documentation,!including!policy!reports,!published!articles,!
working! papers,! presentation! slides,! trial! protocols! and!media! coverage,! some!of!
which!were! publicly! available! and! others! that! were! provided! by! interviewees! or!













overlapping! representations! of! what! constituted! regenerative! medicine! or! cell!












words! producing! what! Silverman! (2011,! p.11)! describes! as! “a! set! of! cumulative!
assumptions!based!on!the!critical!sifting!of!data”.!!











not! have! been! possible! using! a! purely! qualitative! paradigm.! However,! critics! of!
quantitative! research! argue! that! its! reductionist! approach! results! in! the!
oversimplification!of!complex!situations!(Spicer,!2018,!p.307),!and!that!it! relies!on!
the!use!of!an!adMhoc,!subjective!set!of!procedures!to!define,!count!and!analyse!its!
variables!whilst!making! claims! to! objectivity! (Silverman,! 2011,! p.13).!With! this! in!



























treatments!would!have!been!problematic! for!a!number!of! reasons.!Firstly,! it! is!




stands!now!suggests! that! the! treatment!probably!has!a!different!mode!of!action.!
Secondly,!there!was!often!very!little!information!available!about!the!mode!of!action!
of!the!treatment,!meaning!it!would!have!been!difficult!to!accurately!categorise!many!
trials.! Thirdly,! much! of! the! academic! and! policy! literature,! whilst! using! the! term!
‘regenerative!medicine’,!actually!encompasses!all!cell!therapies,!including!those!with!
a!nonMregenerative!mode!of!action!(see!for!instance!House!of!Lords,!2013).!!









leukaemia).!Using!a! list!of! trials!produced!by! the!Cell! and!Gene!Therapy!Catapult!
(CGTC,!2015)!as!a!starting!point,!I!validated!each!trial!as!fitting!my!criteria,!based!on!
the! scope!defined!above.! I! then!verified! that! the! trial!was! currently!underway!by!







This! process! resulted! in! a! set! of! data! about! the! characteristics! of! UK! cell!
therapy!trial!that!is!as!comprehensive!and!valid!as!possible,!however!there!were!a!





there! were! inconsistencies! between! data! sources,! so! there! was! an! element! of!
judgement! and! assumption! involved! in! the! data! collection.! As! this! was! only!
conducted! by! one! individual! there! was! no! opportunity! to! check! for! interMrater!
reliability!(Seale!and!Tonkiss,!2018),!although!I!have!attempted!throughout!to!be!as!






! The! dataset! is! mainly! used! to! address! my! first! research! question! by!
characterising!the!field!of!cell!therapy!trials!in!the!UK,!and!as!such!the!aims!of!the!




defined! it)! I!did!not!use! inferential! statistics,!which!would!be!used! to!explore! the!










the! inductive! analytical! framework,! and! to! enable!me! to! ‘follow! the! thread’! as! I!
described! earlier! in! this! chapter,! I! also! created! analytical! categories! based! on!
emerging!themes!M!for!instance!uncertainty!about!the!mode!of!action!of!cells!began!
to!emerge!as!an!important!concept!during!my!fieldwork,!so!I!included!this!as!one!of!
the! analytical! categories! for! the! dataset.! This! approach! created! a! detailed!
quantitative!analysis!of!the!various!contexts!and!characteristics!of!trials,!and!enabled!
comparisons! with! the! global! picture! reported! in! other! academic! studies.! It! also!





an! account! of! ‘the! field’! that! claims! to! represent! reality,! and! against!which! other!
claims! can! be! judged.! However,! the! uncertainties! and! subjectivities! involved! in!
constructing!the!dataset!that!I!discussed!earlier!suggest!that!it!is!more!appropriately!







than! representing! one! singular! reality! of! cell! therapy! trials,! then,! I! consider! the!
dataset! as! providing! one! particular! perspective! on! the! field,! and! I! focus! on!
interrogating!how! this!aligns!with!or! challenges!other!perspectives! (such!as! those!
presented! in! other!academic! literature,!assumed! in! regulation!or!put! forwards!by!
various!interviewees).!Because!of!this!I!attempt!to!draw!out!in!my!description!and!
analysis!of!the!dataset!the!provisionality!of!its!perspective!M!for!instance!earlier!in!this!













have! been! explored! to! some! extent! in! a! survey! or! standardised! interviews,! but!
qualitative!interviews!have!a!number!of!features!that!made!them!more!appropriate!
for! both! the! aims! of!my! research! and!my! epistemological! position! and! analytical!
approach.!Qualitative!interviews!promote!an!‘exploratory’!analysis!of!a!phenomenon!
rather! than! the! testing! of! hypotheses! (Jones,! 1985,! in! Seale,! 2004),! and! are! thus!
better!suited!to!an!inductive!analytical!approach.!Open!ended!and!flexible!questions!
are! also! more! likely! to! get! a! considered! response! than! closed! questions,! thus!
providing! better! access! to! interviewees! views,! interpretations! of! events,!





approaches! (Byrne!2018),!which!was! important! for!my! study!both!because!of! the!
complexity!of!the!subject!matter!and!the!multiplicity!of!perspectives!that!I!identified!
in! my! background! reading.! Perhaps! one! of! the! most! important! benefits! of! the!
qualitative! interviewing! for! my! study! is! that! the! interviewing! process! prompted!















NHS! Research! Ethics! Committee! approval! was! not! required,! although! for! those!
interviews! taking! place! on!NHS! premises! local! research! governance! approval!was!
potentially!needed.!However,! this!only!applied!to! two! interviews!as!all! the!others!















My! approach! fell! somewhere! inMbetween! the! two,! in! that! I! developed! a! broad!
discussion!guide!(detailed!in!Appendix!1),!but!I!did!not!adhere!rigidly!to!this!during!
the! interviews!but!rather! let!the! interviewee!shape!the!conversation,!only!coming!
back!to!the!discussion!guide!if!they!strayed!significantly!from!the!areas!I!wished!to!
understand.! I! also! adapted! the! discussion! guide! slightly! for! each! interview,! based!
both!on!the!specific!circumstances!of!the!particular!interviewee!and!the!themes!that!







not!possible!to!achieve! large!samples! (particularly!when!the! interviewers!are!only!
conducted!by!one!researcher),!and!as!qualitative!research!does!not!aim!for!statistical!




The!dataset! I! constructed!helped! to!define! the! scope!of! this!wider! population!by!
identifying!the!specific!trials!that!were!taking!place,!and!further!to!this!(in!line!with!
my!situating!of!trials!as!a!social!process)!I!decided!to!focus!specifically!on!individuals!















explore! the! range!of!experiences!of! participation! in! trials,!which!was! the!primary!
focus! of! this! strand! of! the! research.! I! thus! decided! to! select! a! relevant! range! of!









were! willing! to! participate.! I! also! considered! whether! data! saturation! had! been!
reached!(Silverman,!2011,!p.73),!which!was!somewhat!difficult!to!judge!because!the!































because! individuals! who! might! have! tried! and! failed! to! set! up! a! trial! are!
underrepresented.! This! is! to! some! extent! inevitable,! as! it! would! have! been! very!
difficult!to!identify!such!individuals,!however!I!attempted!to!account!for!it!as!much!
as!possible!by!speaking!to!people!from!the!CGTC!preMclinical!database!as!well!as!the!









trials! is! itself! extremely! heterogeneous! and! fragmented,! and! thus! a! more!




word! of!mouth.! I! then! emailed! these! contacts! inviting! them! to! participate! in! an!
interview,!with! a! follow!up! email! sent! two!weeks! later! to! everyone!who!had! not!
responded.!All!those!who!indicated!they!would!be!happy!to!participate!were!then!





For! interviews! conducted! by! telephone! I! obtained! email! consent! prior! to! the!
interview,!or!verbal!consent!at!the!start!of!the!call,!having!confirmed!that!they!had!
read!the!information!sheet!and!answered!any!questions!they!had.!!
In! line! with! the! recommendation! of! the! ethics! committee! and! the!
commitment! made! to! my! interviewees,! all! the! data! from! the! interviews! is!
anonymised!in!the!analysis.!This!proved!to!be!relatively!challenging,!because!the!very!






in! such! circumstances! can! be! problematic! (Saunders! et! al.,! 2015),! and! requires! a!
balance!between!providing!information!to!contextualise!the!findings!and!concealing!
it! in!order! to!protect! identities.! Saunders!et!al.!make! some!useful! suggestions! for!
mitigating!these!issues,!and!inspired!by!these!I!have!adopted!a!specific!approach!to!
the! reporting! of! my! interview! data.! To! maximise! anonymity,! I! refer! to! each!
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‘what! is! happening! here”! and! “from! who’s! point! of! view?”! The! questions! I! paid!
particular!attention!to!included!what!exactly!was!being!described,!why!is!was!being!
described!like!that,!what!meaning!the!interviewee!was!giving!to!it,!and!how!did!this!
relate! to! other! things! they! described! in! the! interview,! as! well! as! things! other!




or! doesn’t! think! is! relevant,! but! they! can! also! be! deliberate! M! a! withholding! of!





my!analysis!because! the!circumstances!were! so!specific! it!would!be! impossible! to!
ensure! he! wouldn’t! be! identified.! The! incident! did! however! point! my! attention!
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indeed! this! is! implied! in! my! use! of! data! from! the! interviews! to! construct! the!
quantitative! dataset.! In! the! qualitative! analysis,! however,! I! was! interested! in!
uncovering! the! range!of!experiences!and!perspectives!my! interviewees!described,!
rather!than!accessing!one!singular!‘truth’!about!these!experiences.!As!such!I!treat!the!
interview!more!as!a!topic!than!a!resource!(Silverman,!2011,!Rivas,!2018)!–!i.e.!I!am!





completely! authentic! accounts,! but! rather! as! a! coMconstructed! (Silverman,! 2011,!
p.181)!between!myself!and!the!interviewee,!influenced!by!a!myriad!of!known!and!
unknown! factors,! such! as! the! constraints! of! confidentiality! or! the! fact! that! the!
interview!may!have!been! the! first! time! the! interviewee! reflected!on! some!of! the!














covered;! the! impact! of! this! was! particularly! noticeable! in! this! study! because! the!
complexity! of! the! issues! being! discussed! meant! a! significant! proportion! of! the!
interview!was! often! spent! covering! only! a! small! portion! of! the! discussion! guide.!




limited! to! what! the! interviewees! were! prepared! to! share! in! a! relatively! formal!
context,! and! shaped!by! their! own! specific! preconceptions! and! concerns,! and! the!




they! think!or! feel! in! the! specific! interview!context,! then!ethnography!provides!an!
alternative! viewpoint! by! turning! the! focus! to! examining!what! people! actually! do!









most! important! insights!generated!by!STS!have!emerged! from! its! rich! tradition!of!
laboratory!ethnographies,!which!have!highlighted!how!scientific!knowledge!emerges!







undertaking! cell! therapy! trials,! with! the! intention! that! these! would! provide!
















were! located!a! long!distance!from!the!University!of!York,!so!the!amount!of!time! I!

























processing! and! scientific! research! labs,! attended! a! large! conference/meeting! the!

























I! have! still! taken! every! possible! step! to! maintain! anonymity! where! possible.! I!
therefore!will!not!identify!the!specific!trial!or!the!site!where!it!took!place,!and!will!
refer!to!it!instead!by!the!pseudonym!ENABLE.!!
! The! ENABLE! site! includes!a! clinical! team! (who!are! involved! in! surgery!and!














governance! approval! and! plan! my! visits! and! interviews.! I! then! visited! the! site!

























fieldworker’s! roles! can! provide! access! to! a!wider! range! of! information,! and! even!
secrets,! than! would! be! possible! through! complete! observational! research,! which!
would!have!had!to!be!at!entirely!publicMfacing!events!(Junker,!1960,!in!Seale,!2004),!
but!also! introduces! reporting! constraints!because!of!ethical! responsibilities! to! the!
participants! who! chose! to! ‘let! me! in’! to! their! world.! During! the! progress! of! my!
fieldwork! I!moved!more! towards! the! role! of! participant! as! observer,! as! I! become!
involved!to!some!extent!in!the!work!being!undertaken!at!the!site.!For!instance,!the!
team!tended!to!view!me!as!an!outside!expert!on!trial!design!and!were!also!aware!
that! I!was! investigating!a!number!of!other!cell! therapy!trials.!Because!of!this!they!
occasionally! asked! for! my! opinion! on! a! particular! methodological! issue,! or! for!
information!about!how!things!were!done!at!other!sites.!In!another!example,!when!






facing,! and! it! also! made!me! feel! more! comfortable! with! the! imposition! that! my!
fieldwork!must!have!placed!on!an!already!busy!department.!I!also!think!that!it!made!
the!team!more!comfortable!around!me,!and!thus!more!forthcoming!than!they!might!















2009,! p.106).!Meetings,! then,! provide! a! rare! and! possibly! unique! opportunity! to!
observe!the!knowledge!practices!at!work!in!clinical!trials,!and!are!in!themselves!an!





meetings! are! where! the! various! different! agendas! and! coalitions! involved! in! an!
organisation!come!together,!and!indeed!the!ENABLE!team!meeting!brought!together!






and! indeed!of! the! trial! itself,! it! is! useful! to! consider! their! specific! characteristics.!
Boden!distinguishes!between!large!formal!meetings,!which!are!primarily!informationM
oriented,! and! smaller! informal! meetings,! which! are! more! decisionMfocused.! The!
ENABLE!meetings!were!largely!informal,!in!that!although!they!were!scheduled!for!a!
particular! time! there!was!no! formal!agenda!or!minuteMtaking,!no!designated! time!
limit! (the!meetings!I!attended!ranged!from!30!to!90!minutes! long),!no!designated!
chairperson! and! no! restricted! or! directed! turnMtaking.! Although! there! was! some!
information! shared! at! the! meetings! (for! instance! Amy! would! normally! provide!
updated! recruitment! figures! and! Mark! would! share! information! about!
upcoming/completed!lab!inspections),!their!purpose!was!primarily!decision!making.!
Most!members!of!the!team!interacted!fairly!regularly!outside!of!the!meetings!and!
shared! trialMrelevant! information! in! various! ways,! so! the! meetings! were! an!
opportunity!to!discuss!this!information!as!a!group!and!make!decisions!that!were,!in!








involved! discussions! of! other! work! activities! not! directly! linked! to! the! trial,! and!
discussions!started!in!the!meeting!were!often!continued!in!various!groupings!after!it!
officially!ended,!and!occasionally!moved!to!other! locations!such!as! the! lab!or! the!
consultant’s!office.!!
! Given!the!importance!of!meetings!in!structuring!the!work!of!an!organisation,!















could! on! occasions! mean! only! one! of! the! team! members! and! me.! Although!
discussions!would!start!as!soon!as!there!were!two!people!in!the!room!to!talk,!this!talk!
would! be! different! depending! on! which! team! members! were! present,! and! in!
meetings!where! individuals!arrived!and!departed!at!different!times!the!discussion!
would! shift,! repeat,! expand! and! contract! depending! on! the! various! voices! and!
concerns!in!the!room.!Of!particular!note!was!the!ongoing!absence!of!the!Research!






















The! interviews! lasted! between! 30! and! 60! minutes! and! were! all! either!
arranged!in!advance!of!one!of!my!regular!visits!or!agreed!during!the!team!meetings.!
I!did!not!use!a!generic!discussion!guide!because!each!of!the!individuals!in!the!team!










meeting! to! start,! or! when! I! was! being! shown! around! parts! of! the! site.! These!
discussions!were!not!recorded!as!they!were!often!quite!ad!hoc,!and!it!would!have!
been!intrusive!to!ask!permission!to!turn!on!the!recorder.!I!also!wanted!to!preserve!













the!thread!whilst!writing!notes! it!could!take!a! long!time!to!pick! it!up!again.! I!also!





distinguishing! between! emic! observations,! which! emerge! from! the! researcher’s!

























note! taking.! I! then! analysed!my! field! notes,! along!with! trialMrelated! documents! I!
acquired!during!my!fieldwork,!using!the!same!thematic!analysis!technique!I!described!
earlier! in! this! chapter.5! These! findings! underpin! the! analysis! in! all! the! empirical!
chapters,!but!are!particularly!drawn!out!in!Chapter!5,!which!discusses!themes!relating!
to!the!challenges!of!cell!therapy!trials!that!emerged!from!case!study!and!interrogates!










agree!with!other! sources,!and!with! this! in!mind!although! I! compared! the! themes!
emerging! in! my! analytical! field! notes! to! findings! from! the! interviews! and! other!
fieldwork,! the!purpose!of! these!comparisons!was!not! to!assess! the!validity!of!my!
analysis!of!the!ENABLE!trial!as!such,!but!rather!to!understand!how!the!experiences!
and! perspectives! I! observed! there! compared! to! the!wider! field! of! cell! therapies.!





in! a! way! they! can! relate! to.! For! this! reason! I! conducted! member! validation! by!

















an! important!step! in!starting!to!reflect!on!the! implications!of!my!findings,!both! in!






field! provided! by! the! dataset,! and! the! range! of! perspectives! and! experiences!
described!in!the!interviews,!this!allows!me!to!examine!the!field!at!both!a!macro!and!











of!recent!changes!to!the! regulatory!framework!that! is! interwoven!with!data!from!
interviews! and! observations,! thereby! shedding! light! on! how! these! changes! have!
affected! the! perceptions! and! actions! of! people! working! in! the! field.! The! second!
section!of!the!chapter!details! the!characteristics!of!current!UK!trials.!This!analysis!
uses!both!quantitative!and!qualitative!data,!allowing!for!a!nuanced!analysis!that!not!
only!addresses!what! is!being!trialled!and!how,!but!also! starts! to!engage!with! the!
question!of!why(this!might!be!the!case,!and!the!implications!for!current!and!future!
innovation! in! the! field.! This! combined! approach! provides! a! ‘broadMbrush’!
understanding! of! the! UK! trials! landscape! that! is! both! informative! and! reflective,!
complementing! and! contextualising! the! more! detailed! thematic! analysis! in!
subsequent! chapters.! Before! this,! however,! I! will! present! a! short! review! of! the!
current!literature!on!regenerative!medicine!trials!globally,!demonstrating!both!how!




characteristics! of! cell! therapy! trials! currently! underway! around! the! world.! Most!
recently,!Heathmann!et!al.! (2015)! found!that!as!of! January!2014!there!were!1342!
ongoing! cell! therapy! trials! registered! on! clinicaltrials.gov! that! met! the! British!
Standards! Institute! definition! of! cell! therapies:! “a! therapy! in! which! cells! are!






‘adult’! cells,! and! neither!appear! to!have! focussed! solely!on! novel!applications.! In!















the! majority! of! trials! were! ‘regenerative’! in! nature! (suggesting! some! sort! of!
permanent! implantation).! Again,! this! difference!may! be! due! to! the! types! of! trial!
included! and/or! the!way! the! trials! were! classified.! Despite! these!methodological!
disparities,! however,! there! are! some! common! themes! that! emerge.! Firstly,! the!
majority! of! cell! trials! are! at! an! early! phase! and! are! either! publiclyMfunded! or!
sponsored!by!small!companies.!Secondly,!most!trials!are!using!relatively!established!
cell! types! (MSCs! and! HSCs)! as! opposed! to! embryonic! or! pluripotent! cells,! and!









use!adult! rather! than!embryonic! stem!cells,! and!are! in! the!early!stages!of! clinical!
investigation.”!
! Although! these! studies! provide! useful! context! in! terms! of! the! number! and!
characteristics!of!cell!therapy!trials,!there!are!also!significant!limitations!when!using!
their! findings! to! characterise! the! UK! landscape,! not! least! because! they! do! not!
specifically! focus! on! the! UK.! Furthermore,! none! of! these! studies! is! completely!
comprehensive,!as!they!all!rely!on!information!from!online!trial!registries,!which,!as!
acknowledged!by!CulmeMSeymour!et!al.,!do!not!necessarily!include!all!trials!outside!
















Human! Use! (Clinical! trials)! Regulations! 2004.! Underpinning! the! Clinical! Trials!
Directive! is! a! requirement! for!all! trials! to!be!conducted! in!accordance!with!Good!
Clinical!Practice! (GCP):! “an! international!ethical!and! scientific!quality!standard! for!




Products! (IMPs)! to! be! manufactured! to! Good! Manufacturing! Practice! (GMP)!





the! Research! Governance! Framework! for! Health! and! Social! Care! 2005,! which!

















used! in!their!original! function! (nonKhomologous(use).!There!are! four!categories!of!
ATMP:! tissue! engineered! products,! gene! therapy! products,! somatic! cell! therapy!







the! same! regulatory! framework! as! pharmaceuticals.! This! has! a! number! of!
implications,!including!the!requirement!for!marketing!authorisation!applications!to!
be!supported!by!significant!clinical!trials!data!demonstrating!safety!and!efficacy,!and!
clinical! trials! to! be! approved! and! inspected! by! the! national! competent! authority,!
which!in!the!UK!is!the!Medicines!and!Health!Research!Authority!(MHRA).!Medicinal!
products!also!must!be!manufactured!to!GMP!standards!using!appropriate!cleanMroom!
technology,! and! require! signMoff! by! a!Qualified!Person! (QP)! (AbouMElMEnein! et! al.,!
2013).!Access!to!these!treatments!is!restricted!in!the!same!way!as!pharmaceuticals,!
meaning! that! an! ATMP! must! have! marketing! authorisation! or! clinical! trial!






a! different! regulatory! regime! that! until! then! had! been! more! associated! with!
pharmaceuticals!(Faulkner,!2009).!Unsurprisingly!in!this!context,!many!interviewees!
reflected! on! how! relevant/appropriate! the!ATMP! classification! is! for! their! specific!











product.! For! instance,! Interviewee! 9! felt! that! he! had! been! caught! up! almost! by!
accident!in!regulations!primarily!aimed!at!a!different!area:!!
“I! think! the! ATMP! regulations! probably! came! in! because! of!
genetically!modified!materials!and!stem!cell!work,!neither!of!which!
ours!is!anywhere!close!to.”!(INT9)!!






injecting! bone! marrow! cells! into! hearts,! in! January! 2013! the!





expansion! of! cells! is! automatically! considered! substantial! manipulation,! other!
processes! are! less! clearMcut.! For! instance,! at! a! meeting! to! discuss! the! challenges!
associated!with!cell!processing,!there!was!a!discussion!about!the!fact!that!enzyme!
digestion! is! considered! substantial! manipulation.! One! delegate! mentioned! that!
pancreatic! islets! are! an! exception! to! this! and! was! asked! whether! there! was! any!
biological! basis! for! this! exception! (i.e.! whether! islets! had! been! shown! to! be! less!
affected! by! enzymatic! digestion).! He! replied! that! he! didn’t! think! so,! and! the!
exemption!was!more!likely!due!to!the!number!of!islet!treatments!already!being!used,!












not! consistent! throughout! the! EU.! This! has! significant! implications! for! anyone!
developing!products! for!distribution! in!Europe,!and! it!also!affects!any!clinical! trial!
taking!place!in!more!than!one!member!state.!A!number!of!interviewees!commented!
on! these! inconsistencies,! for! instance! Interviewee! 12! highlighted! the! different!
interpretations!of!nonMhomologous!use:!!
“The! definition! of! nonMhomologous! is! one! of! the! big! problems!
internationally!…!so!you’ll!have!something!that’s!nonMhomologous!
in!one!regulatory!area,!but!homologous!in!another.”!(INT12)!!







These! examples! highlight! the! complex! and! disjointed! nature! of! the! regulatory!
framework!within!which!cell!therapies!are!being!trialled,!and!we!shall!see!throughout!
this!thesis!the!difficulties!that!this!can!cause.!
! The! introduction! of! the! ATMP! regulations! significantly! increased! the!




of! cell! therapies! being! held! to! a! higher! standard! of! evidence! than! previously.!
Comments! made! about! difficulties! experienced! with! the! regulations! were! often!
3.(Cell(therapies(on(trial:(the(current(UK(landscape!
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qualified! with! an! acknowledgment! that! their! basic! principles! were! ‘right’! or!
‘reasonable’,! and! there!was!general!acceptance! that! the!process!of! proving! these!
therapies!to!be!safe!and!effective!was!both!achievable!and!desirable.!Interviewee!12!






monoclonal! antibodies! M! from! the! invention! of! monoclonal!
antibodies!through!to!the!first!licensed!medicine!was!24!years.!OK,!
within!five!years,! less!than!that,!within!three!years!of!the!ATMP!
regulation!being!published!we!have!three! licensed,! four! licensed!
medicines.”!(INT12)!!
It! seems,! then,! that! there! is! general! support! for! cell! therapies! being! subject! to!
regulation!and!oversight,!but!it!is!the!specific!nature!of!these!regulations,!and!the!
practical!impact!they!have,!that!are!often!viewed!as!problematic.!!
! The! challenges! caused! by! ATMP! classification! can! be! avoided! in! certain!
circumstances,! because! although! ATMPs! generally! require! either! a! marketing! or!
clinical!trial!authorisation,!the!legislation!allows!for!the!exemption!of!treatments!that!
are! “prepared!on!a!nonMroutine!basis!according! to! specific!quality! standards,!and!
used!within!the!same!Member!State!in!a!hospital!under!the!exclusive!professional!
responsibility!of!a!medical!practitioner,!in!order!to!comply!with!an!individual!medical!
prescription! for!a! customMmade!product! for!an! individual!patient”! (Cuende!et!al.,!



















delivery! of! cell! therapies,! because! the! use! of! the! product! is! not! restricted! to! the!
hospital!where!it!was!prepared,!and!indeed!it!makes!it!possible!to!import!and!export!
unlicensed!medicinal! products! (Cuende! et! al.,! 2014).! There! is! no! centralised! data!
available! on! the! number! or! type! of! cell! therapies! being! delivered! under! specials!
licences,!or!how!many!patients!have!been!treated.!However,!there!are!a!total!of!26!
sites!with!licences!to!manufacture!cell!therapies!for!human!use!(MHRA,!2015),!and!a!































“It’s! been! crucial! really! M! I! mean! it’s! not! the! way! to! develop! a!
product,! but! for! this! type! of! ATMP,! or! regenerative! medicine,!
activity! it’s! probably! desirable.! If! you! can,! and! you! can! do! it!
ethically,! then! it’s!desirable!because!you! learn!so!much!not!only!





























new! trials! (NHS! European! Office,! 2014).! A! number! of! interviewees! referred! to!
difficulties! caused! by! the! new! regulations! M! although! these! difficulties! generally!















happened! to! coincide! with! the! ATMP! regulations! being! introduced,! created!
uncertainty!and!confusion!that!may!have!hampered!many!cell!therapy!trials!being!set!
up!during!this!period.!
! There! is! growing! international! recognition! of! the! difficulties! associated!with!
running!clinical! trials! in!general,! and! in!particular!earlyMstage! trials,! and! the!OECD!
(2013)!argues!that!“the!need!to!reMassess!and!strengthen!the!international!clinical!
trial!paradigm!has!never!been!greater.”!Following!the!Road!Map!Initiative!for!Clinical!
Research,!which! brought! together! representatives! of! academic! and! notMforMprofit!
organisations!to!discuss!how!the!European!Trial!Directive!could!be!improved!(OECD,!
2013),! new! EU! trials! regulations!were! brought! in! in! 2014! (NHS! European!Office,!
2014).!The!new!regulations!aim!to!further!streamline!the!process!of!approval!for!new!
trials,! which! should! certainly! be! beneficial! for! cell! therapy! trials! taking! place! in!
multiple!European!countries.!The!other!improvements,!however,!including!a!lighter!
regime!for!trials!of!medicines!that!are!already!authorised!and!pose!minimal!risk,!are!
unlikely! to! be! relevant! to!many! cell! therapy! trials! in! the! short! or!medium! term.!
Furthermore,!although!streamlining!the!trial!regulations!between!EU!member!states!
will!ease!some!of!the!administrative!burden,!the!majority!of!the!concerns!raised!by!






another! important! factor! affecting! clinical! trials! in! the! UK! is! the! clinical! research!
environment.!The!UK!is!distinctive!in!having!a!National!Health!Service!that!provides!
coordinated! healthcare! services! that! are! free! at! the! point! of! use,! providing! a!
centralised! structure! within! which! to! conduct! clinical! research.! This! should!





is,! and! has! always! been,! at! the! very! heart! of! the! NHS”! (NIHR,! 2015).! This! is! the!


















“That! will! I! think! provide! us! with! a! small! amount! of! additional!
support!if!the!trial!is!adopted.!I’m!a!bit!vague!about!this!because!I!
haven’t!got!there!yet,!but! it’s!quite!a! small! amount!of! support! I!
believe.”!(INT5)!













sponsor)!was! the! only!one! to!mention! the!CRN! in! connection! to! recruitment.!He!
explained!that!one!of!his!company’s!motivations!for!opening!trial!sites!in!the!UK!was!
the!existence!of!a!diseaseMspecific!CRN!that!they!believed!would!make!recruitment!
easier.! In! reality,!however,! the!UK! sites! struggled! to! recruit! (in! some!cases!doing!
worse!than!sites!in!other!countries),!and!he!felt!that!this!might!in!part!have!been!due!
to!the!number!of!other!portfolio!studies!taking!place!at!these!sites!at!the!same!time.!
The! CRN! also! aims! to! improve! the! conduct! of! trials! through! training! and! shared!
expertise,!but!this!was!not!mentioned!by!any!interviewees,!even!when!prompted.!It!
appears,!then,!that!the!only!significant!way!in!which!the!CRN!supports!cell!therapy!
trials! is! through! the!provision!of! resources,!and! that!even! this! is!only! relevant!or!
substantial!for!a!subset!of!trials.!
3.2.2$Recent$policy$developments$








(House! of! Lords,! 2013).! Alongside! a! suggestion! that! the! clinical! trials! process! for!
regenerative! therapies! be! reviewed,! the! report! also! proposed! the! creation! of! a!
regenerative! medicine! stream! in! the! Clinical! Research! Network,! with! a! view! to!
overcoming!some!of!these!hurdles!(O'Dowd,!2013).!The!government!response!to!the!
report!did!not!action!this!recommendation,!but!instead!set!up!Regenerative!Medicine!







“The! remit! for! the!expert!groups!was! really!quite!narrow! M! they!





including! regulatory! advice,! training! and! the! provision! of! resources! to! help! with!
recruitment.!
! In!principle,! then,! it! appears! that! the!government! response! to! the!House!of!





challenges! faced! are! largely! dependent! on! the! specifics! of! the! disease,! the!
characteristics!of!the!treatment,!and!the! institutional!setting!where!the!trial! takes!
place.!Indeed,!trialists!themselves!often!don’t!associate!their!work!with!‘cell!therapy’!




asked! me! to! pick! one! of! those! labels! it! would! be! clinical!
immunologist.”!(INT5)!






my,! my! collegiality,! you! know! M! it’s! the! [physiological]! system.”!
(INT2)!













it! was! mentioned,! came! from! a! variety! of! other! sources! (including! trials! units,!
commercial!contacts!and! regulators)!rather!than! from!the!CRN.!This!suggests!that!
although! interviewees! might! have! welcomed! a! more! ‘oneMstopMshop’! service!
providing! advice! and! support! for! cell! therapy! trials,! there! is! nothing! in! their!
experiences! to! suggest! that! the! CRN! in! its! current! form! would! be! the! most!
appropriate!way!to!provide!this.!Another,!potentially!more!appropriate,!initiative!for!
providing! centralised! support! for! cell! therapy! trials! is! the! Cell! and! Gene! Therapy!
Catapult!(CGTC),!which!was!established!in!2012!(as!the!Cell!Therapy!Catapult)!with!
the! aim! of! helping! the! UK! “be! a! global! leader! in! the! development,! delivery! and!
commercialisation!of!cell!therapy”!(CGTC,!2016).!The!Catapult!supports!developers!
of! cell! therapy!products!by!providing! them!with! clinical,! technical,! regulatory!and!
business! expertise,! and! is! also! planning! to! open! its! own!manufacturing! centre! in!
2017,!which!“will!be!used!by!companies!for!the!manufacture!of!late!phase!clinical!








limit! its! utility! for! many! trials.! In! particular,! as! can! be! seen! from! the! mission!
statement!quoted!above,!its! focus! is!primarily!on!the!commercial!development!of!
cell! therapy! products,! and! in! fact!many! interviewees!working! on! publiclyMfunded!
trials!felt!that!its!activities!were!largely!irrelevant!to!them.!For!instance,!Interviewee!















perceived! to! be! irrelevant! for! many! cell! therapies! M! for! instance,! Interviewee! 2!
thought!that!it!would!never!be!practical!for!the!kind!of!therapy!he!was!developing:!!
“It! may! be! that,! you! know,! a! common! service! centre! like! the!
Catapult! will! be! right! for,! maybe! for! things! like! cardiac! where!
you’re!just!taking!the!stem!cells!and!processing!them!for!delivery!
in!a!surgical!clinic.!Certainly!for!the!sort!of!stuff!we’re!doing!in!the!














engagement!has!been! lacking!thus! far! M! for! instance,! Interviewee!10!criticised!the!
Catapult!for!not!having!shown!any!interest!in!his!experience!of!running!a!cell!therapy!
trial:!
“Nobody! from! the! Catapult! has! ever! contacted! me! …! I! think!




















iterative! phases! of! evidence! gathering! and! adaptations! of! the! marketing!
authorisation! to! expand! access! to! the! medicine! to! broader! patient! populations”!
(EMA,!2014).!According!to!Eichler!et!al.!(2015)!two!key!factors!are!driving!the!move!
to! AL:! patient! demands! for! access! to! promising! new! treatments,! and! scientific!




innovative! biomedical! treatments.! The! UK! has! been! at! the! forefront! of! these!
developments,! introducing! schemes! where,! for! instance,! the! manufacturer!
reimburses!drug!costs!if!long!term!endpoints!are!not!met,!or!for!patients!who!don’t!
respond!to!the!treatment,!as!well!as!costMlimiting!schemes!such!as!cost!discounts,!
dose! capping! and! free! first! cycles! to! limit! the! initial! outlay! on! experimental!






the! regulatory!environment.!However,! it! is!notable! that! the!only! interviewee!who!
made!any!reference!to!either!AL!or!RMS!was!a!commercial!cell!therapy!developer,!
indicating! perhaps! yet! another! area! of! policy! that! is!more! aligned! to! commercial!
innovation!than!academic!or!clinical!development.!A!lack!of!commercial!motivation!
or! awareness! amongst! many! trialists! could! mean! they! have! limited! interest! in!
exploring!new!approaches!to!licensing!and!reimbursement,!or!don’t!feel!that!these!
would!be!relevant!to!their!situation.!!
! It! may! be! that! AL! and! RMS! are! most! relevant! to! commercial! cell! therapy!










hundreds! of! thousands! of! pounds.! So! it!might! look! great! to! get!
there!quickly,!but!then!we!might!be!condemning!ourselves!to!any!
iterations! are! going! to! cost! us! a! fortune.! So! as! noMone’s! been!
through!it!yet!we!don’t!know!how!it!will!work.”!(INT17)!!
























basic! preMclinical! research,! with! only! 7%! spent! on! clinical! trials! (Field! notes!
01/05/2014).! Research! council! spending! is! particularly! pertinent! because! the!















“We! had! to! set! everything! up! sort! of! from! scratch! to! be! quite!
honest.”!(INT10)!!
The!absence!of!other!trials!to!learn!from!can!thus!in!itself!be!a!barrier!to!more!trials!
being!conducted,!and! this! is! further! compounded!by! the! fact! that!many! trials!are!
sponsored! by! academic! institutions! that! have! little! experience! in! the! area,! as!
explained!by!Interviewee!2:!!
“And! they! are! largely! academicMled,! the! sponsors! tend! to! be!





trials! in!academic! settings,! in!Chapters!4!and!5,!which!examine! the! ‘doing’!of! cell!
therapy!trials!in!practice.!Before!that,!however,!the!rest!of!this!chapter!will!present!a!











in! the! context! of! the! four! cell! therapy! products! that! have! gained! marketing!


















Number! %! Number! %!
Cancer! 12! 27%! 211! 16%!
Neurological!disease! 8! 18%! 220! 17%!
Cardiovascular!disease! 5! 11%! 349! 27%!
Gastrointestinal!disease! 5! 11%! 120! 9%!
Eye!disease! 3! 7%! 56! 4%!
Other! 2! 5%! 20! 2%!
Immunodeficiency! 2! 5%! 20! 2%!
Cartilage!disease! 2! 5%! 124! 10%!
Liver!disease! 1! 2%! 81! 6%!
Bone!condition! 1! 2%! 60! 5%!
Systemic!rheumatological!disease! 1! 2%! 12! 1%!
Skin!condition! 1! 2%! 10! 1%!
Kidney!condition! 1! 2%! 12! 1%!
Diabetes! 0! 0%! 0! 0%!
Organ!transplantMassociated! 0! 0%! 0! 0%!
Lung!disease! 0! 0%! 0! 0%!
TOTAL! 44! 100%! 1295! 100%!
!
! The!dominance!of!cancer!trials!can!be!linked!to!a!number!of!factors,!including!













all! clinical! areas,! so! learnings! from!early! cancer! trials! can!be!applied! to!other! cell!
therapy! trials! in! the! future.! Likewise,! success! in! one! clinical! area! may! generate!
enthusiasm,!and!possibly!funding,!in!other!areas,!as!suggested!by!Interviewee!9:!!




























attractive! for! cell! therapy! development,!which! is! the! ease! of! delivering! the! cells.!
Although!the!risk!and!simplicity!of!the!procedure!are!clearly!important,!however,!they!
are! not! decisive,! as! there! are! a! number! of! trials! being! undertaken! that! involve!
relatively! highMrisk! procedures,! such! as! injecting! cells! into! the! brain.! Another!




which! is!what! they’re! already! doing! in! terms! of! transplants! and!
such!like.”!(INT9)!
!“Chondrocyte!transplant!M!so!moving!bone!round!the!body!using!






adopting! the! code! frame! used! by! Li! et! al.),! and! shows! that! hematopoietic! and!
mesenchymal!cells!account!for!three!quarters!of!all!treatments!being!tested.!Notably,!
only!4! (9%)!of!the!trials!in!the!dataset!involved!embryonic!cells,!all!of!which!were!
commercial! trials.! These! findings! are! in! line! with! Li! et! al.,! who! found! that!
hematopoietic!and!mesenchymal!cells!represent!80%!of!global!trials.!However,!their!
research! suggested! an! even! split! between! the! two! cell! types,!whereas! in! the!UK!















































No.! %! No.! %! No.! %!
Product! 19! 61%! 6! 46%! 25! 57%!
Procedure! 12! 39%! 7! 54%! 19! 43%!
TOTAL! 31! 100%! 13! 100%! 44! 100%!
!
IndustryMled! 6! 19%! 6! 46%! 12! 27%!
ClinicianMled! 25! 81%! 7! 54%! 32! 73%!




! There! is! a! variety! of! allogeneic! cell! types! being! used,! including! TMcells! (four!





delivery.!Allogeneic!MSCs,! for! instance,!appear! to!be! fairly! straightforward! from!a!
regulatory! perspective,! despite! being!multipotent! and! classified! as! ATMPs.!When!
















in! the!way! that! interviewees! described! their! cells,! and! in! particular! the! extent! to!
which! they! associated! their! treatment!with! the! term! ‘stem! cell’.! Some!were! very!
specific!that!the!treatment!was!a!stem!cell!treatment;!for!instance,!when!asked!about!
the! type! of! treatment,! Interviewee! 3! said:! “yes,( a( stem( cell( transplant.”(Others,!
however,!were!keen!to!distance!themselves!from!the!term:!(











and! great! hope! that! that! would! be! a! very! new! exciting! sort! of!



































concern! that! this!may! become! problematic! in! the! future,! because! regulators! will!
probably! begin! to! ask! for! more! detail! about! the! exact! characteristics! of! the! cell!
population.!A!number!of!interviewees!also!noted!that!using!a!more!homogenous!cell!






















in! the! practicality! of! a! cell! therapy.! Following! Foley! and! Whitaker’s! model! of!
classification,!Table!3.5!details!the!breakdown!of!‘products’!and!‘procedures’!being!
tested! in! UK! cell! therapy! trials,! showing! a! relatively! even! split! between! the! two!
















No.! %! No.! %! No.! %!
Product! 7! 58%! 18! 56%! 25! 57%!
Procedure! 5! 42%! 14! 44%! 19! 43%!





therapies! involve!complicated!procedures! for! cell!harvesting,! even! if! the! resulting!
treatment!can!be!administered!as!a!product.!18!of!the!25!UK!trials!categorised!as!
products! required! relatively! complex! procedures! for! harvesting! the! cells.! The!











to!do! it,!but! they!take!blood! from!normal!healthy!donors! M! they!
don’t!take!blood!from!patients.!If!you’re!going!to!put!a!needle!in!a!
patient!you’ve!got!to!be!CQC’d,!so!that’s!a!hospital.!So!you!can’t,!
through! a! regulatory! cock! up! you’ve! effectively! made! a! trial!
completely!impossible!in!this!country.”!(INT12)!
This! additional! complexity! is! introduced! because! autologous! cell! therapies! are!
distinctive!in!that!they! involve!both!surgical!procedures!and!the!manufacture!of!a!
medicine,!as!Interviewee!12!went!on!to!explain:!(
“Because! many! many! many! of! these! products! require! material!







! Allogeneic! treatments! are! often! perceived! to! be! a! more! viable! option! for!
commercial!development,!in!part!because!they!often!involve!a!simpler!mode!of!cell!







































regenerative! aim.! These!methodological! differences!make! it! difficult! to! judge! the!
extent!to!which!the!UK!differs!from!the!global!picture!in!terms!of!the!types!of!cell!





Cell! Therapy! (cell! therapy! for! purposes! other! than! regeneration,! e.g.!
immunomodulation)!! 11! 25%!




! These! results! indicate! that! rather! than! being! largely! synonymous! with!
regenerative!medicine,! cell! therapy! trials! in! the!UK! are! actually! quite! evenly! split!
between!those!that!aim!to!regenerate!tissue,!those!that!aim!to!utilise!or!boost!the!







interviewees! distinguished! their! work! from! regenerative! medicine! by! specifically!
using!other!terms!to!describe!it,!for!instance!Interviewee!9!described!the!therapy!as!





“We! don’t! believe! they’re! regenerative! in! nature! M! we’re! not!
regenerating! [cell! type]! that! have! been! damaged! from! the!
[disease].!The!cells!may!have!properties!to!help!a!person!mobilise!
their! own! endogenous! stem! cells,! but! we! think! the! cells! go! in!
basically!and!kind!of!quiet!or!call!time!out!on!the!immune,!hyperM
immune! and! hyperMinflammatory! response! that! happens! after!
[acute!clinical!event].”!(INT11)!
Clearly,!then,!not!all!cell!therapy!trialists!relate!to!the!concept!of!regeneration!overall,!




offer! the! potential! to! ‘cure’! a! patient,! rather! than! simply! providing! incremental!
benefits! over! and! above! existing! treatments.! Much! of! the! hype! about! stem! cell!
treatments!and!regenerative!medicines!suggests!that!they!have!the!potential!to!cure!
debilitating! diseases! such! as! diabetes,!multiple! sclerosis! and! Alzheimer’s! disease,!
offering! a! revolutionary! alternative! to! currently! available! drug! treatments.! Many!








These! findings! suggest! that! there! is! a! significant! disconnect! between! popular!
understandings! of! regenerative!medicine! and! the!majority! of! treatments! that! are!
actually!being!trialled!in!the!clinic.!!

















Table! 3.7! (overleaf)! details! the! breakdown!of!UK! cell! therapy! trials! by! phase! and!
primary! outcome! measure,! which! are! indications! of! how! far! the! trialling! has!
advanced.!The!majority!of!trials!are!earlyMphase,!with!over!half!at!either!Phase!1!or!
transitional!Phase!1/2,!and!there!are!only!two!treatments!have!advanced!as!far!as!
Phase! 3! trials.! Both! of! these! trials! M! ASTIC! (Crohn's! disease)! and! BAMI! (acute!






Efficacy! Safety! Safety!and!Efficacy! Total!
No.! %! No.! %! No.! %! No.! %!
Phase!1! 1! 6%! 7! 39%! 4! 44%! 12! 27%!
Phase!1/2! 3! 18%! 7! 39%! 4! 44%! 14! 32%!
Phase!2! 11! 65%! 4! 22%! 1! 11%! 16! 36%!
Phase!3! 2! 12%! 0! 0%! 0! 0%! 2! 5%!








that! the! cell! therapies! being! trialled! in! the! UK,! particularly! those! that! could! be!
considered!regenerative!in!nature,!are!at!a!very!early!stage!of!development.!It!is!likely!
that,!like!the!majority!of!earlyMphase!drug!trials,!many!of!these!treatments!will!fail!to!
show! a! significant! treatment! effect! in! later! confirmatory! trials.! Interviewee! 5!
highlighted!this!issue!by!comparing!the!situation!to!other!earlyMphase!cancer!trials:!!
“[Name!of! cancer! trials!manager]!will! tell! you,!a!new!agent! in!a!
Phase!1!M!if!you!get!a!10%!response!rate!that’s!probably!as!good!as!
it!gets.”!(INT5)!!























that! is! supported! by! data! from! the! interviews.! Interviewee! 17! explained! that! the!
traditional!terminology!for!trials!didn’t!fit!with!how!he!perceived!the!process!for!his!
treatment:!!
“I! think!even! just!the!way!of!calling!things!Phase!1,!2,!3!and!4! is!




trial! or! a! clinical! trial.! But! it! will! only! be! 50! patients! probably.”!
(INT17)!!








“One! of! the! problems!with! these! types! of! trials! M! especially! for!
invasive!therapy!where!you’re!sticking!things!in!people’s!brains!M!!
you!may!say,!well!in!order!to!get!an!effect!you!know!you!need!80!

















In! contrast,! other! interviewees! were! keen! to! follow! the! ‘best! practice’! pathway!
established!by!drug! trials,!but! they!experienced!difficulties!using! traditional!doseM
escalating!methods!for!cellular!treatments:!!
“The! general! aim! of! any! firstMinMman! clinical! trial! is! going! to! be!
about!safety!really.!Determining!the!safety!of!your!new!agent!and!












































He!went!on! to! suggest! that,! from!a! trials!perspective,! tissue!engineered!products!
have!more!in!common!with!surgical!procedures!than!drugs:!!
“Many!of! these! tissue!engineered!products!probably!won’t!ever!




















No.! %! No.! %!
Phase!1! 3! 25%! 0! 0%!
Phase!1/2! 2! 14%! 2! 14%!
Phase!2! 10! 63%! 8! 50%!
Phase!3! 2! 100%! 0! 0%!

































necessary,! which! is! a! separate! question! in! itself,! secondly! it’s!
putting!the!patients!through!quite!a!lot,!so!they!have!to!have!a!little!
hole! drilled! through! their! skull,! they! have! to! be! put! on!
immunotherapy!in!order!to!control!for!that!so!that!carries!with!it!a!
risk!…!and!the!other!issue!is,!you!know,!is!it!a!good!use!of!medical!




likely! to! be! problematic! for! many! tissue! engineered! products,! and/or! those! that!
involve!complex!or!invasive!surgical!procedures.!
! Other! than! randomisation! and! blinding,! sample! size! is! perhaps! the! most!









One!arm! Two!arms! Three!arms! Four!arms! TOTAL!
No.! %! No.! %! No.! %! No.! %! No! %!
≤!10! 9! 38%! ! 0%! 0! 0%! 0! 0%! 9! 20%!
11M50! 14! 58%! 10! 67%! 0! 0%! 0! 0%! 24! 55%!
51M100! 1! 4%! 3! 20%! 1! 25%! 0! 0%! 5! 11%!
101M1000! 0! 0%! 1! 7%! 3! 75%! 1! 100%! 5! 11%!
≥!1001! 0! 0%! 1! 7%! 0! 0%! 0! 0%! 1! 2%!





adaptive! statistical!methods,!such!as! sample!size! reMestimation!or! ‘drop! the! loser’!
designs.!This!may!be!partly!due!to!a!lack!of!awareness!on!the!part!of!the!individuals!
designing!the!trials,!as!many!of!my!interviewees!had!no!or!very!little!knowledge!of!
adaptive! statistical! designs.! However,! even! those! interviewees!who!were! familiar!
with!adaptive!methods!felt!that!they!would!be!problematic!for!cell!therapy!trials.!For!
instance,!Interviewee!17!explained!that!they!had!considered!adaptive!methods!for!
their! Phase! 1! study,! but! had! been! put! off! by! the! need! for! existing! data! on! likely!
outcomes,!the!need!to!specify!in!advance!what!might!be!changed,!the!need!to!have!


















trials! experience! (discussed! further! in! Chapter! 4).! The! design! also! offers! some!
benefits!in!terms!of!the!evidence!generated,!as!highlighted!by!Interviewee!4:!!
“Some!people!think!that’s!a!slightly!unorthodox!approach.!I!think!
that!on! the!whole! it’s! yielded,!and! is!yielding,!more! information!
than!would!otherwise!be!the!case.”!(INT4)!!
This!suggests!that!crossMover!designs!allow!trialists!to!generate!useful!information!for!
the! continued! development! of! a! therapy,! as! well! as! the! more! formal! evidence!
required!by!regulators!M!a!theme!that!I!will!return!to!in!Chapter!6.!Is!also!interesting!





The!most! striking! aspect! of! the!UK! cell! therapy! trials! landscape! described! in! this!
chapter!is!its!fragmentation.!Trials!activity!is!split!between!immunotherapies,!cellular!
therapies!and!regenerative!medicines!(which!account!for!only!a!third!of!all!trials),!and!
there! are! marked! differences! between! trials! in! terms! of! the! procedures! used! to!
harvest! and! deliver! the! cells.! The! interview! data! indicates! a! range! of! differing!














This! heterogeneity! is! an! important! factor! to! consider! when! analysing! the! field,!
because!the!specific!characteristics!of!a!cell!therapy!have!considerable!implications!





it! is! clearly! not! valid! to! use! the! terms! ‘regenerative!medicine’! and! ‘cell! therapy’!
interchangeably:! regenerative!medicine!accounts! for!only!a! subset!of! cell! therapy!
trials,! and!many! cell! therapy! trialists! actively! distance! themselves! from! the! term.!
Likewise,!the!term!‘stem!cell’!is!highly!problematic!scientifically,!and!is!either!actively!
rejected!or!deemed!of!limited!relevance!by!many!trialists!of!cell!therapies.!Despite!

























complex! clinical! procedures,! whereas! clinicians! are! leading! some! of! the! more!
straightforward!‘cellsMasMdrugs’!trials.!It!is!also!notable!that!a!significant!minority!of!
current! trials! are! taking! place! in! clinical! areas! that! are! considered! particularly!
challenging!for!regenerative!medicine,!and!the!clinical!areas!with!the!highest!trials!
activity!do!not!align!with!the!products!that!have!been! licensed!so!far.!All!of! these!




! The! fragmented!nature!of!cell! therapy!trials! is!also!reflected! in!a!number!of!
tensions!within!the!policy!framework!and!clinical!research!environment.!Notably,!the!
majority! of! trialists! align! themselves! more! with! their! clinical! area! than! with!
‘regenerative!medicine’!or!‘cell!therapies’,!suggesting!that!cell!therapy!trialling!is!not!














realities! of! the! trials! taking! place! in! this! country.! The! regulatory! environment,!
however,!is!largely!dictated!by!EU!legislation,!and!until!very!recently!this!meant!that!
any!changes!would!have!to!come!at!a!European!level!(Hitchcock,!2013).!This!situation!
has! potentially! changed,! however,! in! the! light! of! the! 2016! referendum! result,8!
because!if!the!UK!leaves!the!EU!it!could,!in!theory,!change!the!legislation!governing!
both!cell!therapies!and!clinical!trials.!The!EU!Clinical!Trials!Directive!has!already!been!






! Although! leaving! the! EU! presents! an! opportunity! to! address! some! of! the!
limitations!of! the!current! framework,!my! findings! suggest! that! the!UK!adopting!a!
differential!approach!to!cell!therapy!trials!could!be!problematic,!not!least!because!
the! lack! of! harmonisation! between! member! states! already! creates! significant!
challenges!for!trialists.!Adopting!a!different!regulatory!framework!to!the!EU!might!
also! only! have! limited! benefits,! because! very! few! interviewees! described!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!




















clinical! research:! clinicians,! companies! and! patients.! With! its! focus! on! the!
perspectives!and!actions!of!different!actors!within!the!field,!this!provides!a!useful!
framework! for! examining! the! social! dynamics! of! UK! cell! therapy! trials,! and! for!
exploring!the!contingencies!and!provisionality!that!these!dynamics!create.! I!begin!






organisations.!Regardless!of!who!sponsors!or! funds!a!trial,!however,! the! research!
itself!generally!takes!place!in!a!clinical!setting,!with!clinical!staff!undertaking!the!dayM
toMday! tasks! involved! in! recruiting! patients,! administering! the! treatment! and!
collecting!data.9!The!conduct!of!a!trial!therefore!creates!two!distinct!relationships!in!
the! clinic:! that! of! clinicianMpatient! and! that! of! researcherMsubject.! The! clinician! is!
thereby!acting!as!both!caregiver!and!researcher,!and!to!some!extent!these!two!roles!
can! appear! incompatible,! because! the! objectives! and! requirements! of! providing!
treatment!differ!significantly! from!those!of!conducting!research!(Lidz!et!al.,!2004;!
Easter,!2006).!A!number!of!studies!have!shown!that!doctors!experience!trials!as!a!
challenge! to! their! core! task! of! providing! care! (Taylor,! 1992;! Mueller,! 1997).! For!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
9! Clinical! staff! would! include! doctors,! research! nurses! or! other! clinically! trained! staff! such! as!




















trial! arms! would! be! more! beneficial! than! the! other.! Randomisation,! in! these!









they! perceive! to! be! most! appropriate,! for! instance! steaming! open! sealed!
randomisation!envelopes,!breaking!into!locked!offices!and!filing!cabinets,!or!keeping!







famous! examples,! nurses! conducting! a! trial! testing! the! provision! of! oxygen! to!
premature!babies!were! found!to!have!given!oxygen!to!the!control!group!at!night!















participants! as! research! subjects,! whereas! nurses! conceived! of! them! as! patientM
volunteers! in!need!of!treatment,!and!the!balance!between!these!two!perceptions!
was!constantly!in!flux!during!the!conduct!of!the!trial!(Mueller,!1997).!Participation!in!
clinical! trials! thus!clearly!challenges!the!traditional!role!of! clinicians!as!caregivers,!




patients!and! research! subjects.! The! recruitment! of!patients! is! a! crucial! and!often!
problematic! aspect! of! any! clinical! trial,! particularly! Phase! 3! trials! that! need! large!
samples! to! achieve! statistical! power.! Policy! initiatives! often! seek! to! facilitate!
recruitment!by!framing!trial!participation!as!a!“scarce!social!good!that!needs!to!be!














underestimate! the! risks! of! participating! in! medical! research! (Lidz! et! al.,! 2004).!
Crucially,! many! participants! do! not! understand! the! difference! between! research!






that! this! was! really! how! their! treatment! was! allocated,! feeling! that! it! was! too!
‘haphazard’,!and!at!odds!with!the!amount!of! information!they!had!been!asked!to!




! The!difficulties! that!patients!have! in!making!sense!of! their!participation! in!
clinical!trials!mirror!those!of!clinicians,!further!highlighting!the!ways!in!which!trials!
challenge! traditional! concepts! of! care,! and! fundamentally! alter! the! relationship!
between! clinician! and! patient.! In! this! context,! presenting! trial! participation! as! a!
‘scarce! social! good’! may! undermine! informed! consent! by! exacerbating! existing!
misconceptions.! This! is! particularly! pertinent! to! early! trials! of! experimental!
4.(Clinicians,(companies(and(patients:((the(social(world(of(the(RCT!
134!
treatments,!which!are! solely!designed! to! test! toxicity!and!are! therefore!not!even!
intended! to!provide!any! significant!medical!benefit! to!participants.!Despite! these!








trials,! there! is! a! growing! number! of! examples! of! patients! engaging! in! the! clinical!
research! agenda! for! their! collective! benefit,! a! process! that! has! been! termed!








and! received! a! place! as! participants! at! the! clinical! research! table”! (Keating! and!
Cambrosio,!2007).!These!examples!highlight!the!ways!in!which!patients!have!made!
themselves! “part! and! parcel! of! the! networks! of! expertise! on! their! conditions”!
(Rabeharisoa!et!al.,! 2014).!No! longer!viewed!merely!as!passive! research! subjects,!

















2008;!Will,! 2010).! Various!attempts!have!been!made! to!address! these! issues;! for!
instance,! the! CONSORT! statement! aims! to! improve! reporting! standards,! and!
compulsory!trial!registration!aims!to!reduce!publication!bias.!There!are!still!concerns,!
however,! that! the! validity! of! clinical! research! is! undermined! by! the! influence! of!






commercial! trials! is! generally! carried!out!and! published!by!academic! researchers,!
who! in! principle! have! no! interest! in! presenting!a! biased! view!of! the! results.! It! is!
therefore! necessary! to! consider! the! relationship! between! the! researchers!
themselves!and!the!companies!sponsoring!the!research,!and!how!this!could!affect!





more! behavioural! terms,! arguing! that! “sponsorship! …! creates! subtle! influences!
through!the!building!of!relationships!that!lead!researchers!to!see!the!pharmaceutical!
companies!with!which!they!interact,!and!their!products,!in!a!more!favourable!light!







This! brief! review!of! the! sociological! literature! demonstrates! that! far! from!
being! the!neutral! tools!of!EBM!rhetoric,!RCTs!are! in! fact! complex!and! fluid! social!
processes!that!introduce!new!and!shifting!dynamics!between!patients,!clinicians!and!
companies.!Clinicians!must!reconcile!their!conflicting!roles!as!caregiver,!researcher!





greater! transparency! with! the! need! to! restrict! access! to! commerciallyMsensitive!
information.!In!the!rest!of!this!chapter!I!will!examine!how!these!social!dynamics!play!
out!in!UK!cell!therapy!trials,!using!the!framework!provided!by!the!existing!literature!
as! a! starting! point.! This! framework! has! certain! gaps,! however,! that! I! intend! to!
address.!Firstly,!much!of!the!existing!literature!looks!at!nonMUK!trials,!often!focussing!
either! on! the! US,! which! has! a! very! different! healthcare! system,! or! developing!
countries,! where! trials! have! very! different! social! dynamics! and! ethical!
















trials! of! its! hESCMderived! treatments.! Thus,! almost! all! cell! therapy! trials! could! be!
described! as! ‘investigatorMled’,! in! that! the! treatment! is! being! developed! by! or! in!
collaboration!with!the!clinicians!involved! in!the!trial.!This!contrasts!with!the!usual!
model!for!drug!trials,!which!tends!to!involve!a!new!drug!being!developed!by!internal!
research! teams! at! a! pharmaceutical! company,! which! then! searches! for! suitable!
clinical!sites!for!trials!M!a!more!‘arm’s!length’!approach!that!was!only!apparent!in!one!
of!the!trials!I!reviewed!during!my!fieldwork.!There!are!two!main!factors!raised!in!the!





clinical! complexity! necessitates! close! cooperation! with! clinicians! to! ensure! the!
treatments!are!workable!in!a!clinical!setting.!For!both!of!these!reasons,!then,!it! is!
perhaps!unsurprising!that!cell!therapies!being!trialled!in!the!UK!are!generally!being!
developed! by! publiclyMfunded,! clinicallyMled! teams.! In! addition! to! these! reasons!
indicated!by!the!existing!literature,!however,!my!findings!suggest!that!there!are!also!
other! factors! that! tend! to! favour! investigatorMled! trials,! and! that! this! has! both!
practical!and!sociological!implications!for!the!field.!
4.2.1$Practical$implications$of$investigator0led$innovation$




















or! three! people!working! together!who! formed! this! core! driving! force! behind! the!
development!of!a! therapy.! For! instance,! Interviewee!2! (a! scientist)!described! the!
longMterm!partnership!between!himself!and!a!clinical!colleague!as!a!crucial!factor!in!
the!ongoing!development!of!the!treatment,!and!my!observations!at!the!ENABLE!trial!
site! suggested! that! the! success! of! that! unit! was! made! possible! by! longMterm!
collaboration!between!three! individuals! (a!clinician,!a!research!scientist!and!a!cell!
manufacturer).!These!individuals,!or!small!teams,!have!a!resilience!that!helps!them!
to! survive! and! move! forwards! in! what! is! often! challenging! terrain,! a! struggle!
exemplified!by!the!emotive!way!that!Interviewee!13!described!his!experience!over!
the!years:!!
“It’s!a! struggle! to! survive,!but!we’re!used! to! it.! I’ve! lived!on! the!
battlefront!for!I!don’t!know!how!many!years.”!(INT13)!
It! may! be! that! an! investigatorMled! innovation! model,! linked! to! the! careers! of!
individual!or! small! teams!of! clinicians!and!academics,!may!be!more! suited! to! this!



















The! importance! of! trials! expertise! is! highlighted! by! the! contrasting! views! of!





















locus!for!the! longMterm!development!of!cell! therapies,! they!are!also!not!generally!
wellMequipped! to! undertake! the! clinical! testing! that! is! such! a! crucial! step! in! the!
innovation!process.!
4.2.2$Reconceptualising$research$vs.$care$
As! well! as! the! practical! problems! created! by! clinicalMacademic! departments!





usual! role! as! a! caregiver,! and! drug! trials! generally! involve! clinicians! trialling!
treatments!that!they!themselves!have!not!developed,!and!that!may!in!fact!be!at!odds!
with! established! forms! of! care! that! they! strongly! believe! in.! Cell! therapy! trials,!
however,!are!very!different,!in!that!they!are!predominantly!undertaken!by!clinicians!
who!have!a!close!relationship!with!the!treatment!being!developed,!indeed!they!may!
have! dedicated! a! significant! part! of! their! career! to! the! research.! Furthermore,!
although! the! treatments! being! trialled! are! often! very! experimental,! and! little! is!
known! about! their! likely! efficacy! or! side! effects,! they! are! also! often! the! only!
treatment!option!for!very!sick!patients.!Thus,!the!research!vs.!care!dynamic!in!cell!




! My! findings! suggest! that! when! investigators! are! professionally! (and! even!




might! for! a! commerciallyMsponsored! drug! study.! This! was! particularly! noticeable!
during!my!observations! of! ENABLE!meetings,!where! it! became! apparent! that! the!
whole! team!made!a! considerable!effort! to!ensure! the! trial!protocol!was! followed!
correctly.!To!give!one!example,!Mr.!Hamilton!was!very!careful! to!avoid!being!‘unM
blinded’! by! inadvertently! finding! out! which! patient! had! been! given! a! particular!
treatment!(Field!notes!18/12/14).!This!required!active!effort!on!his!part,!because!he!
needed! to! avoid! seeing! identifying! information! on! the! videos! taken! during! the!
surgery! and! the! scans! and! histology! results.! It! also! relied! to! some! extent! on! his!
‘forgetfulness’,!because!the!procedure!for!harvesting!the!cells!was!slightly!different!











This!was! evident! in! the!way! they! discussed! the! likely! outcome!of! the! trial,! using!
phrases! such! as! ‘if! it! turns! out! [treatment! type]! works! better’,! and! also! in! their!





however,! that! the! ENABLE! trial! was! testing! three! different! versions! of! one! cell!
therapy,!and!as!such!could!be!seen!as!merely!refining!the!treatment!the!team!already!
believed!in.!Their!perspective!might!thus!have!been!different!if!‘their’!cell!therapy!























to!patients!outside!of!a! trial,! either!because! they!are!unlicensed!or!because! they!
would!not!be!funded!by!the!NHS!other!than!through!a!clinical!trial.!Cell!therapy!trial!
participants! are! always! patients,! rather! than! healthy! volunteers! (of! which! more!
















tourism! (Field! notes! 01/05/2015).! In! this! context,! then,! it! is! unsurprising! that!
clinicians! involved! in! cell! therapy! trials! do! not! appear! to! experience! a! significant!
conflict!between!conducting!research!and!caring!for!their!patients,!because!to!a!large!
extent!the!research!is!actually!facilitating!or!enabling!that!care.!








as! Mr.! Hamilton’s! desire! to! remain! blinded! demonstrates).! Furthermore,! many!
academic!careers!are!bound!up!in!the!treatments!being!trialled,!and!although!most!
do!not!have!a!commercial!aim,!they!do!need!to! secure!further! funding,!or!simply!
justify! the! commissioning! of! the! treatment! that! they! want! to! provide! to! their!
patients.!Again,!this!creates!a!potential!motivation!for!trials!to!be!manipulated,!either!





not! the!only!way! to! interpret! the! trial! results,! and!has!obvious! similarities! to! the!
examples!in!the!literature!of!pharmaceutical!companies!attempting!to!bury!or!‘spin’!






and! subversion! in! trials,! it! also! does! not! entirely! remove! the! conflict! between!
research!and!care.!Although!my!findings!clearly!suggest!that!the!research!vs.!care!






more!convenient! for! the! patient! (giving!them!more! flexibility!over!when! to! come!
back!to!the!hospital),!but!a!shorter!window!would!be!better!for!the!research!(giving!
more! precision! to! the! findings).! In! another! example,! the! team! spent! a! long! time!





treat( the( patient( appropriately”( (Field! notes! 16/07/15).! Although! this! kind! of!
dilemma!is!not!unique!to!cell!therapies,!it!is!pertinent!that!many!cell!therapy!trials!
require! the! patient! to! go! through! inconvenient! or! invasive! procedures,! such! as!
biopsies!or!scans,!in!order!to!measure!outcomes.!The!treatments!themselves!can!also!

















care,! thus! to! some! extent! reconciling! the! conflict! inherent! in! their! dual! roles! as!












trials,!we! cannot! only! consider! the! perspectives! of! the! clinicians! undertaking! the!
research! and! providing! the! care,! we!must! also! consider! the! experience! of! those!
participating!in!the!research!and!receiving!the!care.!As!discussed!in!Chapter!3,!all!the!
trials! currently!underway! in! the!UK! involve!patients,!despite!many!being!Phase!1!
trials!that!usually!involve!healthy!volunteers.!This!is!partly!because!these!treatments!
are! so! experimental,! meaning! there! would! be! serious! ethical! concerns! about!
administering!them!to!healthy!individuals!who!have!no!possibility!of!benefitting!from!
them.!There!is!also!the!issue!that!many!of!these!treatments!are!produced!to!target!a!
specific! problem! in! a! specific! patient! (such! as! TMcell! therapies! that! are! primed! to!







harvesting!or!delivering! the!cells,!which!would! raise!ethical! concerns!about!using!
healthy!volunteers!in!trials,!to!say!nothing!of!the!likely!difficulties!of!recruiting!them.!!
! Unsurprisingly,!none!of!the!interviewees!mentioned!the!possibility!of!using!




Furthermore,! not! only! are! participants! in! cell! therapy! trials! patients! rather! than!
volunteers,! they! tend! to! be! the! poorliest! patients! M! i.e.! those! with! the! poorest!



















them”! (Field! notes! 01/05/14).! The! appeal! of! stem! cells! is! often! due! to! the!
combination!of!a!very!debilitating!disease!and!a!lack!of!other!treatment!options;!for!
instance,! Interviewee! 3! described! being! inundated! with! phone! calls! after! a!
newspaper!article!was!published!about!the!stem!cell!trial!she!managed:!!
“I!think!most!of!the!people!who!were!contacting!us!were!people!











guaranteed! to! get! stem! cells,! even! though! both! arms! of! the! trial! involved! cell!
therapies,!and!the!nonMstem!cell!arm!was!actually!the!more!proven!therapy.!
! Enthusiasm! for! new,! advanced! treatment! options! means! that! many! cell!
therapy!trials!do!not!struggle!to!recruit!M!!indeed!for!ENABLE!the!problem!was!actually!
how!to!avoid!overMrecruiting,!and!thereby!overloading!the!cell!manufacturing!facility.!




acute! event.! She! felt! that! this! was! a! very! emotional! and! riskMaverse! time! when!











Here! we! can! see! that! using! the! treatment! during! the! trial! can! help! clinicians!

















site,! [but! in! the! UK]! we! have! a! very! healthy! portfolio! of! both!
complex! and! simple! studies,! so!most! of! our! sites!were! running!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
































target! the! poorliest! patients,! there! is! a! risk! that! desperation! could! make! them!




that! has! yet! been! proven! clinically.! Furthermore,! the! risks! associated! with! such!
experimental!treatments!are!potentially!much!greater!than!those!typically!seen!in!
drug!trials,!and!again!the!therapeutic!misconception!suggests!that!patients!are!likely!
to!underestimate! these! risks.! Finally,!given! the!considerable! scientific!uncertainty!















heart! is! severely! damaged! you! shouldn’t! do! it,! it’s! probably!
dangerous! M! and! certainly! with! an! experimental! therapy! you!
shouldn’t!be!doing!it.”!(INT1)!!
Interestingly,!in!this!case!the!inclusion!criteria!were!being!used!to!mitigate!risk!by!
limiting! treatment! to! patients! who! were! clinically! able! to! cope! with! it,! which!








patients! with! certain! previous! treatment,! or! presenting! with! certain! clinical!
conditions.!On!the!one!hand!the!team!was!keen!to!make!the!trial!population!as!wide!
as!possible,!so!that!it!was!representative!of!the!general!patient!population,!as!this!
was! seen! to! be! essential! for! the! results! to! be! credible! for! future! publication,!





! The!use!of! strict! inclusion!criteria! to!minimise! risk!and!control! the! data! is!
complicated! by! the! second! important! component! of! the! way! that! trials! frame!











not,! with! no! grey! areas! in! the! middle.! Trial! protocols! thus! make! sweeping!
generalisations!about!which!patients!will!be!suitable!for!the!trial,!whereas!in!reality!
each! patient! has! a! unique!medical! profile,! including,! amongst! other! things,! their!























So! the! patients! are! aware! of! the! fact! that! there! are! very! good!
treatments!out!there!for![disease],!but!they!don’t!cure!them,!they!
have!side!effects.!And!so,!you!know,!these!young!patients!in!their!




In! this! case,!patient!groups!appear! to! be! framing! the!cell! therapy! treatment! in! a!
particular!way:!as!a! distinct!alternative! to! the! drug!options! currently!available! to!
them,!and!with!the!potential!to!be!more!like!a!‘cure’.!!
The!way!that!patients!frame!a!cell!therapy!can!potentially!conflict!with!how!
the!protocol! frames! it;! for! instance,! Interviewee!17!explained!that!the!strict!entry!
criteria!for!his!trial!required!patients!to!have!exhausted!all!other!treatment!options.!





































involved! in! this.! Interviewee! 7! explained! that! there! was! a! tension! between! the!































not! align! with! an! individual! patient’s! values! and! preferences.! This! aligns! with!
sociological!commentaries!that!have!highlighted!the!ways!in!which!trials!configure!




of! numerous! factors,! including! the! type! of! treatment,! the! disease! area,! and! the!
perspectives!and!aims!of!those!designing!the!trial.!A!good!example!of!this!is!the!way!
that!the!framing!of!risks!and!benefits!to!patients!varies!between!trials:!in!some!cases,!















all,!but! rather!which! research!will!best! suit! their!needs! M! a! situation! in!which! the!
patient!appears!to!be!acting!more!like!an!active!consumer!than!a!passive!research!
subject.!This!active!participation!is!also!reflected!in!the!role!of!patient!advocacy!in!
driving! the! development! of! some! cell! therapies,! demonstrating! that! at! both! an!
individual!and!a! collective! level!patients!are! important!actors! in! the!process.!The!
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sociological! literature! on! patient! advocacy! highlights! the! ways! in! which! patient!










individuals! can! the! specific! risks!and!benefits!of! a! trial!be! considered,! taking! into!





the! uncertainty! of! the! science,! and! the! poor! prognosis! of! many! patients! make!















make! about! protecting! intellectual! property,! or! whether! to! aim! for! marketing!
authorisation.! Nevertheless,! the! role! of! commerce! in! cell! therapy! trials! is! clearly!
different! from! drug! trials,! not! least! because! the! companies! involved! are! very!
different! to! the!multiMnational! corporations! that! dominate! drug! development,! as!
Interviewee!14!highlighted:!!
“A!lot!of!the!companies,!and!I!don’t!mean!all!of!them,!but!a!lot!of!
them! are! smaller! companies.! They! tend! to! be! spin! outs! of!
universities,! just! sort!of! smaller! start!up!organisations! that!have!
found! something! that! works! and! they’re! building! a! company!
around!it.”!(INT14)!!
In! some! ways,! then,! the! companies! involved! in! cell! therapy! trials! have! more! in!
common!with!academic!researchers!than!corporate!drug!manufacturers!(Maciulaitis!
et!al.,! 2009),! and!may!even!be! the! same! individuals.! This! issue!was! raised!by! the!
House! of! Lords! report,! which! described! the! companies! involved! as! “very! small!
companies! or! academic! groups! that! have! no! experience! in! the! field! and! are!
overwhelmed! by! the! entire! complex! regulatory! system”! (House! of! Lords,! 2013).!
There! is! also! evidence! that! lack! of! experience! and/or! resources! makes! small!
companies! less! likely! to! be! successful!when! applying! for!marketing! authorisation!
(Regnstrom!et!al.,!2009).!Rather!than!functioning!very!differently!to!the!academic!
sphere,!then,!these!companies!are!likely!to!face!many!of!the!same!problems!in!terms!










The! literature! reviewed! in! Chapter! 1! highlights! access! to! funding! and! a! credible!
business!model!as!essential!factors!in!the!translation!of!cell!therapies,!and!many!of!
my! interviewees,!whether! from!a!commercial!or!academic!background,!were!very!







This! view!was! also! reflected! by! Interviewee! 10! (a! clinician!who! acted! as! PI! for! a!




because!we!had! those! resources! ...! if! you!were!trying! to!do! this!
academically!it!would!be!really!expensive.”!(INT10)!!
The!economic! realities!of! conducting! clinical! trials!meant! that!many! interviewees!
accepted!the!need!for!cell!therapies!to!be!commercially!successful,!as!Interviewee!5!
(an!academic!researcher)!put!it:!!










This!quote!highlights!both!a! recognition! that! cell! therapy!policy!has!an!economic!
motivation! as! well! as! a! public! health! objective,! and! also! the! way! that! some!
interviewees!at!least!accepted!that!this!is!not!necessarily!unreasonable.!
Some! interviewees! were! not! only! accepting! of! the! need! for! commercial!







not! only! academic! organisations! that! can! benefit! from! commercial! expertise:!
Interviewee! 17! (the! head! of! an! SME! developing! a! cell! therapy! treatment)! also!
described! benefitting! from! discussions! with! a! commercial! research! organisation!
which!had!experience!of!running!large!drug!trials.!!





















and! then! put! through! “illKconceived”! trials! which! failed! to! show! efficacy.! The!
company!then!abandoned!development!of!the!treatment,!which!meant!that!patients!















As! well! as! the! tension! between! commercial! considerations! and! clinical!
priorities,! there! can! also! be! a! conflict! between! commercialisation! and! academic!
research,!particularly!when!it!comes!to!the!publication!of!results.!Interviewee!2!gave!
a! good! explanation! of! the! pressures! imposed! by! commercial! sponsors,! and! the!
struggle!that!he!had!to!protect!what!he!perceived!to!be!the!‘integrity’!of!the!research:!
“You’ve!got!the!dreaded!confidentiality!agreements!…!companies!













The! lack! of! collegiality! in! commercial! research! also! emerged! in! other! ways;! for!
instance,!Interviewee!4!suggested!that!companies!can!use!competition!for!patients!
in!trials!as!a!way!to!prevent!rivals!from!being!able!to!test!their!products:!!
“Some! of! the! pharmaceutical! companies! set! up! trials! to! stymie!
their!rivals!…!they!do!a!trial!they!don’t!really!have!any!great!interest!
in,! but! it! means! there! are! fewer! patients! for! their! rival! with! a!
fundamentally!new!treatment.”!(INT4)!!
In! this! example,! we! can! see! that! the! interests! of! commerce! are! restricting! the!
generation! of! knowledge,! thus! limiting! innovation,! and! Interviewee! 5! described!
another!way!that!this!can!happen:!!
“[Cell! type]! in!particular!are!being!heavily!commercialised!at!the!
moment! because! some! really! remarkable! results! have! been!






the! sharing! of! knowledge! and! resources.! Academic! research! is,! of! course,! not!
immune!to!competitiveness!or!a!lack!of!transparency,!however!this!is!to!some!extent!
offset!by!traditions!of!collegiality!and!collaboration!in!academia,!and!by!institutional!
processes! that! encourage! open! access! to! data! (particularly! for! publiclyMfunded!














cell! therapies! tends! to! be! in! clinicalMacademic! settings,! with! companies! only!
becoming!involved!later:!
“These! are! still! investigator! developed! products,! so! they’re! not!
coming! from!pharmaceutical! companies.! Pharma’s! buying! them,!
after! as! early! as! Phase! 1,! Phase! 2! data,! but! they’re! not! being!


























also! questioned! whether! the! commercial! route,! as! represented! by! applying! for!
marketing!authorisation,!was!even!appropriate!for!their!therapy!at!all.!This!is!partly!
because!some!therapies,!particularly!those!that!cannot!be!mass!produced,!do!not!




that! one! assesses! a! drug! for! a! marketing! authorisation,! that!
something!like!a!tissue!engineered!trachea!or!larynx!or!oesophagus!
could!get!a!marketing!authorisation.”!(INT12)!




“We’ve! just! seen! that! an! Italian! company! has! got! a! marketing!
authorisation! for! limbal! stem! cell! transplants.! I!don’t! know!how!
well!that’s!going!to!stand!up,!or!indeed!if!it’s!defensible!…!To!do!a!
limbal!stem!cell!transplant!you!have!to!take!limbal!cells!from!the!











than! attempting! to! commercialise! the! product! their! approach!was! to! share! their!
knowledge!with!other!clinical!academic!sites,!encouraging!them!to!develop!their!own!













as!academic! researchers!who!are!unfamiliar!with!drug! trials! can!benefit! from! the!
expertise! of! companies!who! have!more! experience! in! the! area.! The! relationship!
between! commercial! and! clinicalMacademic! research! remains! a! problematic! one,!
however,!despite!the!fact!that!most!of!the!companies!involved!are!SMEs!rather!than!
large! multiMnational! corporations.! One! of! the! most! divisive! issues! is! the! lack! of!
transparency!inherent!in!commercial!research,!which!is!at!odds!with!academic!and!
clinical! models! of! knowledge! generation! and! innovation.! As! described! in! the!




results,! meaning! that! systematic! reviews! will! overstate! the! efficacy! of! the! drug!
(Sismondo,! 2008).! My! findings! suggest,! however,! that! cell! therapies! may! be!
vulnerable!to!another!problem!concerning!the!publication!of!results,!which!is!that!





poses! a! problem! for! the! generation! of! evidence;! the! EBM! framework! places!
systematic! reviews! of! RCTs! at! the! top! of! the! evidence! hierarchy,! but! without! a!
detailed!description!of!the!cells!used! it!will!be!extremely!difficult! to!conduct!such!




! This! raises! a! wider! question! about! whether! the! commercial! model! is!




















are! too! expensive! or! because! the! company! decides! to!withdraw! them! for! some!
reason.!Furthermore,!clinicians!and!patients!often!reconcile!the!conflicting!demands!
of! research! and! care! by! reconceptualising! research( as( care,! but! again! this! is!



























that! the! relationship! between! academic! researchers! and! commercial! sponsors! is!
different! to! that! seen! in! drug! trials,! with! different! tensions! and! power! relations!











and! priorities! of! the! patients! themselves,! and! the! potential! for! (and! attitudes!
towards)!commercialisation.!So,!for!instance,!a!trial!might!be!considered!risky!from!









trials! is! heightened! by! the! fact! that! investigatorMled! trials! appear! to! be! driven! by!
individuals! or! small! teams! of! clinicians! and! academics,! meaning! they! take! place!
within!‘pockets’!of!innovation!rather!than!a!more!structured!framework!or!platform,!
such!as!exists!for!cancer!trials!(as!descibed!by!Keating!and!Cambrosio,!2012;!2007).!
This! undoubtedly! contributes! to! the! fragmentation! I! described! in! the! previous!
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chapter,! because! rather! than! specific! variables,! such! as! the! type! of! cell! used,!









The! expense! of! conducting! highlyMregulated! trials! necessitates! a! commercial!
approach!to!cell!therapy!development,!but!this!often!conflicts!with,!and!constrains,!




this! commercial!model! is! appropriate! for! their! treatments.! There! is! currently! no!
alternative!model!for!centres!that!wish!to!develop!treatments!with!no!commercial!
intention;!options!are! limited! to!either! conducting! fullMscale! trials,!with!a!view! to!
applying! for! marketing! authorisation,! or! delivering! treatments! under! the! limited!
confines! of!HE.!My! findings! suggest! that! there! is! an! argument! for! developing! an!
alternative,!nonMcommercial!framework!that!is!better!aligned!with!the!way!many!cell!
therapy!treatments!are!currently!being!developed,!and!which!could!run!alongside!































battle,! and! gave! many! examples! of! the! various! difficulties! and! frustrations! they!
faced.! Clearly,! then,! the! trialling! process! for! cell! therapies! is! experienced! as!
problematic! by! those! involved;! however,! I! was! also! struck! by! a! question! from! a!
clinician!attending!an!MRC!course!on!cell!therapy!trials:!“I’m(struggling(to(see(the(
issue(here(K(aren’t(regulations(the(same(for(all(drugs?(Why(are(stem(cells(different?”!
(Field! notes! 01/05/14).! On! the! face! of! it! this! is! a! valid! question! M! although! cell!
therapies!do!have!a!number!of!characteristics!that!make!them!challenging!from!a!












do! with! scientific! uncertainty,! such! as! the! applicability! of! animal! models! or!
uncertainty!about!mode!of!action!(an!issue!I!will!address!in!Chapter!6),!or!problems!





conducting! a! cell! therapy! trial.! Sanchez! et! al.! (2013),!who! report! the! results! of! a!
workshop!where!cell!therapies!trialists!discussed!the!problems!they!faced,!is!the!only!
peerMreviewed! paper! in! my! literature! review! that! could! be! considered! to! focus!











provide! a! useful! starting! point,! they! fall! some! way! short! of! a! comprehensive!
consideration!of!how! the! trials!process!enables!or! impedes! the! translation!of! cell!
therapies.! The! general! challenges! of! cell! therapy! translation! that! I! discussed! in!


















This! chapter! follows!a! similar!approach,!by!using!observational!data!as!a! starting!













the! therapy! M! the! so! called! ‘excess! treatment! costs’! of! the! trial.! The! team! were!





the! treatment!was! secured.! There!were! also! instances! of! patients! from!different!
counties!being!treated!in!different!ways,! for! instance!a!patient! from!Wales!would!
only!have!the!treatment!reimbursed!if!they!took!part!in!the!trial,!whereas!a!patient!
from!Scotland!was!in!the!opposite!position!and!could!only!receive!funding!offMtrial.!!
Reimbursement!of!excess! treatment! costs!was! further! complicated!by! the!
fact!that!there!was!not!a!direct!link!between!the!funding!received!and!the!cost!of!





this! complex!and! inconsistent! financial! situation!was! significant.!Trial!participants!
who!are!randomised!but!not!treated!due!to!lack!of!funds!must!still!be!included!in!the!
analysis,!thus!diluting!the!results,!and!there!is!also!a!negative!impact!on!the!patients!
themselves,!who!have! spent! time!deciding!whether! to! participate,!and!may!have!
become!emotionally! invested! in! getting! the! treatment! only! to! find! that! they! are!
unable!to!take!part.!There!was!also!an!impact!on!the!management!of!the!trial,!as!a!
significant!amount!of! the! team’s! time!was! spent!dealing!with! these! issues,!and!a!
considerable! effect! on! morale,! demonstrated! by! one! team! member! stating! on!
numerous! occasions! that! he! would! rather! stop! doing! research! altogether! than!
continue!battling!with! the!commissioning!bodies.!The! team!themselves! identified!
reimbursement!as! the!biggest! challenge! they! faced,!and! it!was! clearly! their!most!
significant!concern!about!sustainability!of!their!research!and!clinical!programme!in!
the!future.!





















appeared! to! create! a! platform! for! clinical! research! that! bordered! on! the! style! of!
practice!that!Keating!and!Cambrosio!(2007;!2012)!describe!in!oncology!trials,!albeit!
on!a!much!smaller!scale.!In!particular,!it!allowed!the!team!to!sustain!a!pipeline!of!
trials! M! some! in! followMup,! one! currently! active,! and! others! still! being! planned! M!
creating!an!ongoing!programme!of!research!that!could!continually!build!upon!itself.!

















Interviewee! 3,! who! managed! a! multiMsite! trial,! also! found! reimbursement!
challenging:!!
“The!hardest!thing!about!recruitment!was!getting!the!funding!for!





treated,! and! that! the! way! she! was! able! to! justify! the! treatment! cost! was! to!
demonstrate!the!expected!cost!benefits!to!the!NHS!if!the!treatment!was!successful:!!
“Each!person!you!had!to!do!an!individualised!request!for!money,!
and! really! in! the! end! it! was! a! financial! argument! which! they!
couldn’t!defend!against,!because!the!potential!of!removing!these!
people!from!the!treatments!that!they!were!having!to!have!…!so!you!
know! you! have! a,! sort! of! an! economic! argument! you! can! put!
forward.”!(INT3)!















“You! could! argue! that! the! research! sponsor! [in! this! case! a!
university]! should! pay! the! treatment! costs! for! the! Phase! 1! trial!
because! it’s! pure! research.!Whereas! for! the! Phase! 2! study! you!











the! current! climate! …! where! actually! you! need! to! pay! this!
treatment!which!might! cost! you!know!£50,000! per!patient! for!a!
Phase!1!study!where!at!the!end!of!it!we’re!not!going!to!know!if!it!
works!or!not!…!it’s!just!not!tenable.”!(INT1)!




Alongside! the! challenges! related! to! high! excess! treatment! costs,! some!
interviewees!also!reported!similar!experiences!to!the!ENABLE!trial! in!terms!of!the!




And! the! variation! we! would! get! around! the! country! was! quite!
large.”!(INT3)!!
This! situation! is! exacerbated! by! the! fact! that! cell! therapy! trials! are! generally!














For! instance,! those! that!are! funded!by!external! organisations! that!have! sufficient!
funds! to!meet! the! treatment! costs! do! not! face! such! problems,! as! Interviewee! 5!
found:!















we! have! seen! previously,! the!majority! are! publiclyMfunded,! and! even! commercial!
trials! tend!to!be!funded!by!SMEs!with! limited!resources.!This!type!of! funding!has!
generally!been!sufficient! for!the!earlyMphase!trials! that!academic! institutions!have!




of! Big!Pharma.!A!number!of! interviewees! reported! struggling! to! secure! sufficient!
funding!for!their!trials,!such!as!Interviewee!4:!!






general,! as! well! as! ATMPs! specifically,! which! have! made! it! increasingly! more!
expensive!to!run!cell!therapy!trials.!!




because! again,!when! I! put! the! grant! in! there!was! no! regulatory!
hurdles!at!all,!so!it!wasn’t!factored!in.”!(INT9)!!





















else! giving! you! funding! for! the! translational,! and! vice! versa.”!
(INT16)!!













instance,! Interviewee! 5! experienced! problems! relating! to! intellectual! property!
because! the! trust! where! the! treatment! had! been! developed! had! not! had! a!
commercial!strategy,!and!had!therefore!not!attempted!to!secure!a!patent:!
“If! you!go! to!Pharma!or! to!venture! looking! for!money! to! fund!a!
clinical! trial! and! you! have! no! intellectual! property,! you! have! no!
patent,!they’re!going!to!show!you!where!the!door!is!because!there!
is!no!point!M!the!conversation!ends!there!immediately.!So!we!could!
not! get! any! money! for! this! trial! for! a! long! time.! Eventually! I!








Another! factor! related! to! funder! expectations! that! was! raised! by! the!
interviewees! was! the! fact! that! the! milestones! agreed! in! the! grant! are! often!
unrealistic!for!cell!therapy!trials,!which,!as!we!will!see!in!the!following!section,!are!






















The! funding! model! for! cell! therapy! trials,! and! the! extent! to! which! funders’!
expectations! are! aligned! with! the! realities! of! conducting! a! trial,! appear! to! be!
problematic!for!three!main!reasons.!Firstly,!it!is!questionable!whether!public!funding!
can!be! sufficient! for! the! types!of! trial! that!are! required! for! cell! therapy! research,!
which!links!back!to!the!issue!of!academic!versus!commercial!development!discussed!




trial! funders!have!realistic!expectations!of!cell! therapy!trials,!and! in!particular!the!
time!it!will!take!for!these!trials!to!be!undertaken!(which!is!one!of!the!temporal!factors!




many! cell! therapy! trials,! and! again! this! is! specifically! an! issue! for! academicMled!




even! be! considered! to! challenge! the! premise! of! clinical! equipoise! that! forms! the!
justification!for!the!trial!itself.!Likewise,!raising!such!expectations!risks!adding!to!the!
therapeutic! misconception! that! patients! may! have! about! the! likely! benefits! of!




attempts! to! address! this! by! considering! treatment! costs!much! earlier! in! the! trial!




high! treatment! costs! with! uncertainty! about! outcomes.! Indeed,! the! issue! of!
reimbursement!is!recognised!as!being!one!of!the!main!obstacles!for!the!translation!
of! cell! therapies,! even! once! they! are! licensed! (House! of! Lords,! 2013).! The!
appropriateness! of! the! existing! technology! appraisal! methods! for! assessing! cell!
therapies! was! evaluated! in! a! ‘mock! appraisal’! (RMEG,! 2015),! however! this! only!
addresses!what!could!be!considered!the!adoption!part!of!the!translational!pipeline,!
whereas! my! findings! suggest! that! reimbursement! can! become! an! obstacle! to!













can! be! trialMrelated,! such! as! realising! the! followMup! appointment! window! is! not!
realistic,! siteMrelated,! such! as! the! discussions! about! closing! the! lab,! or! externallyM
triggered,! such! as! taking! account! of! new! reimbursement! guidelines.! All! of! these!























length! of! the! outcome! measure! was! also! a! significant! temporal! factor,! because!
although!the!primary!outcome!was!only!12!months,! longMterm!follow!up!was!also!



















to!prevent! further! delays!or! setbacks.! For! instance,!Mark! (the!cell!manufacturing!
manager)! explained! that! when! first! setting! up! the! lab! over! 15! years! ago,! he!
deliberately!worked!to!pharmaceutical!standards! in!anticipation!of!a!tightening!of!
the! regulations! around! cell! therapies.! This! meant! that! when! the! new! ATMP!
regulations!were! introduced! the! ENABLE! team!were! able! to! continue! their! trials!
without!significant!interruption!(Field!notes!06/11/14).!There!were!also!a!number!of!
discussions!about! the!amount! of! cell! characterisation! that! should!be!undertaken,!
with! some! team! members! arguing! that! even! if! regulators! don’t! require! precise!














an! approximate! timeframe! for! a! particular! therapy! or! breakthrough! to! reach! the!







an! obvious! clinical! use.! It! does! not! take! a! detailed! knowledge! of! the! specific! cell!
therapy!or!clinical!area!to!know!that!this! is!unlikely!to!be!a!realistic!estimate!M!as!







time!the!treatment! is!used! in!a!human’! (i.e.! first! in!man!clinical! trials)! then!10M15!
years!is!not!unrealistic!M!for!instance,!the!first!trials!using!iPSCs!were!authorised!less!
than! 10! years! after! their! discovery! was! first! published! (Cyranoski,! 2014).!
Furthermore,!as!we!saw!in!the!previous!section,!there!is!also!a!strong!motivation!to!
make! claims! for! a! treatment! that! include! an! imminent! translation! into! a! usable!










grant!was!submitted,!and! it! is!not! just! the!overall! length!of! the! trial! that! is!often!
greater!than!expected,!but!also!the!time!(in!person!hours)!required!to!run!the!trial.!
This!point!was!made!by!a!clinician!speaking!at!a!regenerative!medicine!trials!course,!
who!emphasised! the!point! that! if! clinicians!wanted! to!get! involved! in!a! trial! they!
should!be!aware!of! how!much! time! it!would! take,!even! if! they!were!not!actually!





















the! treatment!was!now!classified!as!an!ATMP! the! trial!had! to! stop! to! build!GMP!
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facilities! and! get! approval,! delaying! recruitment! by! seven! years! (Field! notes!







This! quote! highlights! the! way! that! changing! regulations! can! create! a! positive!
feedback!loop,!whereby!delays!in!getting!approval!mean!that!by!the!time!the!trial!is!
ready! to! start! the! regulatory! landscape! has! changed! again,! potentially! further!
delaying!the!start!of!the!trial.!






notes! 01/05/14).! In! another! example,! Interviewee! 5! described!missing! a! funding!








“[The! trial]! got! stopped! a! week! before! the! surgery! with! the!
realisation!…!that!the!injection!implement!that!the!surgeons!were!




produced! and! risk! assessed! within! a! UK! kiteMmarked! stamped!
facility.”!(INT2)!!













gets! done! at! all.! For! instance,! the! trial! that! Interviewee! 7! was! involved! in! was!
































Medicinal!Product!Dossier! (IMPD).!This! feeling!was!articulated!by!another! trialist,!
who!explained!to!other!clinicians!thinking!of!embarking!on!cell!therapy!trials!that!you!
have!to!stop!innovating!at!the!point!of!clinical!trailing,!because!it’s!very!difficult!to!













the!procedure! for! delivering! the!cells,!which!would!benefit!patients!but! could!be!
considered!a!significant!change:!!
“What!we!did!last!time!was!we!took!fluid!from!the!patient’s!joint!








The! issue! of! path! dependency! is! clearly! not! a! straightforward! one! then,! with!
investigators! expecting! to! be! locked! in! to! some! extent! once! the! trialling! process!
starts,!but!unclear!on!exactly!what!this!means.! !
The!future!proofing!strategies!that! I!observed!on!the!ENABLE!trial!were! in!
large! part! an! attempt! to! address! these! linked! issues! of! path! dependency! and!
uncertainty.!A!number!of! interviewees!described!adopting!similar!approaches,! for!



















































long! cell! therapy! trials! are! likely! to! take,! and! to! ensure! that! time! and! funds! are!
allocated!to!allow!for!unexpected!delays.!!
The!time!required!to!undertake!trials!has!clearly!been!unexpected!for!many!
cell! therapy! developers,! who! are! often! unfamiliar! with! the! trialling! process.! This!













that! some! trialists!are!attempting!to! future!proof! their! trials!by!anticipating!what!
regulators!will!require!in!the!future,!for!instance!in!terms!of!cell!characterisation!or!
production! requirements.! These! findings! suggest! that! Faulkner’s! concept! of!
‘governation’!applies!not!only!to!existing!regulations,!but!also!to!the!expectation!of!
future! regulations! M! what! we! might! term! ‘anticipatory! governation’.! What! is!






This! can! lead! to! conflict!or!negotiation!amongst! research! teams,! for! instance! the!
disagreement!in!the!ENABLE!network!about!the!importance!of!cell!characterisation.!
It!can!also!result!in!different!sites!adopting!very!different!approaches;!for!instance,!















the! site! has! its! own! dedicated! GMP! facility.! Despite! this,! however,! my! own!
observations! identified! a! number! of! challenges! raised! by! the! use! of! cells.! Most!
predominantly,! the! fact! that! cells! are! living! organisms!means! that! the! process! of!
manufacturing!a!cell!therapy!is!less!predictable!and!controllable!than!manufacturing!
a! drug.! This! created! specific! problems! with! adhering! to! a! rigid! trial! protocol,! as!
exemplified! by! an! incident! that! was! discussed! in! one! of! the! team! meetings! I!
observed.! A! patient! had! been! randomised! to! a! treatment! arm! that! required! two!
different!types!of!autologous!cells!to!be!produced,!but!only!one!cell!type!had!grown!
adequately! in!the! lab.!The!team!was!faced!with!a!dilemma:!should!the!patient!be!





an! additional! invasive! procedure! for! the! patient! and! would! not! necessarily! be!
successful.!Here!we!can!see!that!the!needs!of!the!research,!in!this!case!the!allocation!
of!the!patient!to!a!specific!treatment!arm,!came!into!conflict!with!the!clinical!care!of!











whole! process,! and! were! encouraging! other! centres! to! set! up! their! own!
manufacturing!facilities!using!the!same!model.!Clearly,! then,!the!availability!of!an!
experienced!manufacturing! centre!was! an! important! factor! in! the! success! of! the!
ENABLE!trial.!However,!there!were!still!manufacturing!challenges!to!be!overcome,!
with!one!of! the!most! important!being! the! issue!of! capacity.!This!was!particularly!
acute!because!the!ENABLE!lab!uses!an!open!system!for!cell!processing,!which!is!more!
labourMintensive!than!a!closed!system.!Additionally,!as!Mark!explained,!his!expertise!
and! experience! were! important! factors! in! the! successful! processing! of! the! cells,!
because!over!the!years!he!had!developed!a!‘feel’!for!which!cell!batches!would!grow!
well!(Field!notes!06/11/14).!The!importance!of!this!tacit!knowledge!would!appear!to!








(such! as! access! to! the! operating! theatre,! the! availability! of! surgeons,! and! MRI!
scanning!slots)!were! in! fact!more!of!an! issue!than!the!availability!of!cells.!Clearly,!
however,! the! needs! of! the! trial!were! at! times! in! conflict!with! the!manufacturing!
process.!This!was!emphasised!by!the!fact!that!although!there!was!a!budget!available!
to! extend! the! lab,! thus! increasing! capacity,! the! team! were! reluctant! to! do! this!
because! it! would! mean! the! lab! being! out! of! action! for! a! few! months! and! trial!
recruitment!would!be!significantly!delayed.!My!ENABLE!fieldwork,! then,! identified!
the!uncertainty!of!manufacturing!cell!therapies!as!an!important!challenge!for!clinical!
trials.!The! issue!of!cell! therapies!being! living!organisms,!and!production!therefore!













problematic! for! autologous! treatments,! where! there! is! greater! uncertainty! in!
production!because!the!cells!are!taken!from!the!patient!and!grown!on!a!caseMbyMcase!
basis.! Sometimes! the! underlying! illness! also!made! the! resulting! cell! product! less!
effective,!as!Interviewee!5!explained:!!
“When! you! do! research! in! the! lab! and! you! take! blood! from! 20!
something!PhD!students,!you!put!your!retrovirus!on!the!TMcells!and!

























Cell! manufacturing! expertise,! including! tacit! knowledge! built! up! over! time,! thus!
appears!to!be!an!important!enabling!factor!for!cell!therapy!trials,!and!again!this!does!
not!align!well!with!the!rigid!expectations!of!a!trial!protocol.!
These! findings! suggest! that! the! unpredictability! of! manufacturing! cell!
therapies!presents!a!significant!challenge!for!clinical!trials.!However,!it!is!important!
to!note!that!although!uncertainty!in!cell!production!was!mentioned!as!a!challenge!by!




variability! in! the!numbers!of! cells!produced! from!each!donor,! she! said! this!didn’t!
create!a!problem!because!there!was!a!steady!stream!of!donors!so!she!was!always!






It! appears,! therefore,! that! although! working! with! a! cell! product! often! creates!
significant! uncertainty! for! clinical! trials,! this! is! not! necessarily! true! for! all! cell!
therapies,!and!is!not!always!problematic!when!it!does!occur.!





“It! would! be! a! disaster! to! have! a! situation!where! you! recruit! a!
patient!…!and!you!can’t!give!them!a!cell!product,!that!would!just!























where! the! physician! also! requests! the! product! as! an! unlicensed!
medicine!to!be!used!and!therefore!…!because!I’ve!got!both!licences!















to!make! things! as! flexible! as! you! possibly! can! to! build! in! safety!
measures.!So!all!of!the!dose!levels!have!a!range,!so!if!we!don’t!hit!



















Trialists! clearly! expend! a! significant! amount! of! effort! to! protect! both! the!
research! and! the! patient! against! the! rigidity! of! a! clinical! trial.! This! endeavour! is!
particularly! challenging! in! the! context! of! manufacturing! clinicalMgrade! (i.e.! GMPM
compliant)!cells.!As!I!observed!at!the!ENABLE!site,!the!availability!of!a!dedicated!GMP!
facility!meant!that!the!team!did!not!experience!significant!problems!manufacturing!
clinicalMgrade! cells! for! the! trial.! Some! interviewees! also! had! access! to! dedicated!






















and! defrosting! it! and! counting! the! cells.! So! this! is! very!
straightforward! but! it! requires! a! certain! …! level! of,! type! of,!
laboratory! and! a! trained! person.! And! essentially! the! NHS! was!
incapable!of!providing!that!…!the!only!labs!that!could!do!this!were!








surpass! the! expertise! of! an! NHS! facility.! As! a! scientist! involved! in! developing!
reprogrammed!cells!for!clinical!use!commented:!“Not(everyone(can(do(this.(Yes,(it’s(
cookery,(but(it’s(cookery(with(lots(of(nuances”((Field!notes!01/05/14).!This!further!
highlights! the! importance! of! experience,! of! accumulated! tacit! knowledge,! that! I!
observed! on! the! ENABLE! trial! M! knowledge! that! is! only! likely! to! develop! in! a! lab!
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dedicated! to! producing! these! cells,! most! likely! in! an! academic! context.!
Unfortunately,!however,!these!labs!have!traditionally!only!produced!researchMgrade!
cells,! and! there!are! significant! financial! and!cultural!obstacles! to! setting!up!GMPM
compliant!facilities!in!academic!settings,!as!explained!by!Interviewee!2:!





He!went! on! to! explain! that! his! university’s! lack! of! experience! of! setting! up! such!
facilities!was!also!a!significant!obstacle:!!!
“The! first! challenge! was! what! the! hell! was! actually! required,!
because! …! production! standards! are! very! different! to! what!
universities,!academics!and!trusts!are!used!to!doing.!So!we!took!
the!regs!and!adapted!the!clean!room!over!a!period!of!a!couple!of!
years,! with! limited! resources.! We! were! able! to! buy! a! limited!
amount! of! external! advice,! but! the! biggest! single! factor! was!
university!estates!departments!simply!don’t!have!a!clue,!and!they!



















NHS! Blood! Transfusion! Centres! or! transplant! facilities;! for! instance,! when!
Interviewee!3!was!asked!if!cell!processing!capacity!was!a!factor!in!selecting!sites!to!
host! the! trial! she! replied:!“Oh( yes.( So( they(were(all(assigned( transplant( centres.”!
When! this! type! of! institutional! support! is! available,! the! process! of! running! a! cell!
therapy!trial!can!be!fairly!straightforward.!However,!the!interviewees!who!reported!
using!existing!systems!were!generally!working!on! trials!using!hematopoietic! cells,!





! As!well! as! having! limited! expertise! in! novel! cell! therapies,! existing! clinical!
facilities!can!also!have!issues!with!capacity,!as!experienced!by!Interviewee!9:!!
“I! think! the! fact! that! the! facility! here! tends! to! deal! with! bone!
marrow!transplant!patients!and!stuff!like!that,!they!just!don’t!have!
the!capacity.”!(INT9)!
Lab! availability! is! particularly! problematic! when! it! interacts! with! the! needs! of!
recruiting!patients!to!the!trial,!as!Interviewee!9!went!on!to!explain:!!
“We! could! only! treat! patients! when! there! was! a! gap! in! their!
schedule,! and! it’s! just! been! a! scheduling! nightmare! to! be! quite!
honest! with! you!…! They! said,! you! know,!we! can! only! do! one! a!














These! examples! suggest! that,! as! with! the! ENABLE! trial,! the! demands! of! the! cell!
manufacturing!process!can!often!clash!with!the!requirements!of!the!trial.!
Although! these!examples!demonstrate! that!access! to! the!cell! lab! can!be!a!













obvious! implications! for! recruitment! and! cost! (Field! notes! 19/01/2013).! She! also!
described!it!as!very!hard!for!the!patients,!with!one!in!particular!being!very!keen!to!
take!part!and!being!devastated!to!find!out!they!would!not!be!able!to!receive!the!new!
treatment! after! all.! Clearly,! then,! the! availability! of! labs! for! acute! treatments! is!
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running! of! cell! therapy! trials.! Sites!which! had! dedicated!GMP! labs! tended!not! to!
experience!significant!problems!with!the!cell!manufacturing!aspects!of!clinical!trials,!
and! indeed!were!often!able! to! support!a!portfolio!of!different! trials.!However,! it!
appears!that!there!can!be!problems!with!the!cost!and!availability!of!academic!GMP!
facilities,!and!setting!up!such!facilities!in!academic!institutions!can!be!very!difficult.!
This! aligns! with! the! findings! of! Pearce! at! al! (2014),! who! found! that! sites! with!











trials,! but! rather! that! there! will! be! a! number! of! different! models! that! will! be!
appropriate!in!different!circumstances.!
! As! well! as! making! the! setMup! of! trials! more! difficult,! the! logistical! issues!

















knowledge! in! favour! of! objective! measures! and! reproducible! evidence.! The!




of! cell! therapy! trials! is! linked! to! the! final! theme! that! I! identified! in! my! ENABLE!






These!meetings!were!held! fortnightly!once! the! trial!was!open,!although! they!had!
been!weekly!during!the!setMup!period,!and!those!meetings!that!I!observed!lasted!on!
average!about!an!hour,!with!some!being!as!long!as!90!minutes!and!others!only!30.!
Regular!attendees! included!the!Chief! Investigator! (Mr.!Hamilton),! the!head!of!the!
research!lab!(Claire),!another!member!of!the!scientific!research!team!(Kelly),!the!trial!
statistician!(John),!the!trial!manager!(Amy),!and!the!head!of!the!cell!manufacturing!







(including! surgery,! nursing! and! clinical! support! services! such! as! radiology),! cell!
manufacture,! scientific! research,! and! evidenceMbased! medicine! (including! trial!
design,!management!and!governance).11!A!fifth!domain,!pharmacy,!was!also!integral!




fact! that! they! almost! always! attended! these! fortnightly! meetings! represented! a!
significant!investment!of!time!on!their!part.!This!confused!me!at!first,!as!many!of!the!
meetings!appeared!to!deal!with!relatively!lowMlevel!administrative!issues.!However,!
as!my! fieldwork!progressed! it!became!apparent! that! these!meetings!were! in! fact!
crucial!to!the!smooth!running!of!the!trial.!!
One! of! the! meetings’! most! important! functions! was! to! provide! a! regular!






Mr.! Hamilton!was! concerned! about! how! the! patient!would! be! treated,! and! also!





work.!Other! terms!used! in! the! literature! do!not! fully! reflect! the! variety! of! activities! I! am! trying! to!









accommodate! a! different! treatment! protocol.! Secondly,! there! was! a! scientific!
implication,!partly!because!Claire!was!interested!in!why!the!cells!hadn’t!grown,!but!
also!because!the!team!had!concerns!about!whether!the!patient!not!being!treated!












This!was! clearly! part! of! the! incomprehensible! ‘trials’!world! rather! than! the!more!
logical!‘clinical’!or!‘scientific’!world!that!they!understood,!but!they!recognised!that!
despite!being!unfamiliar!to!them,!the!requirements!of!the!trial!were!valid,!and!they!







decisions! to! the!domains!that! ‘owned’! them!whilst! retaining!control!of! their!own!
areas.!!
This! event! was! also! a! good! example! of! another! function! of! the! regular!
meetings,!which!is!that!they!helped!the!team!to!resolve!conflict!when!the!needs!of!
different!domains!(or!the!personal!views!of!individuals)!were!at!odds!with!each!other.!




trial! delays! were! primarily! caused! by! bottlenecks! in! the! lab,! theatre! or! patient!




appeared! to! be! an! opportunity! for! these! views! to! be! aired,! so! that! even! if! no!
consensus!was!reached!the!issue!could!be!temporarily!set!aside!and!the!dayMtoMday!
work!of!the!trial!could!continue.!It!was!notable!that!if!a!discussion!became!slightly!





It! seems,! then,! that! these! meetings! were! crucial! to! the! team! dynamic,!
improving!each!domain’s!understanding!of!the!others!and!allowing!conflicts!to!be!
resolved! constructively,! or! allowing! the! team! to! move! on! from! issues! where!
consensus! could!not!be! reached.!Part!of! the! reason! this!was! so! important! is! that!
there! were! so! many! different! domains! involved.! Although! the! clinical! and! trials!
domains! are! generally! involved! in! any! clinical! trial,! it! is! less! usual! to! see!
manufacturing!and!scientific!research!being!so!heavily!involved,!and!in!fact!this!is!one!
of! the! most! distinctive! features! of! cell! therapy! trials.! I! concluded! from! my!
observations!of!the!ENABLE!trial! that!the!smooth! interaction!of!all!of! these!areas!
appears! necessary! for! a! cell! therapy! trial! to! run! successfully! (and! indeed! at! all),!
regardless!of!more!extrinsic! factors!such!as!regulation!and!reimbursement.! It!was!
surprising,!therefore,!to!find!that!few!of!the!other!trials!I!encountered!appeared!to!
have! such! structured! trial! management! processes! in! place.! Nevertheless,! my!












“When! I! said! to! the! surgeons! …! it’s! the! use! of! medicines!
committee,!they!thought! I!was!mad!…!They’re!used!to!getting!a!




“One! of! the! reasons! that!was! difficult! is! because!we’re!working!
across!specialities!…we!have!gastroenterology!patients!undergoing!







because! it’s! a! very!new! treatment,!an!untried! treatment,!a! very!
risky! treatment! M! particularly! for! this! group! of! patients! because!
they’re! prone! to! infection.! And! you! also! have! to! have! the!














As! well! as! being! unfamiliar! to! many! clinicians,! and! requiring! new! links!













M! that! they! don’t! understand! each! other! because! they! use! different! terminology,!






problem! is! that!a! lot!of!people!aren’t! fortunate! enough! to! have!









numerous! examples! of! scientists! being! unfamiliar! with,! or! actively! distancing!














felt! that! it! was! actually! easier! to! secure! funding! for! basic! science! (albeit! with! a!
broadly! translational! aim)! than! for! clinical! research.! Interviewee! 10! felt! that! this!
meant!there!was!little!motivation!for!basic!scientists!to!engage!in!clinical!issues:!!




















the!process.!He!was!one! of! the! few! interviewees!who!didn’t! report!any! logistical!
problems! with! manufacturing,! and! notably! he! was! also! the! one! who! reported!






because! of! the! need! for! manufacturing! to! be! compliant! not! only! with! Good!

















This! is! novel! terrain! for! investigators,! sponsors! and! manufacturers,! and! good!













departments! generally! work! with! drugs,! and! are! unfamiliar! with! the! different!
requirements!of!cell!therapies,!as!Interviewee!12!explained:!!










“Between! pharmacy! and! blood! transfusion! and! systems! in! a!
hospital! they’re! dealing!with! that! sort! of! thing! all! the! time!…! it!
probably!depends!on!the!hospital,!so!this!is!a!very!big!biomedical!
campus,!with!a!thousand!trials!going!on.”!(INT15)!
















It! appears,! then,! that! hospital! pharmacy! departments! are! generally! capable! of!
handling!simple!cell!therapies,!but!can!struggle!with!more!complex!and!unfamiliar!
products,!and!again!communication!is!key!to!overcoming!this.!!
! The! problem! of! pharmacists! being! unfamiliar! with! cell! therapies!was! also!

















9,!who!had! problems! finding! a! local!QP! and! so! arranged! for! one! of! the! hospital!













diverse,! involving! (amongst! other! things)! journals,! clinical! guidelines,! clinical!
researchers,!statisticians,!ethics!and!regulatory!standards,!methods!experts,!CROs,!
trials!units!and!clinical! research!experts.!Clearly,!all!clinical! trials! interact!with!the!
EBM!domain!in!many!different!ways,!and!at!different!times!in!the!process.!Many!of!
these! interactions! concern! the!way! evidence! is! generated,! interpreted! and! used,!
which!I!will!discuss!in!detail!in!Chapter!7.!From!a!dayMtoMday!practice!point!of!view,!






































“Trying! to!get! to! the! point!of!a! statistical! analysis!plan!with! the!
basic!scientists!is!a!challenge,!shall!we!say.!Sometimes!I!think!are!





The! language! barrier! between! EBM! and! clinical! or! scientific! cell! therapy!
researchers!is!most!likely!due!to!a!lack!of!experience!on!both!sides!of!what!the!other!
is!trying!to!achieve.!On!the!one!hand,!clinicians!and!scientists!generally!have!at!best!
a! hazy! understanding! of! the! EBM! framework,! and! most! trials! specialist! have! no!
experience!of!cell!therapies!or!regenerative!medicine.!This!means!that!there!are!very!
few! trial! specialists! who! really! understand! the! needs! of! a! cell! therapy! trial;! for!

















the! involvement! of! these! different! areas:! firstly,! that! cell! therapy! trials! require!
domains! to!work! together! in!ways! that! they! have! not! needed! to! previously;! and!
secondly,!that!these!domains!often!don’t!have!experience!of!cell!therapies,!and/or!
don’t! have! experience! of! interacting! with! the! other! domains.! This! can! cause!
difficulties! at! an! institutional! level;! for! instance,! academic! institutions! may! be!
reluctant!to!fund!the!kind!of!QA!work!needed!to!make!GMP!work,!and!basic!scientific!
research!funders!may!be!unwilling!to!accommodate!the!unfamiliar!requirements!of!
clinical! research.! It! can! also! cause! problems! at! a! team! level:! with! individuals!
struggling!to!understand!the!‘language’!of!the!other!domains,!it!can!be!difficult!to!
align! goals! and! work! towards! a! common! cause.! This! is! a! familiar! theme! from!
sociological!accounts!of!translational!research;!for!instance,!Wainwright!et!al.!(2006)!










! The! involvement! of! these! disparate! domains,! and! their! unfamiliarity! with!
each!other!and/or!with!the!treatment!area,!introduces!a!level!of!complexity!that!is!







2006).! In! order! to! smooth! the! interactions! between! different! disciplines,! regular!
communication!is!seen!to!be!crucial,!and!this!was!certainly!apparent!in!my!research,!




(2011),! who! coined! the! term! ‘science! friction’! to! describe! “the! difficulties!




between!machines,! represents! a! point! of! resistance!where! data! can! be! garbled,!
misinterpreted,!or!lost.”!Their!work,!which!also!highlighted!the!importance!of!regular!




! From! a! normative! perspective,! then,! it! would! be! beneficial! for! more! cell!
therapy!trials!to!follow!the!model!I!saw!in!the!ENABLE!trial,!where!members!of!the!
different! domains! involved! in! the! trial! met! on! a! regular! basis,! and! where! trials!
specialists!(including!the!statistician!and!trial!manager)!were!integral!members!of!the!















the! team! to! interpret! the! confusing! world! of! EBM.! It! is! important! to! recognise,!
however,!that!such!a!model!has!sociological!implications:!as!Keating!and!Cambrosio’s!
work! shows,! the! involvement! of! statisticians! was! part! of! the! development! of! a!
specific! style! of! practice! in! clinical! oncology,! and! this! is! the! model! that! has!
underpinned! the! problematic! framework!of!evidenceMbased!medicine!which! I!will!
discuss! in! Chapter! 7.! For! now,! however,! it! is! sufficient! to! note! that! greater!
engagement!with!trials!specialists!is!likely!to!facilitate!individual!cell!therapy!trials,!
but! it!will! also! further! embed! the! field!within! a!particular! evidentiary! framework!
which!may!not!always!be!appropriate!or!constructive.!
5.5!Discussion!
I! noted! in! the! introduction! to! this! chapter! that! the! existing! literature,!whilst! not!
comprehensive,!suggests!that! funding!constraints!and!the! length!of!time!required!
are! two! aspects! of! the! ‘doing’! of! trials! that! are! problematic! for! cell! therapy!
translation.!My!findings!support!this!conclusion,!and!also!suggest!that!working!with!
cells,!which! is!recognised!as!another!translational!challenge,!has! implications!that!
create! specific! challenges! in! a! trial! context.! My! findings! also! suggest! another!
specifically!challenging!aspect!of!trials!which!has!to!date!received!less!recognition:!
the! need! for! numerous! disparate! domains! to!work! together.!What! is! particularly!














nature! of! working! with! living! cells! as! a! therapeutic! agent.! This! also! introduces!











studied,! none! of! them! were! universal.! Each! trial! appeared! to! have! a! distinct!
configuration!of!challenges,!with!some!being!more!or!less!important,!or!experienced!
in!a!distinctive!way,!and!with!different! links!and! interactions!between! them.!This!
further!emphasises!the!heterogeneity!of!the!field!that!I!have!highlighted!in!previous!
chapters,!and!reinforces!the!point!that!there!is!unlikely!to!be!a!‘one!size!fits!all’!model!
appropriate! for! all! cell! therapy! trials.! Likewise,!most! of! these! challenges! are! not!
unique! to! cell! therapy! trials:! for! instance,! excess! treatment! costs! have! been! a!
significant! issue! in!many! publiclyMfunded! trials,! and! interaction! between!different!
domains!is!often!a!factor!in!complex!intervention!trials.!However,!the!scale!of!these!
challenges,!as!well!as!their!interaction!with!each!other,!does!appear!to!be!particularly!
























balanced! not! only! against! the! research! needs! of! the! trial,! but! also! against! the!
scientific! complexity! and! technological! challenges! introduced! by! using! a! complex!
living!organism!as!a!therapeutic!agent.!Clearly,!then,!the!apparent!rigidity!of!a!trial!















similar! to! existing! treatments,! and! those! that! fit! in! best! with! existing! processes.!
Likewise,!the!fact!that!funding!is!so!difficult!to!source!means!that!those!treatments!
that! can!make! (or!promise)!an!economic! case!are!more! likely! to!get!trialled! than!
others.!It!appears,!then,!that!the!cell!therapy!trials!framework!favours!incremental!
change!through!building!on!existing!knowledge,!particularly!as!many!of!the!domains!

















under!Hospital! Exemption! (HE),! and! those! that! are! not! designated! as!ATMPs! are!
generally!only! subject! to! the! less! stringent! regulations! for!medical!devices,!blood!
transfusion! or! organ! transplantation.! Other! countries! have! varying! levels! of!
regulation! and! oversight,! with! some! having! almost! no! restrictions,! prompting! so!
called!‘stemMcell!tourism’,!whereby!patients!travel!abroad!for!treatments!that!they!
cannot! access! in! their! own! country! (Petersen! et! al.,! 2017).! This! has! caused!












highlighted! the! discord! between! the! scientific! community! and! unregulated!
commercial!clinics!(Bianco!et!al.,!2013a),!and!demonstrated!how!difficult!it!can!be!to!
restrict!access!to!commercial!treatments!when!patients!themselves!are!demanding!
access! to! them.! The! public! sphere! has! not! been! immune! to! these! concerns,! as!
highlighted! by! the! recent! case! of! Paolo! Macchiarini.! One! of! the! highestMprofile!
surgeons! involved! in! regenerative!medicine,! and! a! pioneer! of! synthetic! tracheas!
seeded! with! bone! marrowMderived! cells,! Macchiarini! was! found! to! have!
misrepresented! preMclinical! and! clinical! results,! and! continued! to! treat! patients!
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despite! mounting! evidence! that! the! treatment! was! ineffective! and! potentially!
dangerous! (Nature,! 2016).! His! employer,! the! prestigious! Karolinska! Institute! in!
Sweden,!was!accused!of! failing! to! subject!his!work! to!adequate!oversight,! and!of!




part! of! a! wider! tension! surrounding! the! translational! medicine! agenda! in! cell!
therapies.!Translational!medicine,!or!the!process!of!using!basic!scientific!research!
to!develop!effective!medical!treatments,!is!seen!as!crucial!for!medical!progress!
(Marincola,! 2003),! forms! the! focus! of! much! technology! and! scientific! policy!
(Martin!et!al.,!2008),! and! strongly! shapes! the! research!agendas!of!both! the!UK!
Medical!Research!Council!and!the!US!National!Institutes!of!Health!(Wainwright!et!
al.,!2006).!The! translational!agenda! is!nowhere!more!evident! than! in! stem!cell!
research,! where! policymakers! have! emphasised! its! role! in! improving! the!
competitiveness! of! national! capabilities! in! regenerative! medicine! M! see! for!
instance! the! House! of! Lords! report! (2013),! which! urged! the! government! to!
improve! the! UK’s! capacity! for! clinical! research! in! the! field.! There! is! also! a!
proliferation!of! initiatives!aimed!at! facilitating!translational! stem!cell! research,!
for!instance!the!Cell!and!Gene!Therapy!Catapult,!the!UK!Stem!Cell!Bank,!and!the!





RegenMed! 2.0! is! almost! exclusively! focussed! on! the! pragmatic! translation! of!
great! science! into! routine! clinical! practice.”! Proponents! of! the! translational!
agenda!prioritise!clinical!research!over!basic!science!because!of!both!the!need!to!
prove!clinical!and!commercial!success!in!order!to!attract!funding,!and!a!view!that!
good! clinical! research! will! facilitate! basic! scientific! understanding! (Mason! and!






! The! hype! around! cell! therapies! tends! to! skim!over! the! complexities! and!
uncertainties! of! basic! scientific! research,! because,! in! the! words! of! a! former!
science!editor!for!the!Guardian,!“you!don’t!grab!headlines!by!describing!embryo!
stem!cell! research!as!an!expensive! laboratoryMbased! technology!guaranteed! to!
lead!to!many!years!of!frustration!and!small!flashes!of!enlightenment”!(Kitzinger,!










for! bad! science.”! Experimenting! in! the! clinic! is! viewed! negatively! by! many!
scientific!researchers!because!of!the!high!likelihood!of!failure,!as!highlighted!by!
this! scientist!quoted! in!Cribb!et!al.! (2008):! “They!basically! said,! ‘Oh!we’ve!got!
some! sick! patients,! got! some! cells,! chuck! one! into! the! other! and! see! what!
happens.’!With!absolutely!no! biology!behind! it! at!all!!And,!of! course,! it! didn’t!
work.! It’s! not! surprising.”! Such! a! high! failure! rate! is! seen! as! difficult! to! justify!
ethically,!and!risks!eventual!disillusionment! in!the!field;! for!many,!therefore,! it!
calls!into!question!the!wisdom!of!the!entire!translational!agenda.!
! It!seems,!then,!that!the!dynamics!of!cell!therapy!translation!are!shaped!by!
two! competing! perspectives:! one! which! emphasises! potential! and! pushes! for!
progress,! and! the! other! which! highlights! uncertainty! and! urges! caution.! The!
second,!cautious!approach,!is!particularly!concerned!with!the!unregulated!use!of!




















process! of! reprogramming! somatic! cells! into! a! pluripotent! state,! and! since! then!








for! the! queries! Yamanaka! raises),! or! unknown! (i.e.! some! future! development!will!
change!current!understanding!in!a!way!that!is!not!yet!understood!or!anticipated).!!























therapies,! and! the!way! that! cells! behave!when! administered! in( vivo,! and! also! to!























2! Phenotype:! Positive!(≥95%!+!)! Negative!(≤2%!+!)!
! !! CD105! CD45!
! !! CD73! CD34!
! !! CD90! CD14!or!CD11b!
! !! !! CD79α!or!CD19!









the! adipogenic,! osteogenic,! and! chondrogenic! lineages.”! (Ezquer! et! al.,!
2015)!
“Mesenchymal! stem! cells! (MSCs)! are! defined! by! their! fibroblastMlike!
morphology,! adherence! to! plastic,! expression! of! a! specific! set! of! surface!











with! sustained! stable! phenotype! and! differentiation! potential! toward! several!
mesenchymal!lineages,!such!as!fat,!cartilage,!and!bone.”!!










wide! range! of! clinical! indications,! including! musculoskeletal! conditions,! cardiac!
repair,!stroke,!autoMimmune!diseases!and!multiple!sclerosis.!MSCs!were!also!the!first!
stem! cell! treatment! worldwide! to! receive! a! marketing! authorisation,! with! the!
Canadian!regulator!approving!Prochymal!in!2012!for!the!treatment!of!graft!versus!
host!disease!in!children!(Wei!et!al.,!2013).!

















tissue,! and! indeed! there! is! also! debate! over!whether! such! cells! can! properly! be!
categorised!as!MSCs!at!all!(Bianco!et!al.,!2013b;!Keating,!2012).!!
! These!disagreements!about!what! the!cells! should!be!called! reflect!a!deeper!






extrapolating! the! function! of! these! cells! to! activity! in( vivo(must! be! done! with!
caution.”!More!recently,!the!wellMpublicised!immuneMmodulatory!properties!of!MSCs!
have!prompted!further!queries!over!their!classification,!for!instance!Hoogdijin!(2015)!
argues! that! they! could! in! fact! be! described! as! immune! cells,! as! their!
immunomodulatory! properties! “raise! the! academic! question! whether! MSCs! are!




definitions!and!poor!assays!have!disseminated!across! the! scientific! community!as!
‘gold!standards’”,!and!Keating!(2012,!p.709)!argues!that!“confusion!arising!from!the!
definition!of!the!MSC!population!made!comparisons!among!published!studies!in!the!
1990s! and! 2000s! problematic.”! Keating! goes! on! to! explain! that! the! absence! of! a!
specific!marker! to! define!MSCs! has! been! a! particular! challenge! for! the! field,! and!






! Regardless! of! the! scientific! validity,! or! otherwise,! of! these! different!
perspectives,! these! disagreements! and! inconsistencies! can! make! it! difficult! to!
evaluate!and!compare!scientific!research!on!MSCs,!because!the!term!itself!can!mean!
different! things,! and! it! is! often! not! possible! to!ascertain! from!a! published! article!
exactly!which!definition!the!authors!have!used.!Uncertainty!in!the!reporting!of!the!
basic!science!also!filters!through!to!clinical!MSC!research,!with!Liao!and!Tse!(2013)!
reporting! a! “high! degree! of! heterogeneity! in! terms! of! cell! population,! dose,!





trials! in! their! study,!but!do!not! fully!explain!exactly!what! types!of! therapies! they!
categorise! as! being! MSCMbased,! explaining! only! that! “most! MSC! trials! explicitly!
labelled!their!SC!type!as!mesenchymal,!but!some!did!not.”!They!do!explain!that!they!
categorised! cells! described! as! ‘adiposeMderived! stem! cells’! as! MSCs,! whilst!
recognising!that!“in!some!of!these!CTs,!the!transplant!may!be!of!lipoaspirates,!with!
the! therapeutic! effect! due! to! the! presence! of! MSCs”,! and! they! also! warn! that!
“adiposeMderived!MSCs!likely!have!different!properties!from!those!derived!from!bone!
marrow.”!A!further!complication!relates!to!the!treatment!of!bone!marrowMderived!
mononuclear! cells,! which! will! include! a! variety! of! cell! types! including!MSCs! and!
hematopoietic!stem!cells!(HSCs).!Li!et!al!include!‘mononuclear!fraction’!within!their!
HSC! category,! and! thus! a! trial! such! as! BAMI! M! which! describes! the! cells! used! as!
“autologous!bone!marrow!derived!mononuclear!cells”!M!would!be!categorised!as!an!
HSC! treatment.! The! therapeutic! effect! of! such! treatments,! however,! is! generally!
presented!as!being!due!to!the!MSCs!present!in!the!fraction,!although!as!I!shall!discuss!
later!this!in!itself!is!a!subject!of!much!debate!and!disagreement.!It!is!only!through!Li!










and! 3)! paracrine,! antiMinflammatory! or! immunomodulatory! actions! (Daley,! 2012).!
Daley!argues!that!only!the!first!of!these!is!founded!on!strong!preclinical!evidence!and!
sound! scientific! and! clinical! hypotheses,! although! even! here! he! points! out! that!
“evidence!for!robust!clinical!efficacy!of!MSCs!for!orthopaedic!indications!has!been!
challenging!to!confirm.”!The!potential!for!MSCs!to!regenerate!anything!other!than!
musculoskeletal! tissue! has! largely! been! discredited! over! the! past! ten! years,!with!









cells! “are! neither! transplanted! nor! engrafted! and! do! not! regenerate! tissues.”!





a! number! of! factors! including! inappropriate! dose,! scheduling,! or! route! of!
administration.!Furthermore,!the!coMadministration!of!antiMinflammatory!agents!may!









preclinical! and! clinical! studies,! MSCs! have( been( shown! to! be! highly( efficient! in!
treating!graft!versus!host!disease,!systemic!lupus!erythematosus,!multiple!sclerosis,!
type!1!diabetes,!myocardial!infarction,!liver!cirrhosis,!inflammatory!bowel!disease,!









more! …! It! is! thought,! but! as! yet( unproven,! that! they! may! exert! paracrine,!
immunomodulatory! and! immuneMregulatory! effects! on! endogenous! tissues! upon!
systemic! infusion! or! direct! injection.”! There! are! also! conflicting! views! about! the!
safety!of!MSCs;!it!is!sometimes!suggested!that,!unlike!embryonic!stem!cells,!they!are!
free! from! the! risk! of! immune! rejection! and! teratoma! M! for! instance! Ezquer! et! al.!
(2015)!state!that!“they!are!not!rejected!by!the!recipient’s!immune!system,!even!if!
they!come!from!a!nonMhistocompatible!individual”,!and!Wei!et!al.!(2013)!claim!that!
they! have! “low! immunogenicity! and! no! teratoma! risk.”! These! interpretations! are!
contested!by!others,!however,! for! instance!Bianco!et!al.!argue!that!“as!inherently!
osteogenic! and! adipogenic! cells,! MSCs! could! generate! bone! or! fat! in! the! wrong!
organs!if!transplanted!in!sufficient!numbers”,!and!that!“allogeneic!MSCs!can!trigger!
an!adverse!reaction.”!Clearly,!then,!there!are!differing!interpretations!of!the!safety!
and! efficacy! evidence! for! MSC! therapies,! and,! in! conjunction! with! continuing!
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uncertainties! in! the! basic! science,! this! results! in! a! complex,! contested,! and!
changeable!environment!for!clinical!trials.!
6.2.2$Translating$uncertainty:$MSC$trials$in$the$UK$
My! fieldwork! confirmed! the! popularity! of! MSCMbased! treatments,! which,! as! I!
reported!in!Chapter!3,!represent!almost!a!fifth!of!UK!cell!therapy!trials!(rising!to!a!











The!potential! immune! response!also!did!not!appear! to!be!a!great!concern! for!UK!
trialists,!even!for!allogeneic!MSCs.!Two!of!the!eight!MSC!trials! in!my!dataset!used!
allogeneic!cells,!and!Interviewee!6!(who!produced!allogeneic!MSCs!for!use!under!a!





have!HLA! typing,! and! they’ve! now! reached! the! point!where!we!
know!third!party!donors!is!very!safe.”!
In!addition!to!this!reputation!for!safety!and!efficacy,!MSCs!are!also!appealing!because!











10! described! them!as! “a( relatively( straightforward( product”.! It! seems,! then,! that!
there!are!both!clinical!and!logistical!reasons!for!the!prevalence!of!MSC!trials.!
! The!ease!of!producing!MSCs,!along!with!their!perceived!applicability!to!a!wide!
range! of! conditions,! appears! to! have! encouraged! an! approach! to! innovation! that!
could!be!loosely!be!described!as!‘technology!push’,!as!described!by!Interviewee!16:!
“I!think!in!terms!of!the!commercial!ventures!at!the!moment,!people!
are! taking! cells! that! can! be! produced! and! then! trying! them! in!
different!conditions,!rather!than!producing!the!cells!specifically!for!
a!particular!condition.”!(INT16)!
This! approach! is! seen! as! aligning! with! the! wider! policy! agendas! surrounding!
translation!and!innovation,!as!discussed!by!Interviewee!14,!who!had!been!involved!





them! M! so! you’re!making! tools! that! actually! extend! right! across!
companies,!that!are!fairly!ubiquitous!in!their!use.”!!
















This! uncertainty!was! also! evident! in!my! dataset! of! UK! trials:! of! the! eight! trials! I!
categorised!as!using!MSCs,!three!described!the!cells!as!‘mesenchymal!stem!cells’,!two!
referred! to! ‘mesenchymal! stromal! cells’,! one! referred! to! ‘bone! marrowMderived!
stromal! cells’,! one! simply! used! the! term! ‘MSCs’,! and! one! described! the! cells! as!
‘multipotent!adult!progenitor!cells’.!There!was!also!a!general!lack!of!clarity!about!the!
specifics!of!the!cell!population!and!release!criteria!used,!and!in!fact!for!most!trials!it!
was! difficult! to! find! any! information! about! the! cell!manufacturing! process! at! all.!
Commercial!MSC!products!are!often!referred!to!in!publiclyMavailable!materials!by!a!




commercial! sensitivity! of! the! information,! but! I! also! found! it! difficult! to! find!
information! about! the! cells! used! in! publiclyMfunded! MSC! trials.! To! give! a! typical!
example,!the!clinicaltrials.gov!entry!for!the!ASCAT!trial!simply!refers!to!‘mesenchymal!
stem!cells’!without!giving!any!further!details!about!the!processing,!selection!or!even!
source!of! the!cells.! There!was! significant!variability!between! trials,!however,!with!
some!providing!more!details! than!others:! for! instance,!the!entry! for!the!STREAMS!
trial!specifies!the!dose!to!be!used,!and!the!RegenVOX!entry!specifies!the!source!of!
the!cells!and!the!fact!that!they!are!grown!on!a!scaffold.!None!of!the!trials!I!reviewed,!
however,! provided! complete! information! about! the! cell! processing! in! their! trial!
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scientific! consensus! about! the! differentiation! potential! of! MSCs;! for! instance,!
Interviewee!8!provided!me!with!a!hard!copy!of!the!protocol!for!one!of!the!trials!in!my!
dataset,! which! claimed! that! “stem( cells( from( a( person’s( own( bone( marrow( can(
develop( into( cells( normally( found( in( other( body( organs,( e.g.( heart(muscles.”! This!
reflects!the!prevailing!scientific!understanding!at!the!time!the!protocol!was!written!
















cells! populations,! and! uncertainty! about! the! characteristics! of! different! subsets!
within!them,!can!also!make!it!difficult!to!interpret!the!results!of!a!trial,!as!explained!
by!Interviewee!12:!
“In! many! trials! we! will! inevitably! have! a! situation! where! the!
outcome! is! less! clear! than! with! a! conventional! pharmaceutical,!
because! you’ve! not! got! the! same! degree! of! control! in! your!
product.”!(INT12)!




down! to! the!definition!of!what! is! an!MSC,!because! there! isn’t!a!










when!cells!are!used! in!the!clinic! M!what! I!have!termed!clinical!uncertainties.!These!
clinical!uncertainties!arise!in!part!from!the!sheer!complexity!of!‘life’!in!the!clinic:!each!
patient!represents!a!specific!configuration!of!an!almost!infinite!number!of!variables,!
including! the! specifics! of! their! diagnosis! or! injury,! their! treatment! history,! coM
morbidities,!lifestyle!and!demographics.!This!complexity!is!complicated!by!variability!
in!patient!response,!which!can!make!it!hard!to!predict!the!effects!of!a!treatment!and!















you’ve! been! successful.! But! the! likelihood! of! that! happening!
without!biomarkers!to!tell!you!that!you’re!doing!the!right!thing![is!
very!low].”!(INT9)!!






Sometimes! this! can! be! because! the! disease! presents! differently! in! an! animal,!
particularly!if!it!is!not!a!disease!the!animal!would!naturally!suffer!from.!For!instance,!
one!interviewee!described!problems!with!a!cell!therapy!that!were!not!apparent!in!

















them! into! a! human! they’re! going! to! find! their! native! adhesion!
molecules!to!stick!to!M!they’re!going!to!behave!physiologically!in!the!
human.”!(INT12)!
Such! views! about! the! limitations! of! animal! models! were! expressed! by! most!
interviewees,! however! Interviewee! 16! had! a! contrasting! perspective,! feeling! that!
they!were!relatively!straightforward!in!his!area:(






! A! lack! of! appropriate! animal! models! has! significant! implications! for! trials,!
because!it!makes!it!difficult!to!collect!the!preMclinical!data!that!is!essential!for!gaining!


















There! is! also! uncertainty! about! how!much! the! cells! will! proliferate;! for! instance,!
Interviewee!12!described!one!trial!he!worked!on!where!there!was!an!average!35,000M
fold! increase! in! the! number! of! cells! found! in! the! body! compared! to! the! number!



























regulator’s! unfamiliarity! with! the! product,! as! highlighted! by! this! quote! from!
Interviewee!5:!
“Safety! testing! of! course! is! very! difficult,! because!we’re! dealing!
with!a!human!cell!therapy!product.!And!that!is!all!that!the!MHRA!
really!is!interested!in!M!they!want!to!see!what!work!you!have!done!













He!went! on! to! reflect! that! relying! on! preMclinical! safety! data! from!animal!models!
might!actually!mask!potential!safety!issues:!!
“I! think! preMclinical! experiments! in! regenerative! medicine! and!










! Emerging!from!this!account!of!uncertainty! is!a!picture!of!clinical! trials! taking!
place!in!the!context!of!a!fluid!and!shifting!scientific!base.!Stem!cell!science!is!much!
more! complex,! and! currently! still! much! more! uncertain,! than! the! science!
underpinning! traditional! pharmaceuticals,! and! the! risks! involved! are! potentially!





‘revolutionise’! healthcare.! Furthermore,! scientific! research! is! progressing! at! a!
phenomenal!pace,!which!can!outstrip!the!careful!clinical!testing!required!to!develop!
a! safe!and!effective! treatment.!Although! scientific!uncertainty! is!not!necessarily!a!
barrier! to! therapies! being! used! in! the! clinic,! as! the! high! number! of! MSC! trials!
demonstrates,! it! is!nevertheless!problematic.!My! findings! show! that!uncertainties!
about!the!characteristics!and!behaviour!of!different!cell!populations!make!it!difficult!






! Linked! to,! and! interacting! with,! these! scientific! uncertainties! are! further!
uncertainties!about!how!the!cells!will!behave!when!administered!to!a!patient.!These!
uncertainties,! combined! with! the! unpredictability! of! the! manufacturing! process!
(discussed! in!Chapter! 5)!and! the!general! complexity!of! the!clinic,!means! that! cell!
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could! be! a! combination! of! all! these! factors,! or! of! different! factors! for! different!
patients.!Each!unknown!factor!for!a!cell!therapy,!then,!does!not!just!add!to!the!overall!
uncertainty,!it!effectively!multiplies!it;!this!makes!it!extremely!difficult!to!isolate!the!





significant! factor! in! most! cell! therapy! trials,! and! resolving! these! uncertainties! is!























fieldwork! I! encountered! a! number! of! examples! of! reverse! translation! happening!












back! and! looked! at! the! cancers! and! said! ‘which! one! of! these!
cancers!expressed! the! receptor?’!When! they! looked!at! the!ones!
that! expressed! the! receptor! that! had! the! treatment,! they’d! got!
miles! better! M! and! paradoxically! the! ones! that! didn’t! have! the!
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receptor! got! worse! with! the! chemotherapy.! So! going! back! and!





! Perhaps! because! of! these! early! experiences! of! clinical! findings! helping! to!
contextualise!scientific!research,!some!cell!therapy!trials!are!now!using!this!approach!




a! programme! of! basic! scientific! research! that! characterise! the! cell! populations!
implanted!into!patients,!providing!a!better!understanding!of!their!proliferation!and!
differentiation! potential.! Although! ENABLE! was! by! far! the! most! comprehensive!
























by! creating!more! alignment! between! scientific! and! clinical! research,! but! it! is! not!
















patient’s! subjective! experience! of! pain.! This! issue! was! particularly! complicated!
because! they! were! uncertain! about! both! the! scale! of! any! likely! effect! and! the!


















being! done! in! the! clinic.! Exploratory! outcome! measures! offer! an! opportunity! to!
prospectively! address! this! issue;! for! instance,! one! of! the! exploratory! outcome!
measures! for! the!ENABLE! trial! involves! characterising! the!cell!populations!used! in!
treatments! and! comparing! the! results! to! clinical! outcomes! for! patients,! thus!









characterisation! and! clinicians! generally! being! less! concerned! as! long! as! the!
treatment! appears! to! work.! One! research! scientist,! discussing! the! issue! at! a!
conference,!even!stated!this!division!explicitly:!“I( think( it’s( [cell(characterisation](a(






that! is! being! tested! or! used! in! the! clinic.! Interviewee! 1! reflected! on! this! issue,!










prerequisite! for!efficacy;! for! instance,!when!discussing! the!use!of!MSCs! for!GvHD,!
Interviewee!6!said:!
“Well! the!biology! is!probably! still! unknown! to! some!extent.!The!






! In! positioning! scientific! uncertainty! as! an! acceptable,! and! even! inevitable,!
aspect! of! translation,! some! trialists! drew! parallels! between! experimental! cell!


















Aligning! the! uncertainties! of! experimental! cell! therapies! with! existing,! accepted!
forms!of!treatment!is!thus!a!way!of!positioning!a!certain!level!of!scientific!uncertainty!
as!acceptable!in!the!clinic.!!
! The!acceptance!of!uncertainty! in!cell! therapies!based!on!their!similarities!to!





them.”! Rather! than! accepting! this! argument,! the! first! speaker! responded! that!
perhaps!this!was!also!a!problem,!and!that!rather!than!accepting!a!similar! level!of!




then,! there! is! no! consensus! about! the! amount! of! scientific! uncertainty! that! is!









all! of! them! is! the! fact! that! they! cannot! be! resolved! in( vitro! or! in! animal!models.!
Because! cell! therapy! uncertainties! relate! to! the! way! human! cells! behave! when!
administered! to! a! human,! they! can! only! be! resolved! through! clinical! testing,! as!
Interviewee!12!emphasised:!!
“The! best! test! model! is! a! human,! if! it’s! a! human! who! has! the!
potential!to!benefit!from!it.”!(INT12)!!








One! of! the! most! important! lessons! that! can! be! learnt! from! patients! involves!
understanding!more!about!the!variety!of!responses!to!the!treatment,!as!described!by!
Interviewee!15:!
“What! that! involves! is! a! more! detailed! understanding! of! the!
patient,! then! they’re! given! therapy,! and! then! a! more! detailed!
understanding! of! what! happens! after! the! therapy! M! not! just!
efficacy.”!(INT15)!
In! a! similar! example,! Interviewee! 2! explained! that! his! trial! would! be! used! to!
determine! the! optimum! patient! characteristics! and! delivery! procedures! for! cell!


























toxicity,! it!can!also! improve!efficacy!by!helping!cell!therapy!developers! learn!more!
about!the!optimum!treatment!protocol.!The!importance!of!the!information!gleaned!








company,! you! know! M! are! you! giving! enough! cells,! what’s! the!
optimal!dose,!what’s!the!optimal!timing.”!(INT11)!
It!seems,!then,!that!trials!are!perceived!as!a!means!of!addressing!the!limitations!of!
animal! models! for! cell! therapies! that! were! discussed! earlier! in! this! chapter,! by!




















transport! the!cells!and! treat!patients!elsewhere.!And!one!of! the!
main!aims!of!our!EU!trial!is!to!test!exactly!that.”!(INT1)!!






! Clinical! testing! thus! appears! to! have! an! important! role! in! developing! safe,!
effective! and! practical! cell! therapies.! Crucially,! it! appears! that! this! process! is! an!
incremental!one;!in!order!for!treatment!protocols!and!practical!logistics!to!be!refined,!










new! information! is!accumulated.!The!way! this!happens!during! the! trial!process! is!
highlighted!by!this!quote!from!Interviewee!7,!describing!an!earlyMphase!gene!therapy!
trial!he!had!been!involved!in:!



















things! that! are! maybe! more! valuable! that! you! can! start! to!
incorporate.!So!in!a!way!you!use!the!community!to!help!you!refine!
the!product.”!(INT17)!



















































risk! that! is! acceptable! in! such! testing.! Many! interviewees! advocated! a! cautious!
approach,!as!exemplified!by!these!quotes:!
“I! always! say,! when! we! come! to! stem! cell! based! therapies! for!





“I! didn’t! want! to! put! people! into! this! horrendously! dangerous!
treatment!without!good!thinking!about!it.”!(INT4)!











cases! be!more! aligned!with! the! priorities! of! patients,! who!might! be! prepared! to!





It! seems,! then,! that! views! on! acceptable! clinical! uncertainty! in! a! trial! are! very!
individualised,!and!this!inevitably!conflicts!with!the!ethical!approval!process!for!trials,!











you’ve! spent!2!years! treating!17!patients!and! if!you’d! just!put!a!





“The! surgeon! involved! said! ‘I! really!wish! I’d!never!done! this,!we!











particular! organ! transplantation,! in! terms! of! the! process! required! to! hone! the!
treatment.!However,!organ!transplantation!was!pioneered!in!a!much!less!restrictive!
clinical!research!environment,!and!even!now!surgical!techniques!are!much!less!likely!
than! drugs! to! be! evaluated! in! RCTs.! This! disconnect! between! the! regulatory!
framework! and! the! development! process! for! new! treatments! is! seen! to! have! the!
potential! to! severely! restrict! innovation,! as! highlighted! by! this! quote! from!
Interviewee!12:!“If(organ(transplants(had(been(regulated(as(medicines,(we(wouldn’t(
be(doing(organ(transplants.”(Again,!this!is!a!marked!contrast!between!cell!therapies!
and! drugs,! and! the! balance! between!protecting! patients! and! the! need! to! resolve!















and! given! the! limited! applicability! of! animal! models! this! means! clinical! trials! in!
humans.!A!good!example!of!this!is!the!fact!that!it!is!only!through!clinical!testing!that!
the!difference!between!a!mixed!and!a!purified!population!of!cells!can!be!assessed,!











conflicting! views! on! how! far! such! uncertainty! can! or! should! be! accepted.! The!
positioning!of!cell!therapies!as!akin!to!organ!transplants!is!an!interesting!case!in!point:!
for!some,!the!successful!development!of!transplantation!in!the!absence!of!scientific!
certainty! creates! a! model! for! the! development! of! cell! therapies,! and! an! ethical!
justification! for! accepting! scientific! uncertainty! in! the! clinic.! This! experimental!
approach! to! clinical! development! can! be! seen! in! the!model! of! innovation! for!
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surgical!methods,! for! instance! hip! replacements! (Metcalf! and!Pickstone,!2006),!
and! proponents! of! this! approach! highlight! the! development! of! HSC!
transplantation!as!an!example!of!iterative!clinical!experimentation,!rather!than!
basic! scientific! research,! leading! to! a! therapeutic! breakthrough! (Martin! et! al.,!
2008).!For!others,!however,!the!development!of!transplantation!is!a!cautionary!tale,!
because! of! the! number! of! people! who! died! during! the! early! years! because! the!
underlying!science!was!poorly!understood!(Daley,!2012).!Daley!also!questions!the!
contention! that! such! experimentation! is! necessary! because! successful!
treatments!such!as!HSC!transplantation!would!not!have!been!developed!without!
it,!arguing! instead!that!HSC!transplantation!would!simply!have!taken! longer!to!
emerge! but! would! have! avoided! the! high! mortality! seen! in! the! earliest!






2016).! This! raises! important! concerns! about! institutional! oversight! and! clinical!







translation,! which! assumes! that! scientific! uncertainties! can! largely! be! resolved!
separately! from! clinical! uncertainties,! both! spatially! (i.e.! in! the! laboratory)! and!
chronologically! (i.e.! before! clinical! uncertainties! are! addressed).! The! tension!






to! its!eventual!adoption!by! users.! From! this!perspective,! technological! innovation!
takes!place!separately! from!the!context! in!which! it! is!used,!and!this!is! reflected! in!
typical!representations!of!translational!research,!which!assume!a!‘bench!to!bedside’!
process!whereby!advances!in!scientific!research!are!made!in!the!laboratory!and!then!
‘translated’! into! effective! treatments! for! the! clinic! (Godin,! 2006).! STS! accounts,!
however,! have! challenged! this! linear! model! by! arguing! that! rather! than! being!
technologicallyMdetermined,! innovation! is! in! fact! a! recursive,! highly! contingent!
process!of!stabilisation!and!closure!(Bijker,!1993).!New!technologies!are!thus!shaped!
by! the! social! and! institutional! contexts! in! which! they! are! developed,! and! user!
involvement! in! the! innovation! process! is! a! critical! factor! in! the!way! a! technology!





! Although! this! combined! approach! to! scientific! and! clinical! research,! which!
might! be! thought! of! as! ‘bioMclinical’! trialling,! provides! a!means! of! reconciling! the!
tension!between!cautious!translation!on!the!one!hand!and!the!recursive!nature!of!
innovation!on!the!other,!my!results!suggest!that!such!research!can!face!a!number!of!
obstacles.! Collecting! scientific! as!well! as! clinical!data! increases! the! administrative!
demands! of! a! trial,! and! a! lack! of! resources! is! of! course! already! one! of! the! key!
challenges!facing!cell!therapy!trials.!It!is!unlikely!that!the!scientific!potential!of!clinical!
trials! can!be! fully! realised!without!adequate! funding,!but!we! saw! in! the!previous!
chapter!that! funding!bodies!tend!to!distinguish!between! ‘basic’!and! ‘translational’!
grants,!and!are!reluctant!to!fund!too!much!basic!science!in!a!clinical!study.!Current!
reporting! practices! can! make! it! difficult! to! evaluate! and! compare! the! scientific!
aspects!of!cell!therapy!trials,!and!the!collection!of!scientific!data!can!also!increase!the!
burden!on!patients,!and!could!even!compromise!the!validity!of!clinical!research.!This!
creates! an! additional! dimension! in! the! research! vs.! care! dynamic,! with! potential!









emphasised! in! much! of! the! literature! on! cell! therapy! translation.! Keating! (2012)!
argues! that! “success! is!more! likely! if! clinician! investigators!work!very! closely!with!
laboratory! researchers! to!design!better! clinical! trials”,! and!Lindvall! (2012)! claims!









manufacturing! factors.! However,! achieving! successful! collaboration! between!
these!areas!is!often!hampered!by!acknowledged!tensions!between!clinicians!and!
biologists!(Martin!et!al.,!2008).!These!tensions!result!from!a!wide!range!of!factors,!
including! the! diverging! goals! of! medicine,! which! aims! to! treat! patients,! and!
science,! which! aims! to! accumulate! knowledge,! and! significant! differences!
between! the! two! domains! in! terms! of! culture,! accountability,! funding! and!
conceptualisation!of!risk!(Cribb!et!al.,!2008).!For!cell!therapies,!one!of!the!key!areas!
of! discord! is! likely! to! be! around! the! acceptable! level! of! uncertainty! in! the! basic!
science;!this!is!particularly!highlighted!by!the!lack!of!consensus!about!the!importance!
for! cell! characterisation,!which! is!an!essential!element!of! reverse! translation,!and!
which!clinicians!tend!to!prioritise!less!than!scientists.!
















































improvements.! This! challenge!can! be! understood! in! the! context! of! the! difference!
between!the!development!of!cell!therapies!and!the!drugs!on!which!the!phase!model!
was!based.!A!high!failure!rate!is!effectively!‘builtMin’!to!the!evidenceMbased!medicine!
framework,!with!up! to!70%!of!earlyMphase!drug! trials! failing! (Daley,!2012).!This! is!
because! when! the! modern! phase! system! for! trials! was! developed,! Phase! 1! was!
intended!as!a!screening!stage,!whereby!a!large!number!of!compounds!could!be!tested!
quickly! and! with! minimal! risk,! identifying! those! that! showed! enough! promise! to!
warrant!further!investigation!(Keating!and!Cambrosio,!2012).!This!model,!designed!
for!relatively!simple!chemical!compounds,!is!clearly!problematic!for!the!much!more!
complex! living! tissue! involved! in! cell! therapies,!with!a!multitude!of! variables! that!
could! affect! the! eventual! outcome.! This! suggests! it!may! be! necessary! to! explore!










based!on!an!experimental!model!and!a! clinical! research!culture!which! is! to! some!
extent! rooted! in! a! ‘trial! and! error’! approach! (Wainwright! et! al.,! 2006).! EvidenceM
based!medicine!(EBM)!claims!to!bridge!this!gap!by!applying!the!rigour!of!scientific!
experimentation! to! clinical! research,! and! it! is! this! concept! that! underpins! the!
argument!that!if!experimental!cell!therapies!are!to!be!used!in!the!clinic!this!should!
be!in!‘robust’!clinical!trials.!Implicit!in!this!argument!is!that!certain!types!of!evidence!
are!more! valid! than! others,! as! demonstrated!when!Daley! explicitly! spells! out! the!
characteristics! of! ‘valid’! and! ‘invalid’! evidence:! “We! also! need! to! design! rigorous,!
blinded,!and!when!possible!randomised!trials!where!evidence!for!clinical!efficacy!can!
be! defined! precisely,! rather! than! depend!upon!anecdote! and! clinical( observation!
alone”! (Daley,! 2012).! Daley’s! emphasis! on! randomisation! and! blinding,! and! his!
dismissal! of! clinical! experience,! reflects! the! current! orthodoxy! of! EBM,! and! his!
concern! with! rigour! has! recently! been! given! greater! salience! in! the! field! of! cell!








! There! appears,! then,! to! be! a! fundamental! tension! at! the! heart! of! the! trials!
process!for!cell!therapies:!the!generation!of!‘quality’!evidence!can!be!at!odds!with!




of!evidence! in!detail,! firstly!by! looking!at!how! trialists!themselves!understand! the!
evidence!generated!by!trials,!and!in!particular!outcomes!measures!(which!the!House!








Despite!achieving!hegemonic! status,! there! is!no! universallyMaccepted!definition!of!
exactly!what!EBM!is!or!what!it!entails.!The!original!propositions!largely!focussed!on!
EBM!as!a!clinical!decisionMmaking!tool,!with!the!focus!being!on!encouraging!the!use!
of! systematic! empirical! evidence! when! making! clinical! decisions,! and! equipping!
doctors!with!the!ability!to!critically!appraise!clinical!research.!Over!time,!however,!the!
focus! began! to! move! away! from! individual! clinical! decision! making! towards! the!





clinical! trials! before! licensing! new! treatments! (Dehue,! 2010),! and! there! is! a!
proliferation! of! EBMMinformed! clinical! guidelines! and! care! pathways! which,! to! a!
greater!or!lesser!extent,!dictate!individual!patient!care!(Will!and!Moreira,!2010).!EBM!
principles! also! affect! research! funding! structures! and! the! publication! of! research!








more! reliable!than!others.!At! its!broadest! level,!evidence!has!been!defined!within!
EBM!as! “any! empirical! observation! about! the! apparent! relation! between! events”!
(EBM!Working!Group,!1992).!Within!this!could!be!included!experimental!studies!such!
as!clinical!trials,!observational!studies!such!as!case!control!and!cohort!studies,!and!
unsystematic! observations! such! as! clinical! case! studies! and! accumulated! clinical!
experience!(Bluhm,!2005).!One!of!the!most!important!functions!of!EBM!has!been!the!
introduction!of! hierarchies!which! stipulate! the! relative! importance! that! should!be!
placed!on!each!of!these!different!types!of!evidence.!Such!hierarchies!invariably!place!
randomised!controlled!trials!(RCTs)!and!systematic!reviews!of!such!trials!at!the!top,!
with! nonMrandomised! (or! observational)! studies! lower! down,! and! nonMsystematic!
evidence! such! as! case! studies! forming! the! lowest! tier! of! evidence! (Straus! and!
McAlister,!2000;!Bluhm,!2005).!Theoretical! knowledge,! such!as! that!generated!by!
laboratory!experiments,!is!largely!excluded,!as!is!clinical!experience!or!‘expertise’.!!
! The!primacy!given!to!randomised!trials!means!that!to!some!extent!the!term!
EBM!has! become! “synonymous!with!medicine! based! on! results! of! RCTs”! (Dehue,!
2010).!This!interpretation,!which!has!been!described!as!a!‘crude’!application!of!EBM!
principles! (Brody! et! al.,! 2005),! has! been! challenged! from! the! beginning! by! EBM!
proponents,! who! have! emphasised! the! importance! of! using! various! forms! of!
empirical!evidence,!in!conjunction!with!clinical!experience,!to!make!decisions!about!
the! treatment! of! individual! patients! (Straus! and! McAlister,! 2000).! Although! this!
suggests!that!the!EBM!model!is!in!theory!open!to!a!relatively!nuanced!approach!to!
evidence,! this! type! of! interpretation! has! in! fact! been! largely! limited! to! academic!
discussion! in! journals.! In! practice,! the! increasing! use! of! evidence! hierarchies! and!
clinical!guidelines!often!creates!a!form!of!‘mechanistic!objectivity’!(Cambrosio!et!al.,!









objective,! valid! evidence.! These! key! elements! demarcate! the! method! as!
interventional(rather!than!observational,(and!this!distinction!is!used!by!advocates!to!
characterise! RCTs! as! scientific! experiments! that! allow! for! causal! inferences! to! be!
made,! in! contrast! to! observational! studies! that! can! only! identify! correlation!
(Torgerson!and!Torgerson,!2008).!Terms!such!as!‘controlled’,!‘blinded’!and!‘statistical’!
create!a!rhetoric!that!emphasises!scientific!credibility!(Edwards,!2007;!Marks,!1997),!




Sariola,!2012),!and! it! is! this!claim,!pursued!with!“a!zeal! that!at!times!resembled!a!















methods! can! be! equally! effective! at! preventing! selection! bias! and! addressing!
confounding! variables,! particularly! in! trials! with! small! samples! (Grossman! and!
Mackenzie,! 2005;! Worrall,! 2007).! Worrall! challenges! the! contention! that!
randomisation! is! necessary! for! achieving! scientific! objectivity,! citing! the! point!
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sometimes! raised! by! Bayesian! statisticians! that! randomisation! is! rarely! used! in!
physics,! which! many! would! consider! “the! most! successful! science! we! have”.! He!
highlights! the! fact! that!most! treatments! currently! in! use! today! have! never! been!
subject!to!an!RCT,!and!yet!there!is!no!reason!to!suppose!that!the!majority!of!medicine!
as! currently! practiced! is! ineffective.! Proponents! of! EBM! tend! to! claim! that! the!
importance! of! randomisation! is! ‘proven’! when! a! treatment! that! has! shown!
effectiveness!in!observational!studies!shows!no!significant!effect!in!an!RCT!(Torgerson!
and!Torgerson,!2008).!This!assumption!is!reflected!in!Daley’s!(2012)!argument!that!







other! studies,! that! are! ‘true’,!whereas! in! fact! other! factors! could! have! led! to! the!










in! trials! but! then! showed! different! results! when! adopted! into! general! medical!
practice.! Cartwright! and! Munro! (2010)! argue! that! there! is! a! tradeMoff! between!
internal!and!external!validity:!randomisation!improves!internal!validity!by!accounting!
for!unknown!confounders,!but!because!the!confounders!are!unknown!there!is!no!way!


















that! for! instance! one! small! RCT! with! poorly! chosen! outcome! measures! would!
theoretically! be! given! greater! weight! than! a! number! of! large,! wellMdesigned!
observational!studies.!Others!have!highlighted!the!fact!that!some!safety!issues!may!
only! come! to! light! through! individual! case! reports,! and! are! therefore! likely! to! go!
unrecognised! in! the! EBM!model! which! places! very! little! value! on! such! research!
(Smith,!1996).!More!‘sophisticated’!advocates!of!EBM!might!reject!this!reliance!on!
RCT!evidence!‘at!all!costs’!(Brody!et!al.,!2005),!but!in!practice!the!assumption!that!





decisions.!The! increasing! influence!of!EBM!has!had!significant! implications!for!the!
treatment!of!patients,!both!directly,!by!affecting!individual!clinical!decision!making,!
and!more!indirectly!through!its!influence!on!health!policy,!reimbursement!processes,!




rather! than!experience!or! judgement,!and! that! eliminating!personal!opinions!and!
politics! is! the! best! way! to! achieve! consistent! and! efficient! treatment.! In! reality,!
however,!evidence!can!be!interpreted!in!various!ways!depending!on!the!experience,!
beliefs!and!values!of!those!doing!the!interpreting.!Unsurprisingly,!therefore,!the!use!
of! RCT! results! in! decision! making! is! often! affected! by! personal! and! professional!







mortality.! Proponents! of! home! birth! tend! to! be! those! who! wish! to! reduce! the!
medicalisation!of!childbirth,!and!who!therefore!see!the!reduced!risk!of!intervention!
as! a! considerable! benefit! which! outweighs! a! small! (and! unproven)! additional!
mortality! risk.! Conversely,! proponents! of! hospital! birth! place! less! importance! on!
reducing!the!risk!of!intervention,!and!prioritise!the!fact!that!some!studies!have!shown!
a! slightly! increased! mortality! risk.! Thus,! each! side! takes! the! same! evidence! but!
interprets! it! differently! depending! on! their! own! values,! demonstrating! that! the!
application! of! ‘evidence’! in! evidenceMbased!medicine! is! far! from! being! a! neutral,!
apolitical!process.!
! Given! the! political! and! social! processes! at! work,! as! well! as! the! inherent!
uncertainty! of! the! evidence! itself,! it! is! unsurprising! that! evidenceMbased!
recommendations!can!change!significantly!over!time.!This!can!be!as!a!result!of!new!
(perhaps!more! ‘valid’)!evidence!becoming!available,12!however!guidelines!can!also!




not!be!fed!peanuts!because!of!an!increased!likelihood!of!developing!an!allergy!(Du!Toit et al., 2015).!
13!For!instance,!the!recent!NICE!guidelines!on!caesarean!section!presented!revised!advice!on!the!safety!
of! the! procedure! without! any! new! data! being! used,! instead! the! new! statistics! were! based! on! a!
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framework! itself! acknowledges! the! issue! of! uncertainty:! the! priority! placed! on!
systematic!reviews!and!metaManalyses!acknowledges!that!individual!trials!may!give!
misleading! or! conflicting! results,! and! the! process! of! updating! and! revisiting! both!
reviews!and!clinical! guidelines! is! intended! to!account! for!new!evidence!becoming!
available!and!for!‘improvements’!in!analytical!methods.!There!is!clearly,!therefore,!no!
one! way! to! interpret! evidence,! and! this! ambiguity! means! that! evidenceMbased!
decision!making!can!never!be!a!purely!objective!and!neutral!process.!In!this!context,!



















a! more! nuanced! approach! to! evidence! in! medicine! would! seek! to! understand!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!













! These! calls! for! a! more! nuanced! approach! to! evidence! are! reflected! in!
Cambrosio! et! al.’s! (2006)! discussion! of! mechanistic! versus! regulatory! objectivity.!
Mechanistic! objectivity,! which! is! a! manifestation! of! the! crude! version! of! EBM!
discussed!above,! is!embodied! in!a! system!that! relies!on!checklists!and!guidelines.!
Regulatory! objectivity,! in! contrast,! “turns! the! focus! away! from! objects! towards!
collective! forms! of! expertise! combining! people! (clinicians,! researchers,!
administrators,!patients,!etc.)!and!objects! (entities,!instruments,! tools,! techniques,!
etc.)! connected! by! specific! coordination! regimens.”! Under! this! approach,! which!
reflects!the!more!nuanced!approach!to!evidence!presented!in!much!of!the!academic!
EBM!literature,!the!focus!is!moved!away!from!the!outcome!of!evidence!interpretation!
to! look! instead! at! the!process( through!which! a! consensus! is! reached.! As!well! as!
providing! a! normative! framework! for! a!more! nuanced! approach! to! evidence,! the!
concept! of! regulatory! objectivity! also! provides! a! useful! analytical! framework! for!
exploring! the! role! of! evidence! in! cell! therapy! innovation.! By! focussing! on! how!
evidence!is!conceptualised!and!used!in!decision!making,!we!can!better!understand!
the! complex! and! interdependent! relationship! between! the! different! domains!











therapy! developers! interact! to! produce! and! evaluate! evidence,! shaping! both! the!
development!of!specific!therapies!and!the!very!definition!of!evidence!itself.!
7.2!RCTs!and!cell!therapies!W!the!'right'!kind!of!evidence?!
In! line! with! the! crude! version! of! EBM! described! in! the! previous! section,! many!
interviewees!described!RCTs!being!treated!as!conclusive!proof!of!the!potential!of!a!
new! therapy.! For! instance,! Interviewee!7!described!how! two!RCTs! failing!to! show!
efficacy!effectively!halted!any!further!research!into!a!treatment:!
“The! Americans! then! did! some! doubleMblind! placeboMcontrolled!
trials!where!they!took!patients!and!either!gave!them!a!transplant!








then! they!went! immediately! into! Phase! 3! studies!…! and! there’s!
positive!signals!going!on,!but!they!didn’t!hit!their!primaries!and!so!
they’ve!gone!in!a!different!direction.”!(INT11)!
Interestingly,! it! is! not! just! unsuccessful! lateMphase! trials! that! can! hamper! the!
development!of!a!product;!Interviewee!17!explained!that!he!was!concerned!that!even!















EBM.! In! this! section! I! will! explore! trialists’! perspectives! on! evidence,! first! by!





Most! interviewees! were! in! favour! of! structured,! regulated! clinical! trials! for!
experimental!therapies,!and!rejected!other!forms!of!evidence!(such!as!individual!case!




“It’s! not! good! science! really,! because! what! we! really! need,!
especially!in!cell!therapy,!are!properly!designed!clinical!trials!to!be!
executed! and! completed.! And!we!still! see! even!now! in!my! field!
some! really! uberMeminent! people! publishing! case! reports! and!
series,! and! two!or! three! patients! in! the!New!England! Journal! of!
Medicine.!And!they!are!remarkable!results,!but!that’s!not!a!proper!
clinical!trial.”!(INT5)!







“We! thought! about! specials! licences! and! all! sorts! of! other!ways!
round!it,!but!at!the!end!of!the!day!we!knew!we!wanted!to!publish!
our! data.! And! if! we! didn’t! go! through! the! regulatory! route! we!
wouldn’t!be!able!to!publish!it,!or!we!certainly!wouldn’t!be!able!to!
use!those!data! in!terms!of!the!next!phase!of!our!work!…! I! think!
there!was!some!nagging!doubt!that!had!we!not!gone!through!the!



















than! your! own! ability! to! do! it,! because! it’s! been! done! in! other!














individual! cases,! some! interviewees! did! recognise! that! there! could! be! benefits! to!














Interviewee! 4! said,! “it( may( inform( how( we( do( the( trials”.( Interviewee! 17! also!
























! From! the! trialists’! perspective,! it! appears! that! the! main! drawback! of!
















The! use! of! data! from! individual! cases! also! faces! challenges! associated! with! the!
characteristics! of! the! patients! treated,! equivalent! to! the! exclusion! and! inclusion!
criteria! for!a! trial.! For! instance,! Interviewee!4!explained! that!when! looking!at! the!
outcomes!for!patients!treated!under!HE,!he!had!to!take!into!account!the!reason!they!
had!not!been!in!a!trial!instead,!as!this!was!likely!to!affect!the!outcome:!













“Because! the! clinical! trial! will! have! hopefully! a! reasonably!
standardised!group!of!patients,!as!standardised!as!we!can!because!






from! that! that!will! be! additive! to! the! compassionate! use! data.”!
(INT17)!!
In! this!description,! the! trial! is! actually!more! like!a! series!of! case! studies! M! a! small!
















that! clinical! evidence! should! be! generated! through! regulated! trials,! they! are! not!
necessarily! convinced! that! randomisation! is! essential.! Indeed,! a! number! of!





“You! then! get! a! sequence! effect! as!well,!which! is! obviously! not!








In! this! quote,! Interviewee! 17!was! careful! to! distance! himself! from!any! ‘scientific’!
claims!because!of!the!lack!of!randomisation,!whilst!still!recognising!the!benefits!of!
such!data,!aligning!with!the!previous!quote!which!highlighted!the!additional,!nonM






after! a! transplant! who! has! a! [measure! of! disease! progression]!
which!is!less!that!when!they!presented!25!years!previously,!on!no!


















transplant,! and! then! compared! 11,! 11! and! 12! and! found! no!
significant! effect.! If! they’d! pooled! the! transplants! …they! would!
have!had!a!significant!effect.”!(INT7)!
In!this!example,!the!lack!of!a!significant!effect!is!due!to!a!power!issue:!because!the!


















For! cell! therapy! trialists,! then,! whether! or! not! a! trial! generates! valid! evidence! is!
contingent!on!much!more!than!just!the!typical!EBM!markers!of!‘quality’.!
! We!can!see!here!two!very!different!perspectives!of!evidence!emerging:!the!EBM!








“A! surgical! trial,! where! you’re! tailoring! the! treatment! to! the!
patient,! different! numbers! of! cells! in! different! placements,!
immediately!it’s!anathema!to!a!trial!design!specialist.!You’re!always!
going! to!be!doing! it! in! cases!of!30!or! 40!patients!…!not!600! for!
power!calculations.”!(INT2)!
Sample! size!was! also! a! problem! for! Interviewee! 7,!who!described! his! experience!
discussing!trial!design!with!statisticians!who!were!unfamiliar!with!the!realities!of!cell!
therapies:!























Here! we! can! see! the! extent! to! which! the! pharmaceutical! trial! model,! with! its!
emphasis! on! randomised,! blinded! control! groups,! has! become! the! default!
expectation!in!some!clinical!circles,!and!the!difficulties!this!can!cause!for!a!treatment!
that!does!not!fit!into!this!model.!













“People!have! this!huge! suspicion!of!all!of! this,! and!you! say!well!
there’s! nothing! wrong! with! it! I’m! not! trying! to! sell! a! product.”!
(INT7)!
It! seems,! then,! that! cell! therapy! trialists! may! struggle! to! have! their! version! of!
evidence!accepted!by!a!clinical!community!that!has!been!trained!to!be!suspicious!of!












Scientific!outcomes! for! trials,! then,!do!not!always!have!a! specific!objective!at! the!
outset,!unlike!the!clinical!outcomes!which!(in!theory!at!least)!have!to!be!completely!
specified! before! the! trial! starts.! The! tension! between! these! two! approaches!was!
highlighted!by!Interviewee!8!(a!trials!specialist):!
“The! basic! scientist’s! approach! to! analysis! is! very! different! to! a!
trialist’s!approach.!If!you’re!running!clinical!trials!everything!has!to!
be! preMspecified,! spelled! out,! you! have! very! clear! analysis! plans!
that!we!agree!up!front.!Basic!scientists!don’t!tend!to!work!in!that!
way,! they! do! much! more! exploratory! type! analyses,! or! fishing!
expeditions!as!some!of!us!may!refer!to!them.”!(INT8)!









do! those!analyses!on! the!understanding! that!you!write! them!up!
whatever!they!show.”!(INT8)!










randomisation,! blinding! and! statistical! power,! which! are! at! the! heart! of! EBM’s!
conceptualisation! of! evidence.! Furthermore,!much! of! the! evidence! valued! by! cell!







can!be!multiple!outcomes!of! interest! from!a! trial,! and!multiple!ways! in!which!an!





crude! version! that! insists! on! certain! aspects! of! trial! design! being! essential! for!
evidence!to!be!considered!valid.!This!selfMpolicing!amongst!the!clinical!community!
may!prove!problematic! for! the! future!adoption! of! cell! therapies,!where! these!key!
tenets!of!EBM!are!often!logistically!impossible.!
! The! fact! that!many! clinicians! appear! to! accept,! and! enforce,! the! version! of!
evidence!set!out!by!EBM!is!perhaps!unsurprising,!given!the!extent!to!which! it!has!





cell! therapy! trials,! which! mean,! in! the! words! of! Interviewee! 7,! that! cell! therapy!
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developers! “have( to( be( a( bit( imaginative( in( how( we( do( the( trials”.( Another!
contributory!factor!may!be!the!close!links!between!clinical!cell!therapy!research!and!
basic! science,! which! as! we! saw! in! the! previous! chapter! are! intertwined! and!
interdependent!aspects!of!the!translational!process.!Marincola!(2003)!argues!that!the!
scientific!culture!can!be!problematic!for!translational!research:!for!instance,!the!need!
to! generate! positive! results! for! publication! in! prestige! journals! can! make!
scientists! unwilling! to! embrace! the! uncertainty! of! clinical! research,! instead!
encouraging!them!to! ‘drop!the!ball’!early! in!the!translational!process! if! results!
are!unpromising.!My!findings!suggest!that!this!scientific!culture,!and!in!particular!the!
way! that! it! approaches! evidence,! is! significantly! detached! from! the! dominant!
discourses! of! EBM,! a! tendency! that! is! also! apparent! in! the! philosophy! of! science!
critiques!of!EBM!which!I!discussed!earlier!in!this!chapter.!Thus,!cell!therapy!trials!take!
place! in! a! context! where! alternative! conceptualisations! of! evidence! are! both!































measures! of! safety! and! efficacy! used! to! evaluate! additional! effects! of! the!
intervention;! and! 3)! exploratory! (or! explanatory)! outcomes,! which! are! other!
measures,! not! associated!with! safety! or! efficacy,!which! could! help! to! explain! the!
results!or!aid!in!the!design!of!future!trials!(CONSORT,!2017).!Trials!are!supposed!to!
be!adequately!‘powered’,!which!means!that!the!sample!size!should!be!large!enough!
that! the! expected! effect! of! the! treatment,! if! observed,! would! be! statistically!




























recognise! it! –! the! patients! haven’t! said! that! but! that’s!what!we!
think.! But! it’s! hard! to! put! into!words,!we! don’t! have! very! good!
measurements.”!(INT9)!









This! quote! also! highlights! another! issue! with! outcome!measures,! which! we! first!
encountered!in!the!discussion!of!temporality!in!Chapter!5;!it!is!often!necessary!to!use!
the!same!outcome!measures!as!previous!trials!in!order!to!compare!the!results,!even!











now! quite! toxic! as! well.! So! progressionMfree! survival,! it! doesn’t!







at! this! point! it! would! just! be! about! patientMreported! outcome!
measures!or!something.!Which!would!be!OK,!but!we’re!not!entirely!
getting! to! some!of! the!aspects!of!a! regenerative! therapy,!which!
might!be!to!some!extent!based!on!a!tissue!response.!So!that’s!an!
aspect!that!needs!to!be!brought!into!it.”!(INT15)!
The! difficulties! of! measuring! progress,! and! the! conflicting! priorities! of! patient!
relevance!on!the!one!hand!and!‘measurable’!clinical!difference!on!the!other,!led!some!
interviewees!to!endorse!using!a!number!of!different!measures!in!conjunction:!
“The! only! feasible! approach! is! to! have! a! really! broad,!











worthy! of! consideration,! is! the! appropriate! length! of! outcome!measures! for! cell!
therapy!trials.!Views!on!this!differed!markedly!between!clinical!areas,!for!instance!in!
cancer! there! are! wellMestablished,! accepted! outcome! measures! that! tend! to! be!
relatively! shortMterm,! meaning! a! trial! can! typically! be! conducted,! analysed! and!
reported! in! one! or! two! years.! For! other! conditions,! however,! the! length! of! time!
required!to!measure!outcomes!may!be!much!longer;!this!is!particularly!the!case!for!




















The! speed! with! which! an! outcome! can! be! measured! thus! represents! a! point! of!



















































predict! what! sort! of! effect! might! be! achieved,! as! highlighted! by! Interviewee! 8’s!
response! when! I! asked! if! using! imaging! as! a! primary! outcome! presented! any!
difficulties:!
“It’s! only! more! challenging! if! it’s! a! primary! outcome! that! you!












! To! counter! the! uncertainty! caused! by! unfamiliar! outcomes!measures,! some!
interviewees!described!working!backwards!from!what!would!be!considered!clinically!























“With! the! clinicians!we! set! a! target! of! what!would! be! clinically!





of! statistical! significance! by! focussing! on! the! more! tangible! issue! of! clinical!
















































now! set! it! up! as! a! secondary! endpoint.! Because! referees! and!
statisticians!are!so!rigid!that!they!can’t!quite!see!that!this!was!a!
primary! endpoint! that! said! that! this! is! a! lifeMchanging! therapy.”!
(INT4)!
Such!unrealistic!expectations!of!a!cure!can!have!significant!consequences!not!only!for!





the! Clinton! administration:! a! huge! amount! of! money! for!
Parkinson’s!disease!with!stem!cells!in!the!brain,!and!then!it!all!went!
flop,! and! then! for! 20! years! no! one!would! invest! in! that! …! And!
actually!when!you! look!at!the!data! it!didn’t!go!flop,! it’s! just!that!
people!expected!a!miracle.”!(INT16)!
These!experiences!suggest!that!the!effect!size!a!trial!sets!out!to!test!affects!more!than!
just! the! success! or! failure! of! that! particular! trial,! it! also! has! a! role! in! setting!
expectations!for!the!treatment!more!broadly.!




instance,!Keating!and!Cambrosio! (Keating!and!Cambrosio,!2012)! contend! that! “as!
experiments,!clinical!trials!require!more!than!the!mechanical!application!of!routine!
methodologies;!they!require!the!definition!of!‘appropriate’!research!questions”.!My!
findings! suggest! that! this! is! certainly! the! case! for! cell! therapy! trials,! where! the!
decision!of!what!to!test!and!how!to!measure!it!is!clearly!not!an!objective!or!neutral!
one.! Choosing! a! primary! endpoint! involves! a! number! of! different! and! interlinked!
factors,! including! the! outcome!measure! to! be! used,! the! likely! effect! size! and! the!
sample! needed! to! reach! statistical! significance.!Other! factors! also! come! into! play!




clinical! measures! and! patientMreported! outcomes,! which! are! more! indicative! of!
whether!the!patient!themselves!feels!their!condition!has!improved,!but!potentially!
more!likely!to!be!affected!by!the!patient’s!expectations.!It!seems,!then,!there!are!a!







endpoint! for!any!given! trial! is!not! inevitable,!but! results! from! trialists!balancing!a!




achievable,! and/or! the! likely! impact! if! it! is! not! achieved.! This! suggests! that! the!




the! primary! endpoint! represents! a! complete! cure! then! this! becomes! the! bar! the!
treatment!is!expected!to!meet,!and!failure!to!meet!the!endpoint!means!it!has!failed!
to!live!up!to!those!expectations;!conversely,!if!the!endpoint!is!set!at!a!lower!level,!
then! exactly! the! same! results!might! be! deemed! a! success.! Likewise,! by! setting! a!
















therapy,! how! a! trial! should! be! designed! and! undertaken,! and! whether! it! should!
receive! ethical! approval.! These! decisions! tend! to! involve! the! Medicines! and!
Healthcare!Product!Regulatory!Authority!(MHRA),!with!the!Human!Tissue!Authority!
(HTA)! also! being! involved! in! some! cases.! The! Health! Research! Authority! (HRA),!
Research!Ethics!Committees!(RECs)!and!individual!NHS!trust!R&D!departments!are!





(EMA)! is! responsible! for! assessing! marketing! authorisation! applications,! and!
reimbursement!decisions!could!involve!the!National!Institute!for!Clinical!Effectiveness!
(NICE),! NHS! England! (or! Scotland),! Clinical! Commissioning! Groups! (CCGs)! and!
individual!trust!commissioning!processes.!The!different!ways!that!these!institutions!
approach!evidence!has!a!significant!impact!on!trials!of!cell!therapies,!and!on!their!





The! MHRA! is! the! competent! authority! responsible! for! regulating! and! inspecting!
clinical!trials!for!cell!therapies!designated!as!ATMPs,!and!is!therefore!the!regulatory!
body!which!has!most!input!into!the!trials!process.!Interviewees!who!had!had!dealings!
with! the! MHRA! generally! reported! their! relationship! with! the! regulator! being! a!
positive!one,!as!in!this!typical!example!from!Interviewee!9:!



















































in! discussions! with! the! MHRA! ...! I’ve! joked! with! [MHRA!
representative]! the!other!day,!he! said! ‘we! really! should!get!you!
your!own!pass’,!I’m!at!the!MHRA!so!often.”!(INT12)!
Interestingly,!Interviewee!12!(an!academic!researcher)!went!on!to!make!a!distinction!





us! our! opinion! or! for! our! help,! whereas! academia! are! always!
coming.”!(INT12)!
! The!importance!of!the!MHRA’s!collaborative,!flexible!approach!is!emphasised!
by!a! comparison!with! the!more! rigid!and! less! consultative!approaches! reportedly!
adopted!by!other!institutions.!One!interviewee!had!significant!problems!with!some!
of!the!requirements!imposed!by!the!HTA,!which!is!responsible!for!regulating!any!cell!
therapy! involving! the! transplant!of!human! tissue! (i.e.! allogeneic! therapies).! These!






“They’ve! ruled! that! if! the! law!says!you!have! to!do!an!additional!
blood!test!you!do!it!M!you!don’t!have!to!use!the!data.!So!think!for!
yourself,!in!terms!of!the!welfare!of![the!donor]!at!a!stressful!time!M!













was! also! experienced! by! some! of!my! interviewees! in! their! interaction!with!NICE,!
which! is! the! body! responsible! for! producing! commissioning! guidelines! for! cell!
therapies!delivered!by!the!NHS.!For!most!trialists,!NICE!is!not!involved!in!terms!of!
reimbursement! for! the! actual! trial:! for! publiclyMfunded! trials! the! funding! for! the!





‘right’!evidence! for! reimbursement! at! a! later! stage.! Interviewee! 17! described! the!
process! of! trying! to! ascertain! what! evidence! NICE! would! require! as! extremely!
7.(Evidence(and(expertise:("how(much(can(you(leave(out(and(still(have(an(RCT?”!
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put! on! before! Christmas! about! data! requirements! for! their!








Again,! this! approach! contrasts! with! the!MHRA,!which! appears! to! be!much!more!
willing!to!engage!with!trialists!in!the!early!stages,!discussing!the!types!of!evidence!
that!will!be!required!and!advising!on!the!best!way!to!generate!this!evidence.!
! The! importance! of! understanding!how!NICE! is! likely! to! interpret!evidence! is!
highlighted! by! the! recent! review! of! the! guidelines! on! autologous! chondrocyte!
implantation! (ACI).! Having! reviewed! evidence! about! both! efficacy! and! cost,! NICE!
released!draft!revised!guidelines!stating!that!ACI!should!continue!to!be!funded!only!
if!used!as!part!of!a!clinical!study,!because!the!evidence!of!ACI!outcomes!being!better!
than! microfracture! (an! alternative,! cheaper! treatment)! was! deemed! to! be!
inconclusive!(NICE,!2015).!NICE!deemed!the!evidence!of!ACI’s!effectiveness!to!be!“low!
quality”,!because!of!(amongst!other!things)!small!samples,!inadequate!followMup,!and!










the!basis!of! the!NICE!assessment,! viewed!ACI! itself! as!an!experimental! treatment!
(Field!notes!23/09/15).!Thus,!although!the!NICE!assessment!was!largely!made!on!the!
basis!of!economic(effectiveness!M!a!combination!of!efficacy!and!cost! M! it!was!being!





assessed! by! NICE.! To! some! extent! this! reflects! the! different! remits! of! the! two!
institutions,!with! the!EMA!being! responsible! for!assessing!whether!a! treatment! is!
acceptably! safe! and! effective,! whereas! NICE! is! also! concerned! with! whether! it!
represents! value! for! money.! It! also,! however,! highlights! the! fact! that! different!
institutions!may!have!different!interpretations!of!evidence!‘quality’:!for!instance,!in!
its!approval!of!MACI,!EMA!refers!to!a!study!of!144!patients!and!deems!this!to!have!
demonstrated! its! superiority! to! microfracture! (EMA,! 2013),! which! contrasts! with!
NICE’s!evaluation!that!the!study!was!too!small!to!be!reliable,!and!had!an!insufficient!
followMup! period.! This! apparent! variability! in! assessing! evidence! quality! is! also!
apparent!in!other!EMA!decisions:!for!instance,!the!approval!of!Holoclar!was!based!on!









inconsistent,! in! its! assessment! of! evidence! quality.! For! instance,! the! rejection! of!




chance”! (EMA,!2015c).! In! this! case! the!evidence! submitted!appears! to!have!been!
collected! prospectively!with! the! results! compared! to! historical! controls,!which! in!




















can!cause!consternation!even!amongst!nonMcommercial!developers,! and! for! those!
aiming!to!commercialise!the!treatment!this! is!a!crucial!concern.!Negotiations!with!
the!EMA!then!become!extremely!important,!and!some!of!my!interviewees!reported!

























fit! for!biological! treatments!that!are! living!systems.”! (Field!notes!
01/05/14)!
Another! trialist! speaking! at! the! same! course! highlighted! the! problems! that! this!





Thus,! the! novelty! of! many! of! cell! therapies,! and! the! complexity! of! the! science!














many! cell! therapy! trialists! were! concerned! that! they! might! take! a! riskMaverse!
approach! and! turn! down! anything! that! they! didn’t! understand.! For! instance,!
Interviewee! 7! described! the! difference! between! the! regulation! of! a! familiar!
treatment,!such!as!bone!marrow!cells,!and!a!more!experimental!cell!therapy:!
“Everyone!understands!what!you’re!doing!with!bone!marrow!cells!







The! implication! of! regulators! taking! a! riskMaverse! approach! was! highlighted! by!
Interviewee!9,!who!explained!that!there!was!a!danger!they!would!ask!for!additional!
evidence!which!would!be!difficult!and!time!consuming!to!generate:!!
“When! you’re! peer! reviewing! something! people! tend! to! be!















! Despite! these! concerns,! however,! it! seems! regulators! are! aware! that! the!
novelty!of!many!cell!therapies!means!that!they!may!lack!the!expertise!needed!to!fully!
understand!the!treatment.!This!means!that!the!MHRA,!in!line!with!their!collaborative!
























devote! lots!of! time!and! resource! to! influence! the! right!people.”!
(INT17)!!
It! appears,! then,! that! although! a! flexible! approach! is! valued! by! trialists,! lack! of!
certainty!and!the!need!to! influence!decision!makers!mean! it!can!also!cause!them!
practical!difficulties.!
! Another! issue! that! my! interviewees! experienced! when! negotiating! the!
regulatory! framework! was! the! variety! of! ways! regulators! might! approach! the!








some! bridging!work! that! can! demonstrate! that! while! there! is! a!
change!it!doesn’t!fundamentally!change!what!we’re!trying!to!do.!
And!I!know!that!makes!us!slightly!different,!that!we’re!asking!for!
















in! fact! the!NHSMproduced! product! is! actually!much! cheaper.! In! contrast,! the! EMA!
essentially! treats! these! treatments! as! ‘different’,! having! given! marketing!
authorisations!to!MACI!and!ChondroCelect,!thus,!in!order!to!keep!providing!ACI!in!
the! presence! of! licensed! alternatives,!NHS! sites!must! be! able! to! argue! that! their!
product!is!‘different’!from!those!produced!under!licence.!!
! Uncertainty!about!the!way!that!different!institutions!will!respond!to!evidence!











“The! trouble! is! you! think,! well! why! can’t! people! be! more!
imaginative?!But!I’m!sitting!there!myself!thinking!‘Oh!I!dunno,!I!do!







was! so! experimental! that! there! was! insufficient! background! information! already!











about!what! should! count!as!evidence!of!effectiveness.!He!demonstrates!that! this!
consensus! prioritised! certain! aspects! of! the! therapy! whilst! sidelining! others,!
concluding! that! “rather! than! consensus! regarding! use! of! the! implant! in! children!
having! been! evidenceMbased,! it!was! evidence! that!was! consensusMbased”! (Blume,!
2009).!Blume!is!discussing!a!technology!that!has!now!achieved!widespread!clinical!
adoption,!providing!a!retrospective!account!of!how!this!stabilisation!took!place,!but!
this! process! of! consensus! building! can! also! be! seen! prospectively! in! the! various!
negotiations!regarding!evidence!that!I!have!described!in!this!section.!Evidence!can!
be!mobilised!strategically!to!position!a!therapy! in!a!particular!way!to!facilitate! its!
development,! for! instance!by!demonstrating! it! is! ‘the!same!as’!or! ‘different! from’!
another!therapy,!and!there!are!disagreements!about!the!relative!weight!that!should!
be!afforded!to!different!types!of!evidence,!as!shown!by!the!ongoing!debate!about!
the! cost! effectiveness! of! ACI.! The! way! that! evidence! is! positioned! can! have!
fundamental! implications! for! the! development! of! a! technology,! and! indeed! my!
findings! suggest! that! evidence! might! need! to! be! deployed! in! different! ways! in!






order! to! continue! providing! a! treatment! for! which! another! provider! holds! a!
marketing! authorisation.! Thus,! the! ability! of! various! actors! to! promote! particular!










as! evidence! is! contested,! and! it! is! urged! to! consider! other,! more! experiential!
knowledge!alongside!more!formal!evidence!in!its!assessment!of!cost!effectiveness.!
Nevertheless,! the! initial! assessment! has! created! an! accepted! ‘truth’! about! the!






findings! suggest! that! regulatory! decision! making! for! cell! therapies! is! often! a!
collaborative! process,! involving! both! the! regulatory! agencies! and! the! developers!
themselves.! The! flexible! approach! taken! by! the! MHRA,! made! necessary! by! the!
complex! nature! of! the! science! underpinning! cell! therapies,! suggests! that! the!















that! doesn’t! follow! the! standard! drugs! development!model,! and! the!widespread!
acceptance!of!even!badlyMdesigned!or!preliminary!RCTs!as!being!definitive!proof!of!a!
treatment’s! efficacy.! These! conflicting! approaches! to! the! application! of! EBM!






rather! than! scientific! evidence.! This! is! not! problematic! for! drug! trials,! where! the!
science!and!its!clinical!application!are!quite!distinct,!but,!as!we!saw!in!the!previous!











requirements,! and!of!NICE,!with! its! refusal! to!discuss!evidentiary! requirements! in!
advance.!The!MHRA,!however,!appears!to!demonstrate!more!regulatory!objectivity,!
with!a! focus!on!how!the!decision! is!made!M!a! flexible,!collaborative!approach!that!
ensures!regulatory!oversight!without!imposing!a!strict!and!rigid!framework.!This!is!






engender! trust! and! mutual! understanding,! suggests! a! way! to! overcome! these!
challenges,! but! for! this! to! be! a! sustainable! model! it! must! be! integrated! at! an!
institutional!level,!and!not!embodied!in!individuals!who!can!come!and!go.!Another!




suggests! larger! companies! are! more! likely! to! be! successful! when! applying! for!
marketing!authorisation!(Regnstrom!et!al.,!2009).!This!suggests!that!while!regulatory!
objectivity!might! be! beneficial,! in! that! it! allows! for! a!more! nuanced! approach! to!
evidence,!it!is!important!to!recognise!that!its!outcomes!are!to!some!extent!dependent!
on!the!relative!power!and!influence!of!the!actors!involved!the!process.!




aspect!of!how!evidence! is!defined!and! interpreted! is!negotiated;! for! instance,!the!
aspects! of! trial! design! that! are! considered! essential! or! expendable,! the! choice! of!







that!my! findings! suggest! that! the! resulting! ‘consensusMbased!evidence’! is!entirely!







other! forms! of! evidence,! whether! from! alternative! approaches! to! trialling! or! by!
exploring!the!value!of!evidence!from!other!sources.!In!the!following!chapter!I!will!






This! thesis! has! examined! cell! therapy! trials! from! a! number! of! different! angles,!
providing!a!comprehensive!and!thematicallyMvaried!examination!of!the!field.!In!this!






that! warrants! special! treatment,! cell! therapy! trials! face! distinctive! challenges!
because!of!their!differences!from!the!drug!trials!the!EBM!model!is!based!on,!and!I!go!
on! to! make! some! recommendations! about! how! a! more! sociallyMrobust! trials!
framework!could!address!these!issues.!Such!a!framework,!whilst!not!advocating!any!
significant! exceptionalism! for! cell! therapy! trials,! would! recognise! their! specific!
requirements!and!limitations,!as!well!as!the!limitations!of!the!EBM!model!itself.!The!
chapter! concludes! with! some! suggestions! for! future! research! which! would! help!
support! the! development! and! evaluation! of! such! a! model,! and! with! some! final!
personal!reflections!on!the!future!of!the!field.!Before!embarking!on!the!substantive!
content! of! the! chapter,! however.! I! will! briefly! recap! the! main! findings! from!my!
research,!which!form!the!empirical!basis! for!the!conceptual!analysis!and!practical!













in! much! of! the! literature! on! cell! therapy! development,! does! not! appear! to! be!
particularly!significant!for!trials,!where!the!complexity/risk!of!the!procedure!and!the!
manipulation!of!the!cells!appear!to!be!more!important!factors!than!the!cell!source.!
Most! importantly,! the!fragmentation!of!the!field!means! it!is!not!possible!to!make!
generalisations! about! ‘cell! therapy! trials’! overall.! In! fact,! each! trial! is!much!more!










further! in!Chapter!4.!The!policy!environment! is! largely!aligned!with!a!commercial!
model!of!development,!which!conflicts!with!the!reality!that!most!cell!therapy!trials!
























trialists.!Academic!units!have!traditionally!not!been! involved! in!drug!trials!or! lateM
phase!trials,!and!the!commercial!enterprises!involved!in!cell!therapy!trials!tend!to!be!
small! SMEs! –! often,! in! fact,! university! spinMoff! companies! M! which! are! equally!
inexperienced.!The!discussion!of!dayMtoMday!challenges! in!Chapter!5!suggests!that!
this! is! further! exacerbated! by! the! number! of! different! domains! involved! in! cell!
therapy! trials.! The!complexity!of! cell! therapies!means! that! trials!normally! require!
input!from!basic!scientific!researchers,!clinicians,!cell!manufacturing,!pharmacy!and!
evidenceMbased! medicine,! all! of! which! are! often! unfamiliar! with! the! specific!
requirements!of!either!cell!therapies!or!clinical!trials.!!
Chapter!5!also!highlighted!financial!constraints!as!a!key!dayMtoMday!challenge!
for! trials.! The! preponderance! of! publiclyMfunded! and! SMEMled! trials! means! that!
funding! is!often!woefully! inadequate!for!the!needs!of! large,!complex!and!heavilyM
regulated!CTIMPs,!and!for!publiclyMfunded!trials!this!is!often!further!exacerbated!by!




only! compound! this.! Finally,! the! nature! of! cell! therapies! themselves! presents! a!
significant! challenge! for! trials.! As! living! organisms,! cell! therapies! do! not! lend!
























is! very! little! scientific! uncertainty! about! the! chemical! compound! itself,! and! the!





and!clinical!uncertainties,! their! role! in! the! innovation!process! is!not!uncontested,!
with!differing!opinions!about!the!extent!to!which!uncertainty!should!be!accepted!in!
the!clinic,!even!in!a!regulated,!earlyMphase!trial.!The!need!for!trials!to!contribute!to!









Most! cell! therapy! trialists! are! supportive! of! the! principle! of! clinical! testing! being!
conducted!in!a!structured!and!regulated!way,!but!in!practice!it!is!often!challenging!
to!meet!the!expectations!of!EBM.!EBM!prioritises!certain!aspects!of!trials,!such!as!
randomised! control! groups! and! blinding,! that! are! problematic! for! many! cell!




as! success.! My! research! identified! a! number! of! examples! of! stakeholders!
acknowledging!this!mutability!and!adopting!a!nuanced!approach! to!evidence.! For!






standard! RCT! model.! Inconsistencies! in! the! way! that! different! actors! interpret!
evidence!can!also!be!problematic,!with!different!agencies!placing!differing!weight!on!
the! same! evidence,! and! the! results! of! individual! RCTs! being! used! as! a! definitive!
answer! on! the! success! of! a! therapy,! with! significant! implications! for! its! future!
development.!
8.1!Cell!therapy!trials!and!the!coWproduction!of!knowledge!
The!mutable,! contextualised! and! contingent! nature! of! cell! therapy! trials! and! the!
evidence! they! generate! has! been! a! recurring! theme! throughout! this! thesis,!




however,! in! examining! how! cell! therapy! trials! configure! clinical! practice! and!
processes!of!knowledge!production!and!innovation.!The!most!visible!way!that!trials!
configuring! practice! emerged! in! my! research! was! through! clinicians!
reconceptualising! research! as! care.! This! was! particularly! noticeable! in! my!
observations!of!the!ENABLE!trial,!where!research!was!an!integral!part!of!the!clinical!





clinical! care! of! the! patient.! Likewise,! there! were! examples! of! cell! therapy! trials!
influencing!the!type!of!research!that!might!be!undertaken,!for!instance!finding!new!
ways! to! conceptualise! patients! and! diseases,! in! order! to! better! understand! the!
treatment.! And,! of! course,! the! reverse! translation! approach,! and! the! close! links!












is! that! cell! therapy! trials! are! extremely! heterogeneous! and! tend! to! be! linked! to!
individual!personalities!or!small! teams,!and!specific! local!conditions.!Each!trial,!or!




common!platforms! and! systems! that! create! a!momentum!and! framework!within!
which!trials!take!place!almost!as!a!matter!of!course,!such!as!Keating!and!Cambrosio!








suggests!that!even!as! the! field!expands! it!may!never!develop! the!kind!of! style!of!
practice!that!is!seen!in!oncology.!For!cell!therapies,!then,!we!might!perhaps!expect!
to! see! distinctive! styles! of! practice! developing! at! a! localised! level,! and! perhaps!
eventually!more!widely!in!particular!clinical!areas!or!particular!types!of!therapy!(such!




commercial! model! of! innovation! that! underpins! the! regulatory! and! policy!










those! treatments! and! sites! currently! using! a! localised! clinicalMacademic!






‘expert’! scientific! knowledge! to!make!decisions! in! this! complex!and! fastMchanging!
field,!and!of!course!in!the!positioning!of!trials!as!the!gold!standard!for!generating!
neutral,!‘scientific’!evidence.!The!difference!between!this!and!Miller’s!description!of!
the! IPCC,! however,! is! the! fact! that! the! institutional! positioning! of! cell! therapies!
involves!the! interaction!of!a!number!of!different! institutions!–!such!as!the!MHRA!
deferring! to! expert! knowledge,! and! the! EMA!and!NICE! treating! trials! as! the! gold!
standard!of!evidence.!CoMproduction!in!cell!therapy!trials,!then,!can!be!understood!
as!emerging!from!the!assumptions!and!authorities!invoked!by!a!range!of!institutions,!








for! trialists.! For! instance,! trialists! might! be! unsure! about! what! evidence! will! be!
required!by!NICE!when!making!commissioning!decisions,!or!how!the!MHRA!might!
respond!to!changes!to!a!manufacturing!protocol.!The!very!classification!of!many!cell!






any! inherent! characteristics! of! the! cell! therapy! itself.! There! is! also! significant!
uncertainty! about! the! future( of! cell! therapy! regulation,! which! manifests! in! the!
‘anticipatory!governation’! I!described! in!Chapter!5,!whereby!not!only! the!existing!
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regulatory! framework! but! also! the! predicted! future! framework! impacts! on! the!
trajectories! of! innovation! in! cell! therapies.! Anticipatory! governation! can! take!










Anticipatory! governation! is! a! good! example! of! how! scientific! uncertainty!
creates!what!Jasanoff!and!Wynne!(1998,!p.15)!describe!as!“a!domain!of!interpretive!





























in! specifically! designed!ways.!Wynne! argues! that! this! only! becomes! problematic!
when! scientific! knowledge! travels! outside! of! science! and! is! put! to! use! in! policy!
without! consideration! of! these! fundamental! indeterminacies.! The! contested!
representations!of!MSCs!in!the!clinic!demonstrate!the!impact!of!this!in!practice:!any!
attempt! to! invoke! scientific! authority! in! making! clinical! and! regulatory! decisions!
immediately!uncovers!the!ignorance!and!indeterminacy!involved!in!the!basic!science.!
Rather! than! providing! neutral! authority! for! a! particular! course! of! action,! then,!
science! in! fact! presents! a! range! of! different! representations,! again! providing! a!
repertoire!of!meanings!to!justify!different!paths.!!
The!new!uncertainties!created!by!emerging!biomedical!innovations!such!as!
cell! therapies! raise! important! questions! about!which! voices! should! be! heard! and!
prioritised! in! clinical! decision! making! (Mesman! 2008).! The! STS! literature! has!
documented!a! number!of!examples!of!patients! increasingly!becoming! involved! in!
setting!the!research!agenda!in!specific!clinical!areas,!for!instance!Rabeharisoa!and!
Callon! (2004)! discuss! the! French! Muscular! Dystrophy! association,! which! has!
promoted!the!active!involvement!of!patients!and!their!families!in!the!production!of!
knowledge,!resulting!in!patients!and!clinicians!“engaging!in!collective!experiments,!
the! remarkable!effects!of!which! is! the!mixing!of! lived!experiences!and! laboratory!
results!in!the!characterisation!of!MD.”!In!comparison!to!this!there!appears!to!be!a!











characterised! by! both! high! expectations! and! complex,! uncertain! science.! The!
fragmentation!of!the!field!and!the!lack!of!collective!interest!from!patient!groups!may!
be!making!it!more!difficult!for!patients’!voices!to!be!heard!about!these!uncertainties,!




of! knowledge!described! in! the!STS! literature,!and! the!extent!of! individual! agency!
available!to!patients! in!trials.!There!are!thus!two!different! levels!at!which!patient!
agency!must! be! evaluated! and! understood:! patients!might! be! able! to! shape! the!
direction! of! research! at! a! collective! level,! for! instance! by! mobilising! support! for!
























divergence! between! individual! and! collective! agency! in! cell! therapy! trials! can! be!
understood! in! similar! terms:! although! patient! agency! might! be! mobilised! at! a!
collective! (or! global)! level,! it! only! acquires! meaning! and! significance! at! a! local!
(individual)! level! M! i.e.! the! agency! of! individual! patients! to! understand! and!make!
decisions!about!their!own!participation!in!trials.!






























that! foster! this! behavioural! bias! do! not! only! occur! in! commercial! trials;! amongst!
other!things,!a!close!involvement!with!the!treatment!being!tested,!a!genuine!belief!
in!its!efficacy,!and!the!motivation!to!generate!‘significant’!results!for!research!funding!
and! personal! career! benefits! all! create! the! circumstances! for! behavioural! bias! to!
occur!in!cell!therapy!trials.!!
Cell!therapy!trials,!then,!involve!multiple!intertwined!uncertainties,!allowing!




‘politics’! (Marks! 1997),! but! of! course! the! idiom! of! coMproduction! highlights! the!
absence! of! a! dividing! line! between! the! two.! In! her! examination! of! ‘regulatory!
science’,! Jasanoff! discusses! the! blurring! of! the! boundaries! between! science! and!
politics! that! occurs! when! scientists! become! involved! in! policyMmaking! (see! for!
instance!Jasanoff!1990,!2011).!This!blurring!is!very!visible!in!cell!therapy!trials,!with!






moves! it! around!–! shifting! it!upstream! from! individual! clinical!decision!making! to!
more!general!and!overarching!decisions!about!trial!design!and!regulation.!!
Another!manifestation! of! the! role! of! EBM! in! coMproduction! is! the! role! of!
protocols! in! cell! therapy! trials.! Jasanoff! and!Wynne! (1998,! p.29)! argue! that! legal!
proceedings!and!discourses!are!influential!in!“producing!facts!from!uncertainty,!in!
part!through!techniques!of!boundary!work!that!demarcate!regions!of!profound!social!
and! cognitive! indeterminacy! –! and! even! cognitive! dissonance! –! into! domains! of!
evidence!and! fact! finding.”!Trial!protocols! can! be!understood!as!operating! in! the!







and! regulators! differently,! with! trialists! seeking! contextualised,! nuanced!

















cell! therapies.! This! results! in! trialists! building! flexibility! into! protocols! to! give!
themselves!room!to!manoeuvre!in!their!care!of!patients,!such!as!using!ranges!instead!
of!thresholds!for!exclusion!criteria!or!cell!batches,!thus!again!reintroducing!a!reliance!
on! expertise! and! subjective! opinion! that! EBM! purports! to! replace.! There! is! an!
interesting!parallel!here!to!Mesman’s!description!of!the!subjectivity!involved!in!using!






the! child’s! condition! is! in! itself! subjective,! and! the! distinctions! between! the!
categories!are!vague.!The!decision!about!whether!to!treat!or!not!therefore!involves!
clinicians!interpreting!a!range!of!observations!and!balancing!various!perceptions!of!
risk! and! potential! benefit,! regardless! of! how! ‘evidenceMbased’! or! ‘rational’! the!
guidelines!might!be.!Cell!therapy!trial!protocols!appear!to!function!in!a!similar!way,!
whilst!on!the!surface!corresponding!to!an!EBM!narrative!about!rational,!objective!
decision! making,! they! fail! to! account! for,! or! control,! the! complexity! and!
indeterminacy!of!actual!clinical!situations.!!
Miller!(2004)!argues!that!the!idiom!of!coMproduction!is!useful!for!the!“insights!
it! provides! into! where! knowledgeMorders! remain! unconsolidated,! tentative! and!
fragile”.!It!is!therefore!a!particularly!useful!framework!for!examining!the!field!of!cell!
therapies,!which!is!characterised!by!a!conflicted,!fractured!style!of!practice!where!










of!clinical! trials!attempt!to!control! the!uncertainties!of!cell! therapies! in!the!clinic.!








research! on! coMproduction,! by! exploring! how! the! uncertainties! inherent! in! new!
technologies! present! both! conceptual! and! practical! liminal! spaces! where!
representations!and!discourses!can!be!mobilised!in!shifting!ways.!Most!importantly,!
it!suggests!that!exploring!the!emergence!of!multiple! institutions,!representations,!
discourses! and! identities,! and! examining! the! interactions! and! tensions! between!
them,!can!provide!a!fruitful!understanding!of!how!science!and!social!order!are!being!
coMproduced!in!cell!therapies.!A!third!and!important!contribution!of!the!thesis!is!that!
it! suggests! an! approach! for! deploying! the! ideas! and! techniques! of! STS! in! an!
interdisciplinary! way.! By! adopting! a! balanced! ontological,! epistemological! and!
methodological!standpoint,!and!engaging!with!perspectives!from!biology!and!health!



















between! the! drug! classification,! with! all! of! its! implications! in! terms! of!
commercialisation,! regulation!and!evidence! requirements,! and! the! realities!of! cell!
therapies! being! living! organisms! that! are! largely! being! developed! in! an! academic!
















effect! M!a!conclusion!which!supports!Gardner!et!al.’s! (2015)!view!that!clinical! trials!
present!specific!challenges!for!innovation.!This!does!not!necessarily!mean,!however,!
that!the!key!tenets!of!EBM!should!be!abandoned,!and!indeed!none!of!the!individuals!
















will! be! relevant! to! other! advanced! therapies,! and! indeed! more! broadly! to! EBM!
overall.!My!recommendations!break!down!into!four!areas:!firstly,!overarching!points!
regarding! regulation! and! policy! that! are! relevant! to! all! clinical! research! for! cell!






therapy! trialists,! most! notably! the! classification! of! many! cell! therapies! as! drugs,!
necessitating!highlyMregulated!clinical! trials.!Perhaps!most! important,!however,!are!
the!challenges!caused!by!complex,!inconsistent!and!changeable!regulations.!Most!of!
the! individuals! and! institutions! undertaking! cell! therapy! trials! are! not! experts! or!
professional!trialists;!they!learn!from!trial!and!error!which!is!both!time!consuming!
and!costly.!Complex! regulatory! structures,! and! in!particular! substantial! changes! in!







Finally,! flexibility! and! collaboration! are! very! important! for! effective! regulatory!




! These! regulatory! and! policy! considerations! are! currently! particularly!




cell! therapies.! It! is! important,! however,! that! this! does! not! simply! introduce!more!










clinical! research! increased,! by! ensuring! that! it! interacts!with! and! is! responsive! to!
scientific!and! technical!developments.!A!bioMclinical! approach! should! therefore!be!












to! resolve! scientific! as! well! as! clinical! uncertainties! are! less! likely! to! contribute!
positively!to!the!development!of!a!treatment,!making!it!much!more!difficult!to!justify!
any!additional!risk!to!patients.!Ethics!committees!and!funders!could!also!encourage!





















engineering! network! (a! virtual! space! that! connects! clinicians,! scientists,! and!
manufacturers)!and!the!MRC!Regenerative!Medicine!Centre!in!Edinburgh,!which!is!a!
physical! space! that! brings! together! the! various! technical,! clinical! and! scientific!













approach! to!evidence! that! takes! into!account! the! social! context!and!mutability!of!
trials,!and!the!limitations!as!well!as!the!strengths!of!the!EBM!framework.!For!instance,!
as! Cartwright! (2010)! argues,! decision!makers! should! look! for! a! body! of! vouching!
evidence!when!assessing!the!potential!of!a!treatment!or!the!risk!it!presents,!rather!





for! cell! therapies.! Flexibility! in! the! determination! of!what! counts! as! good! quality!
evidence! is! likely!to!result! in!more!sociallyMrobust!decision!making.!For! instance,! if!
























part! of! cell! therapy! trials! this! would! help! to! foreground! the! patient! perspective,!
particularly!if!it!is!considered!as!part!of!the!body!of!vouching!evidence!for!a!treatment!
and! for! the! design! of! future! trials.! In! particular,! such! research! could! be! used! to!
evaluate!informed!consent!procedures,!ensuring!that!the!process!is!meaningful;!this!
could! include! exploring! how!well! patients! understand! the! participant! information!

















most! important! factors!highlighted!by!my! research,!and! the! implications!of! these!
factors.!This!is!not,!of!course,!an!exhaustive!list,!but!is!a!good!starting!point!when!
considering!trial!design.!Importantly,!many!of!these!factors!mean!that!the!traditional!
drug! designs!may! not! be! appropriate! for! a! cell! therapy! trial.! This! is! certainly! not!
always!the!case,!but!in!many!situations!trialists!may!have!to!look!at!other!methods,!
and! this! should! be! accepted! by! peers! if! the! standard! RCT! has! been! discounted!
because!of!valid!reasons!(i.e.!it!would!not!to!be!possible!to!conduct!one!in!the!future).!
Taking!into!account!the!factors!detailed!in!Figure!8.2,!as!well!as!the!myriad!of!
other! factors!that!can!determine!the!most!appropriate!trial!design,! it! is!clear!that!
there! is! no! one! ‘magic! bullet’! for! cell! therapy! trials! which! will! work! in! all!
circumstances.!Rather,!then,!trialists!need!to!have!access!to!a!variety!of!methods!that!
can!address!the!particular!circumstances!of!their!specific!trial.!It!is!out!of!the!scope!




There! are! a! number! of! adaptive! designs! that! could! offer! some! benefit! for! cell!
therapies,!the!three!with!the!most!potential!being!group!sequential!designs!(which!
allow! for! different! treatment! options! or! combinations! to! be! tested! concurrently),!
enrichment!designs! (which!allow! for! testing! in!a!broad!cohort! of!patients! initially!
























































































trials.! Thirdly,! in!order! for!accumulating!data! to!be!used! to!adapt! the!design,! the!
outcome!measures!(and!in!particular!the!primary!outcome)!must!be!relatively!shortM
term.! However,! the!majority! of! cell! therapies! require! long! outcome!measures! to!
properly!test!efficacy,!so!many!trials!would!have!finished!recruiting!before!sufficient!
outcome! measure! data! would! be! available! to! calculate! any! adaptations.!







































blinded! and/or! involves! no! treatment! other! than! standard! of! care.! Having! an!
additional!control!group!increases!costs,!however,!or!alternatively!if!the!sample!size!
is!kept!the!same!(thus!avoiding!increased!costs)!then!the!number!of!patients!treated!
must! be! reduced! in! order! to! accommodate! a! control! arm,! thus! reducing! the!











Patient!preference! is!difficult!to!address! in!trials,!and!there! is!no!way!to!eliminate!
preference! issues! altogether.! However,! there! are! a! number! of! methodological!
adaptations!that!can!be!used!to!minimise!the!effect!of!patient!preference!on!the!trial,!
and! usefully! these! also! allow! patients! fuller! access! to! the! treatment.! A!
comprehensive!cohort!study,!for!instance,!would!randomise!those!patients!who!are!
indifferent! about! which! treatment! they! get,! whilst! those! who! have! a! significant!
preference!receive!their!preferred!treatment!and!are!followed!up!as!an!observational!




could! be! considered! (although! only! in! very! exceptional! circumstances)! is! Zelen’s!
design,!which!involves!randomising!patients!prior!to!their!consent!being!sought.!This!
avoids! raising! false! hope! for! patients! only! to! have! it! removed!when! they! do! not!
receive!the!new!treatment,!but!of!course!there!are!significant!ethical!issues!about!










associated! with! the! overall! utility! of! animal! models! will! continue! to! present! a!
challenge! for! cell! therapies! following! a! traditional! drug! trial! phased! approach;!
secondly,!the!linearity!of!the!trials!process,!even!if!improved!by!more!efficient!trials,!
is! still! problematic! for! complex! innovation;! and! thirdly,! the! designs! I! describe!






exploring! other! ways! of! generating! evidence! in! addition! to! the! traditional! trial,!
particularly!as!there!are!many!patients!currently!being!treated!‘offMtrial’!under!the!
Hospital! Exemption! (HE).! Under! the! current! system! there! is! little! oversight! or!
structured!evaluation!of!either!the!treatment!or!the!outcomes!of!these!patients.!This!
is! clearly! a! missed! opportunity! to! generate! useful! evidence,! and! also! arguably!









understanding! that! most! cell! therapies! must! be! understood! as! ‘complex!
interventions’! for! research! purposes.! The! term! complex! intervention! is! generally!
understood!as!having!two!implications:!firstly,!that!the!intervention!involves!multiple,!
interacting! components;! and! secondly,! that! the! delivery! and! outcome! is! contextM
specific.!Although! the! term! is!most!often!used! to! refer! to! interventions! in!mental!
health,!policy!and!even!education,!it!has!also!been!used!to!describe!the!dynamics!of!
innovation!in!surgical!practice,!which!has!clear!relevance!to!the!development!of!cell!
therapies.! The! methodological! literature! on! complex! interventions! tends! to!
emphasise!the!need!for!early!development!work!to!refine!the! intervention,!which!
then!feeds!into!clinical!assessment.!In!particular,!the!IDEAL!framework,!summarised!









the! addition! of! prospective! observational!methods! either! at! the! earlier! stages! of!




supplement! trials! in! two!key!ways:! firstly,!by!providing! robust,! structured!preMtrial!
evidence!in!circumstances!where!animal!models!are!inappropriate;!and!secondly,!by!
providing!additional!evidence!alongside!full!trials,!which!would!bolster!the!body!of!
vouching! evidence! available! to! decision! makers,! and! at! the! same! time! provide!





negative! outcomes! are! reliably! reported;! and! thirdly,! the! use! of! prospective!
observational! methods,! such! as! interrupted! time! series,! in! situations! where!
randomisation!is!not!possible.!!
For! such! research! to! be! successful! it! will! need! to! align!with! the! evidence!
generated! by! trials! and! meet! the! expectations! of! decision! makers.! The! specific!
methods! used! will! differ! depending! on! the! circumstances,! but! as! a! minimum! I!
recommend!that!the!following!principles!should!be!incorporated!into!any!research!
conducted!as!part!of!an!offMtrial!research!programme:!








but! should! be! more! comprehensive! than! for! surgery! alone.! Specifically,!
consent! to! the! research! aspects! should! be! documented,! and! participant!
information! sheets/informed! consent! processes! should! be! adopted! that!
ensure!the!patient!is!fully!informed!about!the!experimental!nature!of!the!cell!
therapy!aspect!of!their!treatment.!
3.! Data! collection! should! be! systematised! and! preMspecified,! meaning! there!
















6.! Where! possible! all! sites! using! cells! for! a! particular! indication! should!
participate! in! a! centralised! process,! rather! than! adopting! individual!
approaches.!This!would!ensure!coordinated!data!capture!and!better!coverage!






The! nonMdisciplinary! approach! I! have! taken! has! the! benefit! of! producing! a!
comprehensive!account!of!cell!therapy!trials,!and!of!being!accessible!and!relevant!to!
a! broad! range! of! stakeholders,! including! social! scientists,! policymakers,! basic!






My! findings! highlight! the! importance,! and! the! difficulty,! of! addressing! issues! of!
patient!agency!in!cell!therapy!trials,!and!whilst!my!methodology!engaged!with!the!
patient! perspective! it! did! not! actually! involve! any! direct! research! with! patients.!!
Further!research!in!this!area,!which!lends!itself!to!a!sociological!approach,!would!help!




discourses! of! patient! agency,! such! as! Patient! and! Public! Involvement,! Patient!
Focussed! Medicine! Development! and! Patient! Centricity,! and! how! patients! make!
sense!of!these!supposedly!empowering!concepts.!The!concept!of!patientMled!trials!is!
a! particularly! interesting! recent! development,! as! it! appears! on! the! one! hand! to!





appears! to! have! been! given! by! an! actual! patient! or! patient! group,! and! the! high!
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better! suited! for! cell! therapies,! including! adaptive! and! factorial! designs,! realist!
evaluation,! patient! preference! designs,! the! use! of! routine! data! and! the! IDEAL!





















clinical’! research.! Importantly,! such! research!would! need! to! engage!with! the! two!
domains’! very! different! approaches! to! issues! such! as! preMspecified! protocols! and!
outcomes,!statistical!analysis!and!significance,!and!the!reporting!of!nonMsignificant!








of! the!most! important! healthcare! challenges!we! face!with! the! excitement! of! the!
almost!godMlike!ability!to!create!and!manipulate!life!itself.!We!are,!however,!perhaps!













potential! of! cell! therapies! M!whatever! that!may!be! M!will! only! be! realised! if! these!





thesis! the! complexities! and! contradictions! such! a! framework! involves.! But! these!
difficulties! do! not! mean! the! pursuit! of! robust! evidence! and! oversight! should! be!
abandoned;!rather,!they!suggest!that!there!is!value!in!reassessing!the!form!that!this!
takes,!taking!into!account!the!specific!characteristics!of!cell!therapies.!In!their!review!
of!adaptive!designs! for! clinical! trials,!Kairalla!and!colleagues! (2012)! conclude! that!
“although!ADs!cannot!‘change!the!answer’!regarding!the!effectiveness!of!a!particular!
treatment,! they! can! increase! the! efficiency! in! finding! an! answer.”! My! research!
suggests!that!a!similar!argument!can!be!made!regarding!cell!therapy!trials:!a!more!
sociallyMrobust! approach! to! trials! will! not! make! ineffective! treatments! work,! or!
inefficient! products! costMeffective,! but! it!will!maximise! the! chances! of! identifying!
those!cell!therapies!that!do!have!real!clinical!potential,!and!of!developing!them!into!
workable,! affordable! treatments.! I! hope! that! my! work! goes! some! way! towards!
showing! what! such! an! approach! could! look! like,! and! in! doing! so! supports! the!




























































The!aim!of! this!project! is! to! investigate!how!clinical! trials!are!used! in! the! field!of!





The! research! is! being! undertaken! by! Ruchi!Higham,!who! is! a! PHD! student! in! the!











































































Clinical trials and the challenge of regenerative medicine 
 
I confirm that I have read and understood the Participant Information document for 
the above study dated xxx and have been given the opportunity to ask questions.  
 
I understand that my participation is entirely voluntary and that I am free to 
withdraw at any time without giving a reason.  
 
I understand that I am free to refuse to answer any question during the interview.  
 
I agree to the interview being recorded and later transcribed. 
 
I understand that data from the project will be held securely for three years beyond 
completion of the project to allow for later papers to be produced.  
 
I agree to take part in the above study. 
 
 
We may wish to re-contact you at a later date to arrange another interview. Are you 
happy for us to do this?  YES/NO 
 
 
Participant’s Signature: ...……………………….……………………………… 
 
Participant’s Name:  ………………………………………………………… 
 
Date:    ………………………………………………………… 
 
Researcher’s Signature: ………………………………………………………… 
 
Researcher’s Name:  ………………………………………………………… 
 



















The!aim!of! this!project! is! to! investigate!how!clinical! trials!are!used! in! the! field!of!





The! research! is! being! undertaken! by! Ruchi!Higham,!who! is! a! PHD! student! in! the!





























asked! about! your! work! on! the! trial.! Broadly,! these! interviews! will! cover! the!
background! to! your! involvement! in! the! trial,! your! experiences! of! setting! up! and!
running!the!trial,!and!any!specific!challenges!you!have!faced!and!how!you!think!these!
could!be!addressed! in! future.!Please!feel! free!to!elaborate!on!any!answer!or!area!
which!you!think! is!particularly!relevant!or! important.! Interviews!will!normally! last!




























































Clinical trials and the challenge of regenerative medicine 
 
I confirm that I have read and understood the Participant Information document for 
the above study dated xxx and have been given the opportunity to ask questions.  
 
I understand that my participation is entirely voluntary and that I am free to 
withdraw at any time without giving a reason.  
 
I understand that I am free to refuse to answer any question during the interview (if 
applicable).  
 
I agree to the interview being recorded and later transcribed, and / or to notes being 
taken during team meetings. 
 
I understand that data from the project will be held securely for three years beyond 
completion of the project to allow for later papers to be produced.  
 
I agree to take part in the above study. 
 
 
We may wish to re-contact you at a later date to arrange another interview. Are you 
happy for us to do this?  YES/NO 
 
 
Participant’s Signature: ………………………………………………………… 
 
Participant’s Name:  ………………………………………………………… 
 
Date:    ………………………………………………………… 
 
 
Researcher’s Signature: ………………………………………………………… 
 
Researcher’s Name:  ………………………………………………………… 
 















Clinical(indication( Cell(type( Cell(source( Delivery( Mode(of(action( Phase( Sample(
size(
UKCRN$11288$ Follow$up$ No$ Liver$disease$ Hematopoietic$ Autologous$ Procedure$ Cell$therapy$ II$ 81$
UKCRN$12108$ Follow$up$ No$ Rheumatological$ Other$ Autologous$ Procedure$ Immunotherapy$ I$ 12$
2010H021463H32$ Recruiting$ Yes$ Gastrointestinal$ Other$ Autologous$ Product$ Regeneration$ II$ 252$
NCT01600755$ Recruiting$ Yes$ Gastrointestinal$ Other$ Autologous$ Product$ Regeneration$ I/II$ 30$
NCT02064062$ Set$up$ No$ Other$ Mesenchymal$ Autologous$ Product$ Regeneration$ II$ 10$
NCT01606215$ Follow$up$ No$ Neurological$ Mesenchymal$ Autologous$ Product$ Cell$therapy$ II$ 13$
NCT01898390$ Set$up$ No$ Neurological$ Neural$ Allogeneic$ Procedure$ Regeneration$ I$ 40$
NCT01151124$ Follow$up$ Yes$ Neurological$ Embryonic$ Allogeneic$ Procedure$ Regeneration$ I$ 12$
NCT02117635$ Recruiting$ Yes$ Neurological$ Embryonic$ Allogeneic$ Procedure$ Regeneration$ II$ 41$
UKCRN3827$ Suspended$ No$ Neurological$ Neural$ Allogeneic$ Procedure$ Regeneration$ I$ 20$
NCT01436487$ Follow$up$ Yes$ Neurological$ Mesenchymal$ Allogeneic$ Product$ Cell$therapy$ II$ 140$
NCT01932593$ Recruiting$ No$ Neurological$ Hematopoietic$ Autologous$ Product$ Cell$therapy$ I$ 6$
NCT01815632$ Recruiting$ No$ Neurological$ Hematopoietic$ Autologous$ Product$ Cell$therapy$ II$ 80$
!360$
NCT00297193$ Follow$up$ No$ Gastrointestinal$ Hematopoietic$ Autologous$ Product$ Immunotherapy$ III$ 48$
NCT02166177$ Recruiting$ No$ Gastrointestinal$ Hematopoietic$ Autologous$ Procedure$ Immunotherapy$ I/II$ 26$
NCT02327221$ Recruiting$ Yes$ Gastrointestinal$ Hematopoietic$ Autologous$ Procedure$ Immunotherapy$ II$ 160$
NCT01175239$ Recruiting$ No$ Immunodeficiency$ Hematopoietic$ Autologous$ Product$ Immunotherapy$ I/II$ 10$
NCT01380990$ Recruiting$ No$ Immunodeficiency$ Hematopoietic$ Autologous$ Procedure$ Immunotherapy$ I/II$ 10$
UKCRN$12383$ Recruiting$ No$ Cartilage$disease$ Mesenchymal$
and$other$
Autologous$ Procedure$ Regeneration$ II$ 114$
UKCRN$11523$ Closed$ No$ Bone$condition$ Mesenchymal$ Autologous$ Procedure$ Regeneration$ II$ 60$
2010H024162H22$ Recruiting$ Yes$ Cartilage$disease$ Mesenchymal$ Autologous$ Procedure$ Regeneration$ I$ 10$
NCT01795976$ Suspended$ No$ Cancer$ Hematopoietic$ Autologous$ Product$ Immunotherapy$ II$ 28$
NCT01195480$ Recruiting$ No$ Cancer$ Hematopoietic$ Allogeneic$ Product$ Immunotherapy$ I/II$ 30$
NCT01818323$ Recruiting$ No$ Cancer$ Hematopoietic$ Autologous$ Procedure$ Immunotherapy$ I$ 30$
2011H001192H39$ Recruiting$ Yes$ Cancer$ Hematopoietic$ Autologous$ Product$ Immunotherapy$ II$ 60$
2011H001788H36$ Recruiting$ Yes$ Cancer$ Hematopoietic$ Allogeneic$ Product$ Immunotherapy$ I/II$ 15$
NCT01621724$ Recruiting$ No$ Cancer$ Hematopoietic$ Autologous$ Product$ Immunotherapy$ I/II$ 18$
2008H006649H18$ Suspended$ No$ Cancer$ Hematopoietic$ Allogeneic$ Product$ Immunotherapy$ I$ 10$
NCT01827579$ Recruiting$ No$ Cancer$ Hematopoietic$ Allogeneic$ Product$ Immunotherapy$ II$ 24$
!361$
NCT01948180$ Recruiting$ Yes$ Cancer$ Hematopoietic$ Autologous$ Product$ Immunotherapy$ II$ 30$
NCT02550535$ Recruiting$ No$ Cancer$ Hematopoietic$ Autologous$ Product$ Immunotherapy$ I/II$ 30$
NCT02431988$ Set$up$ No$ Cancer$ Hematopoietic$ Autologous$ Product$ Immunotherapy$ I$ 12$
NCT02443831$ Set$up$ No$ Cancer$ Hematopoietic$ Autologous$ Product$ Immunotherapy$ I$ 18$
NCT00765453$ Set$up$ No$ Cardiovascular$ Hematopoietic$ Autologous$ Procedure$ Cell$therapy$ I/II$ 100$
NCT01569178$ Recruiting$ No$ Cardiovascular$ Hematopoietic$ Autologous$ Procedure$ Cell$therapy$ III$ 3000$
2006H000280H28$ Recruiting$ No$ Cardiovascular$ Hematopoietic$ Autologous$ Product$ Cell$therapy$ I/II$ 40$
NCT01916369$ Recruiting$ Yes$ Cardiovascular$ Embryonic$ Allogeneic$ Product$ Regeneration$ I$ 9$
UKCRN$4434$ Follow$up$ No$ Cardiovascular$ Hematopoietic$ Autologous$ Product$ Cell$therapy$ II$ 60$
UKCRN$11185$ Follow$up$ No$ Eye$disease$ Limbal$ Autologous$ Procedure$ Regeneration$ II$ 20$
2010H024409H11$ Follow$up$ No$ Eye$disease$ Limbal$ Allogeneic$ Procedure$ Regeneration$ I/II$ 20$
NCT01469832$ Follow$up$ Yes$ Eye$disease$ Embryonic$ Allogeneic$ Procedure$ Regeneration$ I/II$ 16$
NCT02129881$ Recruiting$ No$ Kidney$condition$ Hematopoietic$ Autologous$ Product$ Immunotherapy$ I/II$ 12$
NCT01977911$ Recruiting$ No$ Other$ Mesenchymal$ Autologous$ Procedure$ Cell$therapy$ I/II$ 10$
2012H001394H87$ Set$up$ No$ Skin$condition$ Mesenchymal$ Allogeneic$ Procedure$ Cell$therapy$ I$ 10$
$ $
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Abbreviations,
!
ACI! Autologous!Chondrocyte!Implantation!
ATMP! Advanced!Therapy!Medicinal!Product!
CGTC! Cell!and!Gene!Therapy!Catapult!(formally!Cell!Therapy!Catapult)!
CI! Chief!Investigator!
CRN! Clinical!Research!Network!
CRO! Clinical!Research!Organisation!
CTIMP! Clinical!Trial!of!an!Investigational!Medicinal!Product!
EBM! EvidenceGBased!Medicine!
EMA! European!Medicines!Agency!
ESRC! Economic!and!Social!Research!Council!
GCP! Good!Clinical!Practice!
GMP! Good!Manufacturing!Practice!
GvHD! Graft!vs.!Host!Disease!
HE! Hospital!Exemption!
HTA! Health!Technology!Assessment!
hESC! Human!Embryonic!Stem!Cell!
IMP! Investigational!Medicinal!Product!
IMPD! Investigational!Medicinal!Product!Dossier!
iPSC! Induced!Pluripotent!Stem!Cell!
MHRA! Medicines!and!Healthcare!products!Regulatory!Agency!
MRC! Medical!Research!Council!
MSC! Mesenchymal!Stem!Cell!(or!Mesenchymal!Stromal!Cell)!
NICE! National!Institute!for!Health!and!Care!Excellence!
NHS! National!Health!Service!
NIH! National!Institute!for!Health!(US)!
NIHR! National!Institute!for!Health!Research!(UK)!
PI! Principal!Investigator!
RCT! Randomised!Controlled!Trial!
REC! Research!Ethics!Committee!
RM! Regenerative!Medicine!
RMEG! Regenerative!Medicine!Expert!Group!
! !
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